P-value | ln(P) | Term | GO Tree | GO ID | # of Genes in Term | # of Target Genes in Term | # of Total Genes | # of Target Genes | Common Genes |
6.000e-10 | -21.23 | prostate-carcinoma | COSMIC cancer mutations | prostate-carcinoma | 9000 | 46 | 16828 | 49 |
AHCYL2,FBXL7,LIFR,SPARCL1,RYR3,BMPR1B,DTNA,LSAMP,GLIS3,HIF3A,ZBTB20,SLC4A4,PITPNC1,SFXN5,FGFR3,PARD3B,NEBL,MSI2,PTPRZ1,FMN2,GPC5,MAML2,CTNND2,SLC1A3,NTM,GLUD1,ATP13A4,MACF1,NHSL1,SOX5,SLC1A2,NKAIN3,NFIA,NRXN1,NPAS3,PCDH9,PREX2,ITPR2,ABLIM1,RORA,CPE,NTRK2,GPM6A,TRPS1,CDH20,TNIK |
1.443e-09 | -20.36 | acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_B_cell_leukaemia | 3828 | 31 | 16828 | 49 |
HIF3A,GLIS3,LSAMP,PREX2,PCDH9,ZBTB20,ITPR2,SLC4A4,NEBL,CPE,RORA,NTRK2,PTPRZ1,GPM6A,CTNND2,SLC1A3,MAML2,FMN2,GPC5,TNIK,NTM,FBXL7,ATP13A4,LIFR,SLC1A2,BMPR1B,SOX5,RYR3,NKAIN3,NFIA,NRXN1 |
1.443e-09 | -20.36 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | 3828 | 31 | 16828 | 49 |
SLC4A4,ITPR2,ZBTB20,PREX2,PCDH9,LSAMP,GLIS3,HIF3A,TNIK,FMN2,MAML2,GPC5,SLC1A3,CTNND2,GPM6A,PTPRZ1,NTRK2,RORA,CPE,NEBL,LIFR,FBXL7,ATP13A4,NTM,NRXN1,NFIA,NKAIN3,SOX5,RYR3,SLC1A2,BMPR1B |
9.497e-09 | -18.47 | brainstem | COSMIC cancer mutations | brainstem | 3102 | 27 | 16828 | 49 |
LIFR,FBXL7,ATP13A4,AHCYL2,NKAIN3,SOX5,RYR3,SLC1A2,FGFR3,SFXN5,ITPR2,PCDH9,PREX2,ZBTB20,NPAS3,LSAMP,SLC1A3,CTNND2,GPC5,FMN2,MAML2,TNIK,CDH20,GPM6A,PTPRZ1,RORA,CPE |
9.808e-09 | -18.44 | PRNP (prion protein (Kanno blood group)) | protein interactions | 5621 | 1118 | 16 | 19454 | 50 |
PTPRZ1,MACF1,TRPS1,CPE,SLC1A3,GPM6A,SLC4A4,AHCYL2,LSAMP,ABLIM1,ATP1A2,GLUD1,NHSL1,MSI2,SPARCL1,MAML2 |
1.790e-08 | -17.84 | lymph_node | COSMIC cancer mutations | lymph_node | 1703 | 20 | 16828 | 49 |
GPM6A,TRPS1,SLC1A3,CTNND2,MAML2,TNIK,GPC5,SOX5,RYR3,NEBL,DTNA,NTRK2,SFXN5,LIFR,ITPR2,PARD3B,FGFR3,LSAMP,ATP13A4,PCDH9 |
2.195e-08 | -17.63 | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | 2531 | 24 | 16828 | 49 |
NKAIN3,RYR3,SOX5,LIFR,ATP13A4,FBXL7,AHCYL2,FMN2,MAML2,TNIK,GPC5,CTNND2,SLC1A3,PTPRZ1,GPM6A,CDH20,RORA,CPE,ITPR2,SFXN5,ZBTB20,PCDH9,PREX2,LSAMP |
2.342e-08 | -17.57 | cerebellum | COSMIC cancer mutations | cerebellum | 769 | 14 | 16828 | 49 |
PTPRZ1,MAML2,GPC5,CTNND2,NRXN1,CPE,NEBL,RYR3,NTRK2,ITPR2,ABLIM1,PARD3B,NPAS3,PCDH9 |
2.351e-08 | -17.57 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | 2119 | 22 | 16828 | 49 |
NPAS3,FBXL7,PCDH9,PREX2,ATP13A4,AHCYL2,LSAMP,NHSL1,ITPR2,NKAIN3,NTRK2,CPE,SLC1A2,BMPR1B,SOX5,RYR3,GPC5,MAML2,FMN2,SLC1A3,CTNND2,GPM6A |
2.351e-08 | -17.57 | Burkitt_lymphoma | COSMIC cancer mutations | Burkitt_lymphoma | 2119 | 22 | 16828 | 49 |
AHCYL2,FBXL7,ATP13A4,NHSL1,SLC1A2,BMPR1B,SOX5,RYR3,NKAIN3,LSAMP,NPAS3,PREX2,PCDH9,ITPR2,CPE,NTRK2,GPM6A,GPC5,FMN2,MAML2,CTNND2,SLC1A3 |
2.815e-08 | -17.39 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | 7205 | 40 | 16828 | 49 |
MACF1,LIFR,NHSL1,GLUD1,NTM,AHCYL2,FBXL7,ATP13A4,NRXN1,RYR3,SOX5,SLC1A2,NKAIN3,NFIA,SFXN5,SLC4A4,PITPNC1,ITPR2,PARD3B,ABLIM1,FGFR3,GLIS3,LSAMP,PREX2,PCDH9,ZBTB20,NPAS3,PTPRZ1,GPM6A,TRPS1,CTNND2,SLC1A3,GPC5,MAML2,TNIK,FMN2,NEBL,RORA,CPE,NTRK2 |
2.907e-08 | -17.35 | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | COSMIC cancer mutations | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | 653 | 13 | 16828 | 49 |
ABLIM1,PARD3B,ITPR2,NPAS3,PCDH9,MAML2,CTNND2,NRXN1,PTPRZ1,NTRK2,CPE,NEBL,RYR3 |
2.960e-08 | -17.34 | SHH_subtype | COSMIC cancer mutations | SHH_subtype | 654 | 13 | 16828 | 49 |
NTRK2,NPAS3,PCDH9,CPE,NEBL,RYR3,MAML2,ABLIM1,PARD3B,CTNND2,NRXN1,ITPR2,PTPRZ1 |
5.958e-08 | -16.64 | diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | diffuse_large_B_cell_lymphoma | 4151 | 30 | 16828 | 49 |
FBXL7,ATP13A4,AHCYL2,SPARCL1,MACF1,LIFR,NKAIN3,DTNA,SOX5,RYR3,SLC1A2,PREX2,PCDH9,LSAMP,FGFR3,ATP1A2,ITPR2,NTRK2,RORA,CPE,NEBL,FMN2,GPC5,TNIK,MAML2,SLC1A3,CTNND2,GPM6A,TRPS1,CDH20 |
1.045e-07 | -16.07 | nodular | COSMIC cancer mutations | nodular | 1515 | 18 | 16828 | 49 |
FMN2,CTNND2,PTPRZ1,CDH20,NTRK2,CPE,NEBL,ABLIM1,SPARCL1,FGFR3,ATP1A2,MACF1,SLC4A4,NPAS3,PREX2,ATP13A4,GLIS3,HIF3A |
2.237e-07 | -15.31 | mantle_cell_lymphoma | COSMIC cancer mutations | mantle_cell_lymphoma | 2849 | 24 | 16828 | 49 |
SOX5,RYR3,SLC1A2,NKAIN3,ATP13A4,FBXL7,LIFR,CPE,NEBL,NTRK2,GPM6A,TRPS1,MAML2,FMN2,GPC5,SLC1A3,CTNND2,LSAMP,HIF3A,PREX2,PCDH9,ITPR2,SFXN5,PARD3B |
2.894e-07 | -15.06 | chondroblastoma | COSMIC cancer mutations | chondroblastoma | 534 | 11 | 16828 | 49 |
FMN2,GPC5,CTNND2,GPM6A,SFXN5,NKAIN3,PCDH9,LSAMP,AHCYL2,SOX5,RYR3 |
4.615e-07 | -14.59 | nervous system development | biological process | GO:0007399 | 2185 | 20 | 18204 | 50 |
CTNND2,PTPRZ1,BMPR1B,NTRK2,SOX5,NFIA,CTNNA2,TNIK,SLC1A2,LSAMP,PREX2,NTM,GLUD1,ATP1A2,NRXN1,MSI2,GPM6A,PCDH9,SLC1A3,RORA |
5.011e-07 | -14.51 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | 2737 | 23 | 16828 | 49 |
LIFR,ITPR2,SFXN5,PARD3B,LSAMP,HIF3A,PCDH9,PREX2,FBXL7,GPM6A,TRPS1,GPC5,MAML2,FMN2,SLC1A3,CTNND2,CPE,SOX5,RYR3,SLC1A2,NEBL,NKAIN3,NTRK2 |
6.436e-07 | -14.26 | plasma membrane | cellular component | GO:0005886 | 5538 | 31 | 19108 | 49 |
FGFR3,PREX2,NTRK2,PTPRZ1,CST3,PCDH9,CDH20,ATP1A2,ATP13A4,ITPR2,TNIK,DTNA,BMPR1B,NTM,FMN2,NRXN1,PARD3B,LIFR,CTNNA2,MACF1,NKAIN3,CPE,HIF3A,CTNND2,GPM6A,GPC5,SLC4A4,SLC1A2,RYR3,LSAMP,SLC1A3 |
8.806e-07 | -13.94 | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | 1946 | 19 | 16828 | 49 |
SLC4A4,MACF1,ITPR2,PARD3B,FGFR3,AHCYL2,PCDH9,ZBTB20,NPAS3,GPM6A,NRXN1,TNIK,MAML2,FMN2,SOX5,RYR3,BMPR1B,NEBL,RORA |
8.947e-07 | -13.93 | larynx | COSMIC cancer mutations | larynx | 1948 | 19 | 16828 | 49 |
FMN2,TNIK,MAML2,NRXN1,GPM6A,RORA,RYR3,SOX5,BMPR1B,NEBL,FGFR3,PARD3B,SLC4A4,MACF1,ITPR2,ZBTB20,NPAS3,PCDH9,AHCYL2 |
1.129e-06 | -13.69 | system development | biological process | GO:0048731 | 3533 | 25 | 18204 | 50 |
CTNND2,NEBL,PTPRZ1,HIF3A,TRPS1,CTNNA2,NFIA,GLUD1,NTM,RORA,MSI2,NTRK2,SOX5,BMPR1B,FGFR3,TNIK,SLC1A2,ATP1A2,CPE,LSAMP,PREX2,SLC1A3,GPM6A,PCDH9,NRXN1 |
1.153e-06 | -13.67 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 3608 | 26 | 16828 | 49 |
FGFR3,ATP1A2,ITPR2,PCDH9,PREX2,LSAMP,GPC5,TNIK,MAML2,FMN2,CTNND2,GPM6A,CDH20,RORA,CPE,NEBL,SPARCL1,MACF1,LIFR,FBXL7,ATP13A4,AHCYL2,NKAIN3,SOX5,RYR3,SLC1A2 |
1.167e-06 | -13.66 | cell periphery | cellular component | GO:0071944 | 6020 | 32 | 19108 | 49 |
PARD3B,LIFR,NRXN1,BMPR1B,FMN2,NTM,ATP13A4,DTNA,TNIK,ITPR2,PCDH9,ATP1A2,CDH20,CST3,PTPRZ1,FGFR3,PREX2,NTRK2,SPARCL1,RYR3,LSAMP,SLC1A3,GPC5,SLC1A2,SLC4A4,GPM6A,HIF3A,CTNND2,MACF1,CPE,NKAIN3,CTNNA2 |
1.343e-06 | -13.52 | blood_vessel | COSMIC cancer mutations | blood_vessel | 2211 | 20 | 16828 | 49 |
NTRK2,NKAIN3,RYR3,SOX5,SLC1A2,NEBL,CTNND2,SLC1A3,FMN2,GPC5,MAML2,CDH20,GPM6A,PTPRZ1,FBXL7,PCDH9,PREX2,LSAMP,FGFR3,ITPR2 |
1.377e-06 | -13.50 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | 764 | 12 | 16828 | 49 |
SLC1A2,SOX5,RYR3,NKAIN3,NTRK2,MAML2,GPC5,LSAMP,PREX2,FBXL7,PCDH9,ATP1A2 |
1.771e-06 | -13.24 | generation of neurons | biological process | GO:0048699 | 1158 | 14 | 18204 | 50 |
RORA,SLC1A3,GPM6A,NRXN1,NTM,PREX2,TNIK,CTNNA2,NFIA,NTRK2,SOX5,BMPR1B,CTNND2,PTPRZ1 |
1.990e-06 | -13.13 | cell morphogenesis | biological process | GO:0000902 | 687 | 11 | 18204 | 50 |
BMPR1B,CTNND2,PTPRZ1,TNIK,NFIA,CTNNA2,CDH20,PREX2,SLC1A3,NRXN1,GPM6A |
2.256e-06 | -13.00 | skin-trunk-malignant_melanoma-nodular | COSMIC cancer mutations | skin-trunk-malignant_melanoma-nodular | 1291 | 15 | 16828 | 49 |
NEBL,CPE,NTRK2,CDH20,PTPRZ1,CTNND2,HIF3A,GLIS3,ATP13A4,PREX2,NPAS3,MACF1,ATP1A2,ABLIM1,SPARCL1 |
2.521e-06 | -12.89 | multicellular organism development | biological process | GO:0007275 | 3957 | 26 | 18204 | 50 |
SLC1A3,GPM6A,PCDH9,NRXN1,ATP1A2,CPE,CDH20,LSAMP,PREX2,SLC1A2,TNIK,NTRK2,SOX5,BMPR1B,FGFR3,RORA,MSI2,GLUD1,NTM,HIF3A,TRPS1,CTNNA2,NFIA,CTNND2,PTPRZ1,NEBL |
2.948e-06 | -12.73 | anatomical structure morphogenesis | biological process | GO:0009653 | 2225 | 19 | 18204 | 50 |
HIF3A,ABLIM1,TNIK,CTNNA2,NFIA,SOX5,NTRK2,BMPR1B,FGFR3,NEBL,PTPRZ1,CTNND2,RORA,SLC1A3,GPM6A,NRXN1,CPE,PREX2,CDH20 |
3.130e-06 | -12.67 | humerus | COSMIC cancer mutations | humerus | 546 | 10 | 16828 | 49 |
NKAIN3,AHCYL2,NEBL,HIF3A,SOX5,FMN2,GPC5,PARD3B,GPM6A,SFXN5 |
3.494e-06 | -12.56 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | 1523 | 16 | 16828 | 49 |
FBXL7,PREX2,PCDH9,LSAMP,ITPR2,NTRK2,NKAIN3,SOX5,RYR3,NEBL,RORA,SLC1A3,CTNND2,MAML2,GPC5,FMN2 |
3.494e-06 | -12.56 | acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | acute_myeloid_leukaemia_therapy_related | 1523 | 16 | 16828 | 49 |
LSAMP,PREX2,FBXL7,PCDH9,ITPR2,NEBL,RYR3,SOX5,RORA,NKAIN3,NTRK2,CTNND2,SLC1A3,FMN2,GPC5,MAML2 |
3.540e-06 | -12.55 | trunk | COSMIC cancer mutations | trunk | 3554 | 25 | 16828 | 49 |
SOX5,RYR3,NRXN1,ATP13A4,MACF1,LIFR,SPARCL1,CPE,NEBL,NTRK2,PTPRZ1,TRPS1,CDH20,MAML2,SLC1A3,CTNND2,LSAMP,GLIS3,HIF3A,NPAS3,PCDH9,PREX2,ABLIM1,FGFR3,ATP1A2 |
4.001e-06 | -12.43 | myelodysplastic_syndrome | COSMIC cancer mutations | myelodysplastic_syndrome | 1174 | 14 | 16828 | 49 |
LSAMP,NPAS3,FBXL7,PREX2,FGFR3,ATP1A2,RYR3,SOX5,SLC1A2,BMPR1B,NFIA,NKAIN3,NTRK2,TNIK |
4.001e-06 | -12.43 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | 1174 | 14 | 16828 | 49 |
NFIA,NKAIN3,NTRK2,SOX5,RYR3,BMPR1B,SLC1A2,TNIK,PREX2,FBXL7,NPAS3,LSAMP,ATP1A2,FGFR3 |
4.805e-06 | -12.25 | neuron differentiation | biological process | GO:0030182 | 1081 | 13 | 18204 | 50 |
NTM,PREX2,GPM6A,NRXN1,RORA,SLC1A3,CTNND2,PTPRZ1,NTRK2,BMPR1B,CTNNA2,NFIA,TNIK |
5.357e-06 | -12.14 | soft_tissue-blood_vessel-angiosarcoma | COSMIC cancer mutations | soft_tissue-blood_vessel-angiosarcoma | 2192 | 19 | 16828 | 49 |
LSAMP,FBXL7,PREX2,PCDH9,ITPR2,SLC1A2,NEBL,SOX5,RYR3,NTRK2,NKAIN3,CDH20,GPM6A,PTPRZ1,SLC1A3,CTNND2,FMN2,GPC5,MAML2 |
5.357e-06 | -12.14 | angiosarcoma | COSMIC cancer mutations | angiosarcoma | 2192 | 19 | 16828 | 49 |
LSAMP,PREX2,PCDH9,FBXL7,ITPR2,NEBL,SLC1A2,SOX5,RYR3,NTRK2,NKAIN3,CDH20,GPM6A,PTPRZ1,CTNND2,SLC1A3,GPC5,MAML2,FMN2 |
7.388e-06 | -11.82 | pharynx | COSMIC cancer mutations | pharynx | 2696 | 21 | 16828 | 49 |
CTNND2,FMN2,GPC5,PTPRZ1,DTNA,NTRK2,NFIA,RYR3,SLC1A2,NHSL1,PARD3B,ATP1A2,FGFR3,SFXN5,SLC4A4,MACF1,PITPNC1,PCDH9,PREX2,ATP13A4,NPAS3 |
7.407e-06 | -11.81 | bone | COSMIC cancer mutations | bone | 8157 | 39 | 16828 | 49 |
PTGDS,ATP13A4,AHCYL2,SPARCL1,LIFR,MACF1,NKAIN3,DTNA,SOX5,RYR3,NRXN1,ZBTB20,NPAS3,CST3,PREX2,PCDH9,GLIS3,LSAMP,HIF3A,FGFR3,ABLIM1,ATP1A2,PARD3B,ITPR2,SLC4A4,SFXN5,NTRK2,CPE,RORA,NEBL,MAML2,FMN2,TNIK,GPC5,SLC1A3,CTNND2,TRPS1,PTPRZ1,GPM6A |
8.073e-06 | -11.73 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | 476 | 9 | 16828 | 49 |
PCDH9,ATP13A4,LSAMP,RYR3,MAML2,GPC5,CTNND2,GPM6A,SFXN5 |
9.205e-06 | -11.60 | neurogenesis | biological process | GO:0022008 | 1334 | 14 | 18204 | 50 |
TNIK,NFIA,CTNNA2,BMPR1B,SOX5,NTRK2,PTPRZ1,CTNND2,SLC1A3,RORA,NRXN1,GPM6A,PREX2,NTM |
1.167e-05 | -11.36 | oesophagus-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-carcinoma-squamous_cell_carcinoma | 6486 | 34 | 16828 | 49 |
HIF3A,GLIS3,PCDH9,PREX2,NPAS3,ZBTB20,SFXN5,SLC4A4,PITPNC1,ITPR2,PARD3B,ATP1A2,ABLIM1,FGFR3,NEBL,CPE,PTPRZ1,GPM6A,TRPS1,CTNND2,GPC5,FMN2,MAML2,TNIK,GLUD1,ATP13A4,FBXL7,MACF1,LIFR,SPARCL1,SOX5,RYR3,BMPR1B,NRXN1 |
1.311e-05 | -11.24 | anatomical structure development | biological process | GO:0048856 | 5207 | 29 | 18204 | 50 |
NTM,GLUD1,MSI2,RORA,CTNND2,SPARCL1,NEBL,PTPRZ1,CTNNA2,NFIA,HIF3A,TRPS1,ABLIM1,FMN2,CDH20,LSAMP,PREX2,ATP1A2,CPE,GPM6A,PCDH9,NRXN1,SLC1A3,FGFR3,NTRK2,SOX5,BMPR1B,SLC1A2,TNIK |
1.668e-05 | -11.00 | neuron development | biological process | GO:0048666 | 859 | 11 | 18204 | 50 |
TNIK,CTNNA2,NTRK2,BMPR1B,PTPRZ1,CTNND2,SLC1A3,GPM6A,NRXN1,NTM,PREX2 |
1.766e-05 | -10.94 | PDZD2 (PDZ domain containing 2) | protein interactions | 23037 | 20 | 3 | 19454 | 50 |
NRXN1,CTNND2,CST3 |
1.836e-05 | -10.91 | CTNNA1 (catenin alpha 1) | protein interactions | 1495 | 325 | 7 | 19454 | 50 |
NEBL,CTNNA2,MACF1,NHSL1,TNIK,DTNA,ABLIM1 |
1.886e-05 | -10.88 | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | 6953 | 35 | 16828 | 49 |
NTM,FBXL7,ATP13A4,MACF1,NHSL1,RYR3,SOX5,SLC1A2,DTNA,NRXN1,HIF3A,LSAMP,PCDH9,PREX2,CST3,ZBTB20,SFXN5,SLC4A4,PITPNC1,ITPR2,PARD3B,ATP1A2,ABLIM1,FGFR3,NEBL,RORA,CDH20,GPM6A,PTPRZ1,TRPS1,CTNND2,GPC5,FMN2,MAML2,TNIK |
2.057e-05 | -10.79 | cell junction | cellular component | GO:0030054 | 2224 | 17 | 19108 | 49 |
CDH20,ATP1A2,PCDH9,PTPRZ1,CTNND2,NTRK2,FGFR3,CTNNA2,SPARCL1,NFIA,PARD3B,SLC1A3,NRXN1,SLC1A2,GPM6A,TNIK,DTNA |
2.256e-05 | -10.70 | MAPT (microtubule associated protein tau) | protein interactions | 4137 | 948 | 11 | 19454 | 50 |
ATP1A2,SLC1A2,TNIK,CTNNA2,CTNND2,ABLIM1,LSAMP,GPM6A,NTM,NEBL,SLC1A3 |
2.465e-05 | -10.61 | bone-humerus-other-chondroblastoma | COSMIC cancer mutations | bone-humerus-other-chondroblastoma | 301 | 7 | 16828 | 49 |
AHCYL2,SOX5,NKAIN3,GPM6A,SFXN5,GPC5,FMN2 |
2.773e-05 | -10.49 | developmental process | biological process | GO:0032502 | 5716 | 30 | 18204 | 50 |
FMN2,PREX2,CDH20,LSAMP,CPE,ATP1A2,PCDH9,GPM6A,NRXN1,SLC1A3,FGFR3,SOX5,NTRK2,BMPR1B,NHSL1,SLC1A2,TNIK,NTM,GLUD1,MSI2,RORA,SPARCL1,NEBL,PTPRZ1,CTNND2,CTNNA2,NFIA,HIF3A,TRPS1,ABLIM1 |
2.973e-05 | -10.42 | lymphoid_neoplasm | COSMIC cancer mutations | lymphoid_neoplasm | 12233 | 47 | 16828 | 49 |
NTM,AHCYL2,GLUD1,ATP13A4,FBXL7,MACF1,LIFR,SPARCL1,NHSL1,RYR3,SOX5,BMPR1B,SLC1A2,NFIA,NKAIN3,DTNA,NRXN1,GLIS3,LSAMP,HIF3A,NPAS3,ZBTB20,PREX2,PCDH9,SLC4A4,PITPNC1,ITPR2,SFXN5,ABLIM1,FGFR3,PARD3B,ATP1A2,RORA,CPE,NEBL,NTRK2,MSI2,GPM6A,PTPRZ1,TRPS1,CDH20,MAML2,GPC5,TNIK,FMN2,CTNND2,SLC1A3 |
3.062e-05 | -10.39 | oesophagus-carcinoma | COSMIC cancer mutations | oesophagus-carcinoma | 4269 | 26 | 16828 | 49 |
NTM,PTGDS,FBXL7,ATP13A4,MACF1,LIFR,NHSL1,RYR3,SOX5,NFIA,HIF3A,ZBTB20,PREX2,PCDH9,SLC4A4,ITPR2,FGFR3,PARD3B,NTRK2,GPM6A,PTPRZ1,TRPS1,CDH20,FMN2,TNIK,CTNND2 |
3.254e-05 | -10.33 | autonomic_ganglia | COSMIC cancer mutations | autonomic_ganglia | 4005 | 25 | 16828 | 49 |
RYR3,SLC1A2,NFIA,FBXL7,MACF1,NHSL1,NEBL,NTRK2,PTPRZ1,GPM6A,TRPS1,CTNND2,TNIK,FMN2,MAML2,HIF3A,GLIS3,PREX2,PCDH9,NPAS3,SLC4A4,PITPNC1,PARD3B,ATP1A2,FGFR3 |
4.501e-05 | -10.01 | multicellular organismal process | biological process | GO:0032501 | 6177 | 31 | 18204 | 50 |
NFIA,CTNNA2,ABLIM1,TRPS1,HIF3A,DTNA,CTNND2,NEBL,PTPRZ1,MSI2,PTGDS,RORA,SLC4A4,NTM,GLUD1,TNIK,SLC1A2,FGFR3,BMPR1B,NTRK2,SOX5,NRXN1,GPM6A,PCDH9,RYR3,SLC1A3,LSAMP,CDH20,PREX2,ATP1A2,CPE |
4.590e-05 | -9.99 | Neurotransmitter uptake and Metabolism In Glial Cells | REACTOME pathways | R-HSA-112313 | 4 | 2 | 10285 | 29 |
SLC1A2,SLC1A3 |
4.590e-05 | -9.99 | Astrocytic Glutamate-Glutamine Uptake And Metabolism | REACTOME pathways | R-HSA-210455 | 4 | 2 | 10285 | 29 |
SLC1A3,SLC1A2 |
4.606e-05 | -9.99 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | 1263 | 13 | 16828 | 49 |
ATP13A4,NTRK2,RYR3,NEBL,NTM,CTNND2,ABLIM1,FMN2,TNIK,FGFR3,GPM6A,MACF1,TRPS1 |
4.606e-05 | -9.99 | plasma_cell_myeloma | COSMIC cancer mutations | plasma_cell_myeloma | 1263 | 13 | 16828 | 49 |
MACF1,FGFR3,ABLIM1,NTM,ATP13A4,TRPS1,GPM6A,TNIK,FMN2,CTNND2,NEBL,RYR3,NTRK2 |
4.882e-05 | -9.93 | neuron projection morphogenesis | biological process | GO:0048812 | 486 | 8 | 18204 | 50 |
TNIK,NRXN1,GPM6A,CTNNA2,BMPR1B,PTPRZ1,PREX2,CTNND2 |
4.916e-05 | -9.92 | Proximal tubule bicarbonate reclamation | KEGG pathways | ko04964 | 23 | 3 | 7161 | 23 |
ATP1A2,SLC4A4,GLUD1 |
4.916e-05 | -9.92 | Proximal tubule bicarbonate reclamation | KEGG pathways | hsa04964 | 23 | 3 | 7161 | 23 |
SLC4A4,ATP1A2,GLUD1 |
5.246e-05 | -9.86 | plasma membrane bounded cell projection morphogenesis | biological process | GO:0120039 | 491 | 8 | 18204 | 50 |
NRXN1,GPM6A,CTNNA2,TNIK,CTNND2,PREX2,PTPRZ1,BMPR1B |
5.396e-05 | -9.83 | scalp | COSMIC cancer mutations | scalp | 2110 | 17 | 16828 | 49 |
MACF1,SLC4A4,FGFR3,ATP1A2,NTM,LSAMP,ATP13A4,PREX2,PTPRZ1,TRPS1,GPC5,FMN2,NRXN1,RORA,SOX5,NEBL,NFIA |
5.634e-05 | -9.78 | cell projection morphogenesis | biological process | GO:0048858 | 496 | 8 | 18204 | 50 |
PREX2,PTPRZ1,CTNND2,BMPR1B,GPM6A,CTNNA2,NRXN1,TNIK |
6.856e-05 | -9.59 | high-affinity L-glutamate transmembrane transporter activity | molecular function | GO:0005314 | 5 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
6.856e-05 | -9.59 | glutamate:sodium symporter activity | molecular function | GO:0015501 | 5 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
7.355e-05 | -9.52 | D-aspartate import across plasma membrane | biological process | GO:0070779 | 5 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
7.355e-05 | -9.52 | D-aspartate transmembrane transport | biological process | GO:0070777 | 5 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
7.513e-05 | -9.50 | neurotransmitter uptake | biological process | GO:0001504 | 30 | 3 | 18204 | 50 |
SLC1A3,SLC1A2,ATP1A2 |
8.255e-05 | -9.40 | NTM (neurotrimin) | protein interactions | 50863 | 33 | 3 | 19454 | 50 |
LSAMP,GPM6A,NTM |
9.059e-05 | -9.31 | transport across blood-brain barrier | biological process | GO:0150104 | 86 | 4 | 18204 | 50 |
SLC4A4,ATP1A2,SLC1A3,SLC1A2 |
9.059e-05 | -9.31 | vascular transport | biological process | GO:0010232 | 86 | 4 | 18204 | 50 |
SLC1A3,SLC1A2,ATP1A2,SLC4A4 |
9.314e-05 | -9.28 | autonomic_ganglia-neuroblastoma | COSMIC cancer mutations | autonomic_ganglia-neuroblastoma | 3970 | 24 | 16828 | 49 |
FBXL7,MACF1,NFIA,SLC1A2,RYR3,NPAS3,PCDH9,PREX2,GLIS3,HIF3A,FGFR3,ATP1A2,PARD3B,PITPNC1,SLC4A4,NTRK2,NEBL,MAML2,TNIK,FMN2,CTNND2,TRPS1,GPM6A,PTPRZ1 |
9.354e-05 | -9.28 | neuroblastoma | COSMIC cancer mutations | neuroblastoma | 3971 | 24 | 16828 | 49 |
MACF1,FBXL7,NFIA,RYR3,SLC1A2,FGFR3,PARD3B,ATP1A2,SLC4A4,PITPNC1,NPAS3,PCDH9,PREX2,GLIS3,HIF3A,FMN2,TNIK,MAML2,CTNND2,PTPRZ1,GPM6A,TRPS1,NTRK2,NEBL |
1.004e-04 | -9.21 | response to auditory stimulus | biological process | GO:0010996 | 33 | 3 | 18204 | 50 |
NRXN1,SLC1A3,ATP1A2 |
1.064e-04 | -9.15 | Ryanodine_IP3_receptor | interpro domains | IPR015925 | 6 | 2 | 18521 | 50 |
RYR3,ITPR2 |
1.064e-04 | -9.15 | Ins145_P3_rcpt | interpro domains | IPR014821 | 6 | 2 | 18521 | 50 |
RYR3,ITPR2 |
1.064e-04 | -9.15 | RIH_dom | interpro domains | IPR000699 | 6 | 2 | 18521 | 50 |
ITPR2,RYR3 |
1.064e-04 | -9.15 | RyR/IP3R_RIH_dom_sf | interpro domains | IPR035910 | 6 | 2 | 18521 | 50 |
RYR3,ITPR2 |
1.064e-04 | -9.15 | RIH_assoc-dom | interpro domains | IPR013662 | 6 | 2 | 18521 | 50 |
ITPR2,RYR3 |
1.101e-04 | -9.11 | L-aspartate import across plasma membrane | biological process | GO:0140009 | 6 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
1.101e-04 | -9.11 | D-amino acid transport | biological process | GO:0042940 | 6 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
1.152e-04 | -9.07 | Ins145_P3_rec | pfam domains | PF08709 | 6 | 2 | 17795 | 50 |
RYR3,ITPR2 |
1.152e-04 | -9.07 | RYDR_ITPR | pfam domains | PF01365 | 6 | 2 | 17795 | 50 |
ITPR2,RYR3 |
1.152e-04 | -9.07 | RIH_assoc | pfam domains | PF08454 | 6 | 2 | 17795 | 50 |
ITPR2,RYR3 |
1.219e-04 | -9.01 | tibia | COSMIC cancer mutations | tibia | 836 | 10 | 16828 | 49 |
MACF1,GPM6A,ABLIM1,TNIK,FGFR3,CTNND2,CPE,LSAMP,NKAIN3,PREX2 |
1.329e-04 | -8.93 | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 22 | 16828 | 49 |
SLC1A3,CTNND2,TNIK,FMN2,GPC5,PTPRZ1,MSI2,NTRK2,CPE,PARD3B,PITPNC1,SLC4A4,PCDH9,PREX2,NPAS3,LSAMP,DTNA,BMPR1B,RYR3,LIFR,MACF1,FBXL7 |
1.329e-04 | -8.93 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 22 | 16828 | 49 |
NTRK2,MSI2,CPE,TNIK,GPC5,FMN2,CTNND2,SLC1A3,PTPRZ1,NPAS3,PCDH9,PREX2,LSAMP,PARD3B,PITPNC1,SLC4A4,DTNA,BMPR1B,RYR3,FBXL7,LIFR,MACF1 |
1.342e-04 | -8.92 | mouth | COSMIC cancer mutations | mouth | 9004 | 39 | 16828 | 49 |
NTRK2,RORA,NEBL,FMN2,GPC5,MAML2,TNIK,SLC1A3,CTNND2,PTPRZ1,GPM6A,TRPS1,CDH20,NPAS3,ZBTB20,CST3,PREX2,PCDH9,LSAMP,HIF3A,ABLIM1,FGFR3,PARD3B,ATP1A2,SLC4A4,PITPNC1,ITPR2,SFXN5,DTNA,SOX5,RYR3,SLC1A2,NRXN1,ATP13A4,FBXL7,NTM,NHSL1,MACF1,LIFR |
1.345e-04 | -8.91 | IP3 receptor type 1 binding core, RIH domain | gene3d domains | 1.25.10.30 | 6 | 2 | 14470 | 44 |
ITPR2,RYR3 |
1.374e-04 | -8.89 | C11orf52 (chromosome 11 open reading frame 52) | protein interactions | 91894 | 310 | 6 | 19454 | 50 |
AHCYL2,ABLIM1,DTNA,TNIK,FMN2,MACF1 |
1.378e-04 | -8.89 | monoatomic ion transmembrane transporter activity | molecular function | GO:0015075 | 752 | 9 | 18094 | 48 |
RYR3,GPM6A,SLC4A4,ITPR2,SLC1A3,ATP1A2,SLC1A2,ATP13A4,SFXN5 |
1.487e-04 | -8.81 | Na-dicarboxylate_symporter_CS | interpro domains | IPR018107 | 7 | 2 | 18521 | 50 |
SLC1A3,SLC1A2 |
1.487e-04 | -8.81 | Na:dicarbo_symporter_sf | interpro domains | IPR036458 | 7 | 2 | 18521 | 50 |
SLC1A2,SLC1A3 |
1.487e-04 | -8.81 | Na-dicarboxylate_symporter | interpro domains | IPR001991 | 7 | 2 | 18521 | 50 |
SLC1A3,SLC1A2 |
1.534e-04 | -8.78 | metal ion transmembrane transporter activity | molecular function | GO:0046873 | 442 | 7 | 18094 | 48 |
SLC1A3,RYR3,ATP1A2,ITPR2,SLC4A4,SLC1A2,GPM6A |
1.583e-04 | -8.75 | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | 1425 | 13 | 16828 | 49 |
PITPNC1,SLC4A4,SFXN5,FGFR3,ATP1A2,NHSL1,ATP13A4,PREX2,FMN2,CTNND2,SLC1A2,NFIA,NTRK2 |
1.583e-04 | -8.75 | nasopharyngeal_carcinoma | COSMIC cancer mutations | nasopharyngeal_carcinoma | 1425 | 13 | 16828 | 49 |
FMN2,CTNND2,SLC1A2,NTRK2,NFIA,SLC4A4,PITPNC1,SFXN5,FGFR3,NHSL1,ATP1A2,ATP13A4,PREX2 |
1.610e-04 | -8.73 | SDF | pfam domains | PF00375 | 7 | 2 | 17795 | 50 |
SLC1A2,SLC1A3 |
1.662e-04 | -8.70 | cellular response to alkaloid | biological process | GO:0071312 | 39 | 3 | 18204 | 50 |
SLC1A3,RYR3,SLC1A2 |
1.721e-04 | -8.67 | Salivary secretion | KEGG pathways | ko04970 | 90 | 4 | 7161 | 23 |
CST3,RYR3,ITPR2,ATP1A2 |
1.721e-04 | -8.67 | Salivary secretion | KEGG pathways | hsa04970 | 90 | 4 | 7161 | 23 |
CST3,RYR3,ITPR2,ATP1A2 |
1.810e-04 | -8.62 | lung-carcinoma-small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-small_cell_carcinoma | 9908 | 41 | 16828 | 49 |
NTRK2,MSI2,RORA,CPE,NEBL,GPC5,TNIK,FMN2,MAML2,CTNND2,GPM6A,PTPRZ1,TRPS1,CDH20,CST3,NPAS3,PREX2,PCDH9,HIF3A,ABLIM1,FGFR3,PARD3B,ATP1A2,SLC4A4,PITPNC1,ITPR2,NFIA,NKAIN3,DTNA,RYR3,SOX5,BMPR1B,NRXN1,FBXL7,ATP13A4,NTM,AHCYL2,GLUD1,SPARCL1,MACF1,LIFR |
1.838e-04 | -8.60 | small_cell_carcinoma | COSMIC cancer mutations | small_cell_carcinoma | 9913 | 41 | 16828 | 49 |
PTPRZ1,GPM6A,TRPS1,CDH20,FMN2,MAML2,GPC5,TNIK,CTNND2,RORA,CPE,NEBL,NTRK2,MSI2,SLC4A4,PITPNC1,ITPR2,ABLIM1,FGFR3,PARD3B,ATP1A2,HIF3A,NPAS3,CST3,PCDH9,PREX2,NRXN1,RYR3,SOX5,BMPR1B,NKAIN3,NFIA,DTNA,MACF1,LIFR,SPARCL1,NTM,AHCYL2,GLUD1,FBXL7,ATP13A4 |
1.841e-04 | -8.60 | beta-catenin binding | molecular function | GO:0008013 | 107 | 4 | 18094 | 48 |
RORA,CTNNA2,CDH20,CTNND2 |
1.874e-04 | -8.58 | bone-tibia-other-chondroblastoma | COSMIC cancer mutations | bone-tibia-other-chondroblastoma | 98 | 4 | 16828 | 49 |
NKAIN3,CTNND2,GPM6A,LSAMP |
1.879e-04 | -8.58 | Sodium:dicarboxylate symporter | gene3d domains | 1.10.3860.10 | 7 | 2 | 14470 | 44 |
SLC1A2,SLC1A3 |
1.949e-04 | -8.54 | cell morphogenesis involved in neuron differentiation | biological process | GO:0048667 | 443 | 7 | 18204 | 50 |
PTPRZ1,PREX2,CTNND2,BMPR1B,NRXN1,CTNNA2,SLC1A3 |
2.071e-04 | -8.48 | right_upper_lobe | COSMIC cancer mutations | right_upper_lobe | 10376 | 42 | 16828 | 49 |
BMPR1B,SLC1A2,RYR3,SOX5,DTNA,NKAIN3,NFIA,NRXN1,AHCYL2,NTM,FBXL7,ATP13A4,LIFR,MACF1,NEBL,CPE,RORA,NTRK2,CDH20,TRPS1,PTPRZ1,GPM6A,CTNND2,SLC1A3,TNIK,FMN2,GPC5,HIF3A,LSAMP,GLIS3,PCDH9,PREX2,NPAS3,ZBTB20,SFXN5,PITPNC1,ITPR2,SLC4A4,ATP1A2,PARD3B,FGFR3,ABLIM1 |
2.071e-04 | -8.48 | lung-right_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_upper_lobe-carcinoma-adenocarcinoma | 10376 | 42 | 16828 | 49 |
PITPNC1,ITPR2,SLC4A4,SFXN5,FGFR3,ABLIM1,ATP1A2,PARD3B,GLIS3,LSAMP,HIF3A,ZBTB20,NPAS3,PCDH9,PREX2,TRPS1,GPM6A,PTPRZ1,CDH20,GPC5,FMN2,TNIK,SLC1A3,CTNND2,CPE,RORA,NEBL,NTRK2,LIFR,MACF1,AHCYL2,NTM,FBXL7,ATP13A4,NRXN1,SLC1A2,BMPR1B,SOX5,RYR3,NKAIN3,NFIA,DTNA |
2.117e-04 | -8.46 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | 7307 | 34 | 16828 | 49 |
ATP13A4,FBXL7,AHCYL2,GLUD1,SPARCL1,NHSL1,MACF1,LIFR,NKAIN3,RYR3,SOX5,BMPR1B,SLC1A2,PCDH9,PREX2,LSAMP,GLIS3,ABLIM1,PARD3B,ITPR2,SFXN5,NTRK2,RORA,CPE,NEBL,MAML2,FMN2,TNIK,GPC5,CTNND2,SLC1A3,PTPRZ1,GPM6A,CDH20 |
2.152e-04 | -8.44 | Transport of inorganic cations/anions and amino acids/oligopeptides | REACTOME pathways | R-HSA-425393 | 107 | 4 | 10285 | 29 |
AHCYL2,SLC1A3,SLC1A2,SLC4A4 |
2.276e-04 | -8.39 | monoatomic cation transmembrane transporter activity | molecular function | GO:0008324 | 630 | 8 | 18094 | 48 |
GPM6A,SLC4A4,RYR3,SLC1A2,ATP13A4,ITPR2,SLC1A3,ATP1A2 |
2.300e-04 | -8.38 | cervix-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | cervix-carcinoma-squamous_cell_carcinoma | 11789 | 45 | 16828 | 49 |
SPARCL1,LIFR,FBXL7,DTNA,RYR3,BMPR1B,PARD3B,ATP1A2,FGFR3,SFXN5,SLC4A4,PITPNC1,CST3,ZBTB20,HIF3A,GLIS3,LSAMP,CTNND2,SLC1A3,FMN2,MAML2,GPC5,PTPRZ1,NEBL,NHSL1,MACF1,ATP13A4,GLUD1,NTM,NRXN1,NFIA,SOX5,SLC1A2,ABLIM1,ITPR2,PCDH9,PREX2,NPAS3,TNIK,CDH20,GPM6A,TRPS1,NTRK2,RORA,CPE |
2.304e-04 | -8.38 | LSAMP (limbic system associated membrane protein) | protein interactions | 4045 | 9 | 2 | 19454 | 50 |
NTM,LSAMP |
2.304e-04 | -8.38 | NEGR1 (neuronal growth regulator 1) | protein interactions | 257194 | 9 | 2 | 19454 | 50 |
LSAMP,NTM |
2.328e-04 | -8.37 | cervix | COSMIC cancer mutations | cervix | 11793 | 45 | 16828 | 49 |
ATP13A4,NTM,GLUD1,NHSL1,MACF1,NFIA,SLC1A2,SOX5,NRXN1,NPAS3,PREX2,PCDH9,ABLIM1,ITPR2,NTRK2,CPE,RORA,TNIK,TRPS1,GPM6A,CDH20,FBXL7,SPARCL1,LIFR,DTNA,BMPR1B,RYR3,ZBTB20,CST3,LSAMP,GLIS3,HIF3A,FGFR3,ATP1A2,PARD3B,PITPNC1,SLC4A4,SFXN5,NEBL,MAML2,GPC5,FMN2,SLC1A3,CTNND2,PTPRZ1 |
2.383e-04 | -8.34 | lung-right_lower_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_lower_lobe-carcinoma-adenocarcinoma | 5692 | 29 | 16828 | 49 |
DTNA,NKAIN3,SOX5,RYR3,ATP13A4,FBXL7,GLUD1,NTM,AHCYL2,MACF1,LIFR,NTRK2,NEBL,SLC1A3,CTNND2,GPC5,MAML2,FMN2,CDH20,GPM6A,PTPRZ1,TRPS1,CST3,NPAS3,LSAMP,PARD3B,ATP1A2,SLC4A4,ITPR2 |
2.383e-04 | -8.34 | right_lower_lobe | COSMIC cancer mutations | right_lower_lobe | 5692 | 29 | 16828 | 49 |
GLUD1,NTM,AHCYL2,FBXL7,ATP13A4,MACF1,LIFR,SOX5,RYR3,DTNA,NKAIN3,LSAMP,CST3,NPAS3,SLC4A4,ITPR2,PARD3B,ATP1A2,NEBL,NTRK2,CDH20,GPM6A,PTPRZ1,TRPS1,SLC1A3,CTNND2,FMN2,GPC5,MAML2 |
2.551e-04 | -8.27 | acidic amino acid transport | biological process | GO:0015800 | 45 | 3 | 18204 | 50 |
NTRK2,SLC1A2,SLC1A3 |
2.645e-04 | -8.24 | NA_DICARBOXYL_SYMP_2 | prosite domains | PS00714 | 7 | 2 | 12186 | 44 |
SLC1A3,SLC1A2 |
2.645e-04 | -8.24 | NA_DICARBOXYL_SYMP_1 | prosite domains | PS00713 | 7 | 2 | 12186 | 44 |
SLC1A2,SLC1A3 |
2.833e-04 | -8.17 | carcinoid-endocrine_tumour | COSMIC cancer mutations | carcinoid-endocrine_tumour | 7752 | 35 | 16828 | 49 |
SFXN5,ITPR2,SLC4A4,ATP1A2,FGFR3,ABLIM1,LSAMP,GLIS3,PCDH9,PREX2,CDH20,TRPS1,PTPRZ1,GPM6A,SLC1A3,CTNND2,MAML2,FMN2,TNIK,GPC5,NEBL,CPE,RORA,NTRK2,LIFR,MACF1,NHSL1,AHCYL2,ATP13A4,FBXL7,SLC1A2,BMPR1B,RYR3,SOX5,NKAIN3 |
3.003e-04 | -8.11 | monoatomic ion transmembrane transport | biological process | GO:0034220 | 804 | 9 | 18204 | 50 |
SLC1A2,SLC1A3,RYR3,ATP13A4,ITPR2,GPM6A,ATP1A2,SFXN5,SLC4A4 |
3.165e-04 | -8.06 | central nervous system development | biological process | GO:0007417 | 995 | 10 | 18204 | 50 |
SLC1A2,RORA,MSI2,PCDH9,CTNNA2,BMPR1B,GLUD1,NTRK2,ATP1A2,PTPRZ1 |
3.170e-04 | -8.06 | MIR_dom_sf | interpro domains | IPR036300 | 10 | 2 | 18521 | 50 |
RYR3,ITPR2 |
3.170e-04 | -8.06 | MIR_motif | interpro domains | IPR016093 | 10 | 2 | 18521 | 50 |
RYR3,ITPR2 |
3.281e-04 | -8.02 | neuronal action potential propagation | biological process | GO:0019227 | 10 | 2 | 18204 | 50 |
NTRK2,ATP1A2 |
3.281e-04 | -8.02 | action potential propagation | biological process | GO:0098870 | 10 | 2 | 18204 | 50 |
ATP1A2,NTRK2 |
3.281e-04 | -8.02 | cellular response to cocaine | biological process | GO:0071314 | 10 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
3.346e-04 | -8.00 | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_III | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_III | 114 | 4 | 16828 | 49 |
PREX2,RYR3,SOX5,SLC1A2 |
3.407e-04 | -7.98 | Bicarbonate transporters | REACTOME pathways | R-HSA-425381 | 10 | 2 | 10285 | 29 |
AHCYL2,SLC4A4 |
3.432e-04 | -7.98 | MIR | pfam domains | PF02815 | 10 | 2 | 17795 | 50 |
ITPR2,RYR3 |
3.766e-04 | -7.88 | soft_tissue | COSMIC cancer mutations | soft_tissue | 5828 | 29 | 16828 | 49 |
TRPS1,PTPRZ1,GPM6A,CDH20,FMN2,MAML2,GPC5,CTNND2,SLC1A3,RORA,NEBL,NTRK2,ITPR2,FGFR3,PARD3B,LSAMP,GLIS3,NPAS3,PREX2,PCDH9,SLC1A2,RYR3,SOX5,NFIA,NKAIN3,MACF1,SPARCL1,NHSL1,FBXL7 |
3.838e-04 | -7.87 | EDTRNSPORT | prints domains | PR00173 | 7 | 2 | 5227 | 23 |
SLC1A3,SLC1A2 |
4.003e-04 | -7.82 | L-aspartate transmembrane transport | biological process | GO:0070778 | 11 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
4.003e-04 | -7.82 | L-glutamate import across plasma membrane | biological process | GO:0098712 | 11 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
4.146e-04 | -7.79 | regulation of chondrocyte differentiation | biological process | GO:0032330 | 53 | 3 | 18204 | 50 |
BMPR1B,TRPS1,SOX5 |
4.404e-04 | -7.73 | Ig_I-set | interpro domains | IPR013098 | 132 | 4 | 18521 | 50 |
FGFR3,NTRK2,NTM,LSAMP |
4.466e-04 | -7.71 | neuron projection | cellular component | GO:0043005 | 1331 | 11 | 19108 | 49 |
CTNND2,SLC1A3,ATP1A2,PCDH9,CTNNA2,GPM6A,DTNA,SLC1A2,AHCYL2,NTRK2,BMPR1B |
4.673e-04 | -7.67 | skin-face-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-face-carcinoma-squamous_cell_carcinoma | 2036 | 15 | 16828 | 49 |
ITPR2,MACF1,FGFR3,ABLIM1,LSAMP,PREX2,PCDH9,TRPS1,PTPRZ1,GPM6A,FMN2,GPC5,NEBL,RORA,MSI2 |
4.698e-04 | -7.66 | amino acid transport | biological process | GO:0006865 | 132 | 4 | 18204 | 50 |
SFXN5,NTRK2,SLC1A3,SLC1A2 |
4.795e-04 | -7.64 | auditory behavior | biological process | GO:0031223 | 12 | 2 | 18204 | 50 |
SLC1A3,NRXN1 |
4.806e-04 | -7.64 | intestinal_adenocarcinoma | COSMIC cancer mutations | intestinal_adenocarcinoma | 7225 | 33 | 16828 | 49 |
LSAMP,ZBTB20,NPAS3,CST3,PREX2,PCDH9,PITPNC1,ITPR2,SLC4A4,SFXN5,FGFR3,ATP1A2,PARD3B,RORA,NEBL,NTRK2,TRPS1,PTPRZ1,CDH20,MAML2,FMN2,CTNND2,NTM,ATP13A4,FBXL7,LIFR,MACF1,NHSL1,SLC1A2,SOX5,RYR3,NFIA,NRXN1 |
4.806e-04 | -7.64 | stomach-carcinoma-intestinal_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-intestinal_adenocarcinoma | 7225 | 33 | 16828 | 49 |
NFIA,SLC1A2,RYR3,SOX5,NRXN1,ATP13A4,FBXL7,NTM,NHSL1,LIFR,MACF1,NTRK2,NEBL,RORA,CTNND2,FMN2,MAML2,CDH20,TRPS1,PTPRZ1,PCDH9,PREX2,NPAS3,ZBTB20,CST3,LSAMP,ATP1A2,PARD3B,FGFR3,SFXN5,PITPNC1,ITPR2,SLC4A4 |
5.053e-04 | -7.59 | Ion homeostasis | REACTOME pathways | R-HSA-5578775 | 56 | 3 | 10285 | 29 |
ATP1A2,ITPR2,RYR3 |
5.060e-04 | -7.59 | cell body | cellular component | GO:0044297 | 556 | 7 | 19108 | 49 |
GPM6A,CTNND2,SLC1A3,NRXN1,SLC1A2,ATP1A2,BMPR1B |
5.115e-04 | -7.58 | I-set | pfam domains | PF07679 | 132 | 4 | 17795 | 50 |
LSAMP,NTM,NTRK2,FGFR3 |
5.522e-04 | -7.50 | neuron projection development | biological process | GO:0031175 | 693 | 8 | 18204 | 50 |
PTPRZ1,PREX2,CTNND2,BMPR1B,NRXN1,GPM6A,CTNNA2,TNIK |
5.545e-04 | -7.50 | ductolobular_carcinoma | COSMIC cancer mutations | ductolobular_carcinoma | 1619 | 13 | 16828 | 49 |
FMN2,CTNND2,PTPRZ1,CDH20,DTNA,CPE,RORA,FGFR3,ABLIM1,PARD3B,LIFR,MACF1,PREX2 |
5.545e-04 | -7.50 | breast-carcinoma-ductolobular_carcinoma | COSMIC cancer mutations | breast-carcinoma-ductolobular_carcinoma | 1619 | 13 | 16828 | 49 |
PREX2,PARD3B,ABLIM1,FGFR3,MACF1,LIFR,DTNA,RORA,CPE,CTNND2,FMN2,CDH20,PTPRZ1 |
5.566e-04 | -7.49 | ovary-carcinoma-serous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-serous_carcinoma | 10710 | 42 | 16828 | 49 |
GLIS3,LSAMP,PCDH9,PREX2,CST3,ZBTB20,NPAS3,SFXN5,ITPR2,SLC4A4,ATP1A2,PARD3B,FGFR3,NEBL,CPE,RORA,MSI2,NTRK2,CDH20,TRPS1,PTPRZ1,SLC1A3,CTNND2,MAML2,FMN2,GPC5,TNIK,GLUD1,AHCYL2,NTM,FBXL7,ATP13A4,PTGDS,LIFR,MACF1,NHSL1,BMPR1B,SLC1A2,SOX5,RYR3,DTNA,NRXN1 |
5.629e-04 | -7.48 | MIR | prosite domains | PS50919 | 10 | 2 | 12186 | 44 |
ITPR2,RYR3 |
5.865e-04 | -7.44 | neurotransmitter transport | biological process | GO:0006836 | 140 | 4 | 18204 | 50 |
SLC1A3,SLC1A2,ATP1A2,NRXN1 |
6.145e-04 | -7.39 | L-glutamate transmembrane transporter activity | molecular function | GO:0005313 | 14 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
6.412e-04 | -7.35 | cell adhesion molecule binding | molecular function | GO:0050839 | 560 | 7 | 18094 | 48 |
PTPRZ1,NRXN1,CDH20,CPE,CTNNA2,MACF1,CTNND2 |
6.545e-04 | -7.33 | NAKATPASE | prints domains | PR00121 | 9 | 2 | 5227 | 23 |
ATP1A2,ATP13A4 |
6.588e-04 | -7.33 | mechanosensory behavior | biological process | GO:0007638 | 14 | 2 | 18204 | 50 |
SLC1A3,NRXN1 |
6.588e-04 | -7.33 | sodium ion export across plasma membrane | biological process | GO:0036376 | 14 | 2 | 18204 | 50 |
SLC4A4,ATP1A2 |
6.866e-04 | -7.28 | adult behavior | biological process | GO:0030534 | 146 | 4 | 18204 | 50 |
NRXN1,PREX2,ATP1A2,SLC1A2 |
6.932e-04 | -7.27 | cell projection | cellular component | GO:0042995 | 2398 | 15 | 19108 | 49 |
NTRK2,MACF1,CTNNA2,ATP1A2,PCDH9,CTNND2,FMN2,AHCYL2,SLC1A2,BMPR1B,ABLIM1,DTNA,GPM6A,SLC1A3,NRXN1 |
6.985e-04 | -7.27 | cell development | biological process | GO:0048468 | 2236 | 15 | 18204 | 50 |
CTNNA2,TNIK,NEBL,PTPRZ1,CTNND2,BMPR1B,NTRK2,MSI2,NRXN1,GPM6A,SLC1A3,RORA,PREX2,NTM,FMN2 |
7.220e-04 | -7.23 | dendrite morphogenesis | biological process | GO:0048813 | 64 | 3 | 18204 | 50 |
CTNNA2,PREX2,CTNND2 |
7.282e-04 | -7.22 | MIR | smart domains | SM00472 | 10 | 2 | 9717 | 40 |
ITPR2,RYR3 |
7.592e-04 | -7.18 | CNTNAP2 (contactin associated protein 2) | protein interactions | 26047 | 16 | 2 | 19454 | 50 |
MACF1,CPE |
7.721e-04 | -7.17 | active monoatomic ion transmembrane transporter activity | molecular function | GO:0022853 | 274 | 5 | 18094 | 48 |
SLC1A2,ATP13A4,SLC4A4,SLC1A3,ATP1A2 |
7.916e-04 | -7.14 | face | COSMIC cancer mutations | face | 2139 | 15 | 16828 | 49 |
PREX2,PCDH9,LSAMP,ABLIM1,FGFR3,MACF1,ITPR2,MSI2,NEBL,RORA,GPC5,FMN2,PTPRZ1,GPM6A,TRPS1 |
8.077e-04 | -7.12 | sodium ion transmembrane transporter activity | molecular function | GO:0015081 | 158 | 4 | 18094 | 48 |
SLC4A4,SLC1A2,ATP1A2,SLC1A3 |
8.086e-04 | -7.12 | human chr3q13.31 | chromosome location | human chr3q13.31 | 22 | 2 | 26134 | 50 |
ZBTB20,LSAMP |
8.516e-04 | -7.07 | spindle | COSMIC cancer mutations | spindle | 386 | 6 | 16828 | 49 |
MACF1,FGFR3,CTNND2,CPE,PREX2,PCDH9 |
8.632e-04 | -7.05 | inorganic cation transmembrane transporter activity | molecular function | GO:0022890 | 589 | 7 | 18094 | 48 |
GPM6A,SLC1A2,SLC4A4,ATP1A2,SLC1A3,ITPR2,RYR3 |
8.795e-04 | -7.04 | retina development in camera-type eye | biological process | GO:0060041 | 156 | 4 | 18204 | 50 |
GPM6A,NFIA,NTRK2,BMPR1B |
8.890e-04 | -7.03 | cellular response to endogenous stimulus | biological process | GO:0071495 | 1135 | 10 | 18204 | 50 |
RYR3,SLC1A3,SLC1A2,NFIA,ITPR2,BMPR1B,SOX5,NTRK2,ATP1A2,FGFR3 |
9.444e-04 | -6.96 | cell adhesion | biological process | GO:0007155 | 942 | 9 | 18204 | 50 |
NTM,CTNND2,CDH20,LSAMP,SPARCL1,CTNNA2,PCDH9,PARD3B,NRXN1 |
9.763e-04 | -6.93 | oligoastrocytoma_Grade_III | COSMIC cancer mutations | oligoastrocytoma_Grade_III | 263 | 5 | 16828 | 49 |
SLC1A2,SOX5,RYR3,FGFR3,PREX2 |
1.022e-03 | -6.89 | Htt (huntingtin) | protein interactions | 15194 | 77 | 3 | 19454 | 50 |
LSAMP,NTM,GPM6A |
1.026e-03 | -6.88 | acidic amino acid transmembrane transporter activity | molecular function | GO:0015172 | 18 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
1.026e-03 | -6.88 | intracellularly gated calcium channel activity | molecular function | GO:0015278 | 18 | 2 | 18094 | 48 |
ITPR2,RYR3 |
1.030e-03 | -6.88 | FLOT1 (flotillin 1) | protein interactions | 10211 | 453 | 6 | 19454 | 50 |
FMN2,MACF1,SOX5,ABLIM1,DTNA,GLUD1 |
1.043e-03 | -6.87 | synapse | cellular component | GO:0045202 | 1473 | 11 | 19108 | 49 |
SPARCL1,TNIK,GPM6A,DTNA,NTRK2,SLC1A2,NRXN1,SLC1A3,CTNND2,PTPRZ1,ATP1A2 |
1.059e-03 | -6.85 | regulation of cartilage development | biological process | GO:0061035 | 73 | 3 | 18204 | 50 |
SOX5,TRPS1,BMPR1B |
1.063e-03 | -6.85 | ATPase_P-typ_cation-transptr_N | interpro domains | IPR004014 | 18 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
1.066e-03 | -6.84 | lung-left_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-left_upper_lobe-carcinoma-adenocarcinoma | 556 | 7 | 16828 | 49 |
RYR3,SLC4A4,LIFR,TRPS1,CTNND2,FBXL7,NTRK2 |
1.089e-03 | -6.82 | left_upper_lobe | COSMIC cancer mutations | left_upper_lobe | 558 | 7 | 16828 | 49 |
RYR3,FBXL7,NTRK2,TRPS1,LIFR,SLC4A4,CTNND2 |
1.096e-03 | -6.82 | transporter activity | molecular function | GO:0005215 | 1211 | 10 | 18094 | 48 |
PITPNC1,ITPR2,ATP1A2,SLC1A3,SFXN5,ATP13A4,SLC1A2,RYR3,SLC4A4,GPM6A |
1.112e-03 | -6.80 | monoatomic ion transport | biological process | GO:0006811 | 964 | 9 | 18204 | 50 |
ATP13A4,SLC1A3,RYR3,SLC1A2,ITPR2,GPM6A,SFXN5,ATP1A2,SLC4A4 |
1.150e-03 | -6.77 | Cation_ATPase_N | pfam domains | PF00690 | 18 | 2 | 17795 | 50 |
ATP13A4,ATP1A2 |
1.179e-03 | -6.74 | RHOB (ras homolog family member B) | protein interactions | 388 | 832 | 8 | 19454 | 50 |
AHCYL2,ABLIM1,DTNA,TNIK,SLC1A3,FMN2,MACF1,PARD3B |
1.186e-03 | -6.74 | PAS_fold | interpro domains | IPR013767 | 19 | 2 | 18521 | 50 |
HIF3A,NPAS3 |
1.209e-03 | -6.72 | serous_carcinoma | COSMIC cancer mutations | serous_carcinoma | 10987 | 42 | 16828 | 49 |
MACF1,LIFR,NHSL1,NTM,AHCYL2,GLUD1,PTGDS,ATP13A4,FBXL7,NRXN1,RYR3,SOX5,BMPR1B,SLC1A2,DTNA,SLC4A4,ITPR2,SFXN5,FGFR3,PARD3B,ATP1A2,GLIS3,LSAMP,NPAS3,CST3,ZBTB20,PREX2,PCDH9,PTPRZ1,TRPS1,CDH20,FMN2,GPC5,MAML2,TNIK,SLC1A3,CTNND2,RORA,CPE,NEBL,NTRK2,MSI2 |
1.226e-03 | -6.70 | GSC (goosecoid homeobox) | protein interactions | 145258 | 82 | 3 | 19454 | 50 |
SOX5,NFIA,TRPS1 |
1.227e-03 | -6.70 | cartilage condensation | biological process | GO:0001502 | 19 | 2 | 18204 | 50 |
BMPR1B,SOX5 |
1.235e-03 | -6.70 | response to endogenous stimulus | biological process | GO:0009719 | 1402 | 11 | 18204 | 50 |
NFIA,ITPR2,PTGDS,RYR3,SLC1A3,SLC1A2,FGFR3,BMPR1B,SOX5,ATP1A2,NTRK2 |
1.247e-03 | -6.69 | solute:sodium symporter activity | molecular function | GO:0015370 | 80 | 3 | 18094 | 48 |
SLC1A3,SLC4A4,SLC1A2 |
1.283e-03 | -6.66 | dicarboxylic acid transport | biological process | GO:0006835 | 78 | 3 | 18204 | 50 |
SLC1A2,SLC1A3,NTRK2 |
1.283e-03 | -6.66 | PAS | pfam domains | PF00989 | 19 | 2 | 17795 | 50 |
HIF3A,NPAS3 |
1.290e-03 | -6.65 | cartilage development | biological process | GO:0051216 | 173 | 4 | 18204 | 50 |
BMPR1B,SOX5,NFIA,FGFR3 |
1.293e-03 | -6.65 | transmembrane receptor protein kinase activity | molecular function | GO:0019199 | 81 | 3 | 18094 | 48 |
NTRK2,BMPR1B,FGFR3 |
1.314e-03 | -6.63 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 748 | 8 | 16828 | 49 |
ITPR2,TRPS1,SLC1A3,CTNND2,SOX5,NEBL,NTRK2,DTNA |
1.332e-03 | -6.62 | mucosal | COSMIC cancer mutations | mucosal | 2009 | 14 | 16828 | 49 |
LIFR,ABLIM1,SPARCL1,FGFR3,ATP1A2,PREX2,ATP13A4,PCDH9,FMN2,CTNND2,RORA,CPE,NEBL,BMPR1B |
1.332e-03 | -6.62 | skin-mucosal-malignant_melanoma | COSMIC cancer mutations | skin-mucosal-malignant_melanoma | 2009 | 14 | 16828 | 49 |
PREX2,ATP13A4,PCDH9,LIFR,ATP1A2,SPARCL1,ABLIM1,FGFR3,NEBL,BMPR1B,RORA,CPE,CTNND2,FMN2 |
1.357e-03 | -6.60 | plasma membrane bounded cell projection | cellular component | GO:0120025 | 2285 | 14 | 19108 | 49 |
ATP1A2,PCDH9,CTNND2,NTRK2,MACF1,CTNNA2,SLC1A3,FMN2,SLC1A2,AHCYL2,BMPR1B,ABLIM1,GPM6A,DTNA |
1.361e-03 | -6.60 | adherens junction | cellular component | GO:0005912 | 188 | 4 | 19108 | 49 |
CTNND2,CTNNA2,CDH20,PARD3B |
1.361e-03 | -6.60 | positive regulation of chondrocyte differentiation | biological process | GO:0032332 | 20 | 2 | 18204 | 50 |
BMPR1B,SOX5 |
1.361e-03 | -6.60 | aspartate transmembrane transport | biological process | GO:0015810 | 20 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
1.398e-03 | -6.57 | pancreas-carcinoid-endocrine_tumour | COSMIC cancer mutations | pancreas-carcinoid-endocrine_tumour | 7250 | 32 | 16828 | 49 |
NKAIN3,SLC1A2,BMPR1B,SOX5,RYR3,FBXL7,ATP13A4,AHCYL2,NHSL1,LIFR,MACF1,NTRK2,NEBL,CPE,RORA,SLC1A3,CTNND2,GPC5,MAML2,FMN2,CDH20,GPM6A,PCDH9,PREX2,LSAMP,GLIS3,ATP1A2,FGFR3,ABLIM1,SFXN5,ITPR2,SLC4A4 |
1.425e-03 | -6.55 | behavior | biological process | GO:0007610 | 619 | 7 | 18204 | 50 |
NRXN1,SLC1A2,SLC1A3,PTPRZ1,PREX2,ATP1A2,NTRK2 |
1.439e-03 | -6.54 | thyroid-carcinoma | COSMIC cancer mutations | thyroid-carcinoma | 4126 | 22 | 16828 | 49 |
CTNND2,NRXN1,TNIK,GPC5,PTPRZ1,TRPS1,DTNA,NFIA,SOX5,RYR3,CPE,ATP1A2,SPARCL1,FGFR3,MACF1,ITPR2,LIFR,ATP13A4,PCDH9,HIF3A,GLIS3,LSAMP |
1.499e-03 | -6.50 | neuronal cell body | cellular component | GO:0043025 | 489 | 6 | 19108 | 49 |
NRXN1,GPM6A,SLC1A3,CTNND2,BMPR1B,ATP1A2 |
1.502e-03 | -6.50 | positive regulation of glycolytic process | biological process | GO:0045821 | 21 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
1.502e-03 | -6.50 | positive regulation of nucleotide catabolic process | biological process | GO:0030813 | 21 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
1.502e-03 | -6.50 | cell aggregation | biological process | GO:0098743 | 21 | 2 | 18204 | 50 |
BMPR1B,SOX5 |
1.502e-03 | -6.50 | positive regulation of purine nucleotide catabolic process | biological process | GO:0033123 | 21 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
1.563e-03 | -6.46 | haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_neoplasm | 11082 | 42 | 16828 | 49 |
DTNA,NFIA,NKAIN3,BMPR1B,SLC1A2,RYR3,SOX5,NRXN1,ATP13A4,FBXL7,AHCYL2,NTM,NHSL1,SPARCL1,LIFR,MACF1,MSI2,NTRK2,NEBL,CPE,RORA,CTNND2,SLC1A3,FMN2,TNIK,GPC5,MAML2,CDH20,PTPRZ1,PREX2,PCDH9,NPAS3,HIF3A,GLIS3,LSAMP,ATP1A2,PARD3B,FGFR3,ABLIM1,SFXN5,ITPR2,SLC4A4 |
1.594e-03 | -6.44 | DEP_dom | interpro domains | IPR000591 | 22 | 2 | 18521 | 50 |
FMN2,PREX2 |
1.620e-03 | -6.43 | OCLN (occludin) | protein interactions | 100506658 | 495 | 6 | 19454 | 50 |
TNIK,ABLIM1,DTNA,FMN2,MACF1,NTRK2 |
1.632e-03 | -6.42 | cellular response to organic cyclic compound | biological process | GO:0071407 | 464 | 6 | 18204 | 50 |
ITPR2,SLC1A2,RYR3,SLC1A3,RORA,ATP1A2 |
1.644e-03 | -6.41 | chondrocyte differentiation | biological process | GO:0002062 | 85 | 3 | 18204 | 50 |
FGFR3,SOX5,BMPR1B |
1.649e-03 | -6.41 | intracellular sodium ion homeostasis | biological process | GO:0006883 | 22 | 2 | 18204 | 50 |
SLC1A3,ATP1A2 |
1.664e-03 | -6.40 | monoatomic cation transmembrane transport | biological process | GO:0098655 | 636 | 7 | 18204 | 50 |
ATP13A4,RYR3,SLC1A3,GPM6A,ITPR2,ATP1A2,SLC4A4 |
1.683e-03 | -6.39 | amino acid:sodium symporter activity | molecular function | GO:0005283 | 23 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
1.689e-03 | -6.38 | skin-scalp-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-squamous_cell_carcinoma | 1596 | 12 | 16828 | 49 |
PTPRZ1,TRPS1,NRXN1,GPC5,SOX5,RORA,SLC4A4,MACF1,ATP1A2,FGFR3,LSAMP,ATP13A4 |
1.714e-03 | -6.37 | leg | COSMIC cancer mutations | leg | 969 | 9 | 16828 | 49 |
ATP13A4,ZBTB20,NEBL,HIF3A,NTM,FGFR3,FMN2,PTPRZ1,SLC4A4 |
1.757e-03 | -6.34 | TIAM1 (TIAM Rac1 associated GEF 1) | protein interactions | 7074 | 201 | 4 | 19454 | 50 |
DTNA,GLUD1,RYR3,ATP1A2 |
1.832e-03 | -6.30 | P-type ion transporter activity | molecular function | GO:0015662 | 24 | 2 | 18094 | 48 |
ATP1A2,ATP13A4 |
1.832e-03 | -6.30 | P-type transmembrane transporter activity | molecular function | GO:0140358 | 24 | 2 | 18094 | 48 |
ATP1A2,ATP13A4 |
1.848e-03 | -6.29 | cell surface | cellular component | GO:0009986 | 896 | 8 | 19108 | 49 |
FGFR3,GPC5,SLC1A2,SLC4A4,NRXN1,SLC1A3,LIFR,ATP1A2 |
1.854e-03 | -6.29 | CASK (calcium/calmodulin dependent serine protein kinase) | protein interactions | 8573 | 204 | 4 | 19454 | 50 |
NRXN1,PARD3B,ABLIM1,DTNA |
1.911e-03 | -6.26 | cell-cell junction | cellular component | GO:0005911 | 513 | 6 | 19108 | 49 |
ATP1A2,CDH20,PARD3B,PCDH9,CTNND2,CTNNA2 |
1.912e-03 | -6.26 | Cation_ATPase_N | smart domains | SM00831 | 16 | 2 | 9717 | 40 |
ATP1A2,ATP13A4 |
1.913e-03 | -6.26 | human chr3q26.2-q26.31 | chromosome location | human chr3q26.2-q26.31 | 1 | 1 | 26134 | 50 |
TNIK |
1.913e-03 | -6.26 | human chr15q13.3-q14 | chromosome location | human chr15q13.3-q14 | 1 | 1 | 26134 | 50 |
RYR3 |
2.021e-03 | -6.20 | skin-face-malignant_melanoma-lentigo_maligna | COSMIC cancer mutations | skin-face-malignant_melanoma-lentigo_maligna | 23 | 2 | 16828 | 49 |
PREX2,FGFR3 |
2.023e-03 | -6.20 | NRCAM (neuronal cell adhesion molecule) | protein interactions | 4897 | 26 | 2 | 19454 | 50 |
GLUD1,MACF1 |
2.039e-03 | -6.20 | Glutamate Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-210500 | 24 | 2 | 10285 | 29 |
SLC1A2,SLC1A3 |
2.041e-03 | -6.19 | export from cell | biological process | GO:0140352 | 485 | 6 | 18204 | 50 |
SLC4A4,NRXN1,NTRK2,ATP1A2,CPE,PTGDS |
2.130e-03 | -6.15 | L-glutamate transmembrane transport | biological process | GO:0015813 | 25 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
2.146e-03 | -6.14 | synapse organization | biological process | GO:0050808 | 333 | 5 | 18204 | 50 |
GPM6A,NFIA,SPARCL1,CTNND2,NRXN1 |
2.152e-03 | -6.14 | extrinsic component of plasma membrane | cellular component | GO:0019897 | 100 | 3 | 19108 | 49 |
CDH20,DTNA,CTNNA2 |
2.181e-03 | -6.13 | KCNJ12 (potassium inwardly rectifying channel subfamily J member 12) | protein interactions | 3768 | 27 | 2 | 19454 | 50 |
DTNA,ABLIM1 |
2.185e-03 | -6.13 | LYN (LYN proto-oncogene, Src family tyrosine kinase) | protein interactions | 4067 | 713 | 7 | 19454 | 50 |
MACF1,ABLIM1,DTNA,TNIK,SLC1A3,MSI2,FMN2 |
2.196e-03 | -6.12 | adenoma | COSMIC cancer mutations | adenoma | 2873 | 17 | 16828 | 49 |
HIF3A,PCDH9,NPAS3,ZBTB20,MACF1,LIFR,FGFR3,SOX5,RYR3,BMPR1B,NEBL,NTRK2,CDH20,GPM6A,PTPRZ1,CTNND2,GPC5 |
2.200e-03 | -6.12 | EZR (ezrin) | protein interactions | 7430 | 526 | 6 | 19454 | 50 |
MACF1,TNIK,DTNA,AHCYL2,ABLIM1,NEBL |
2.259e-03 | -6.09 | Transmembrane transport of small molecules | REACTOME pathways | R-HSA-382551 | 677 | 7 | 10285 | 29 |
ATP1A2,RYR3,SLC1A3,SLC1A2,ATP13A4,SLC4A4,AHCYL2 |
2.282e-03 | -6.08 | transmembrane transporter activity | molecular function | GO:0022857 | 1110 | 9 | 18094 | 48 |
RYR3,SLC4A4,GPM6A,ITPR2,SLC1A3,ATP1A2,SFXN5,ATP13A4,SLC1A2 |
2.302e-03 | -6.07 | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 7434 | 32 | 16828 | 49 |
SPARCL1,LIFR,MACF1,PTGDS,ATP13A4,NRXN1,NKAIN3,DTNA,SOX5,RYR3,FGFR3,ABLIM1,ATP1A2,PARD3B,ITPR2,SLC4A4,ZBTB20,NPAS3,CST3,PREX2,GLIS3,HIF3A,TNIK,MAML2,FMN2,CTNND2,SLC1A3,TRPS1,PTPRZ1,NTRK2,RORA,NEBL |
2.304e-03 | -6.07 | C4-dicarboxylate transport | biological process | GO:0015740 | 26 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
2.341e-03 | -6.06 | actin filament binding | molecular function | GO:0051015 | 211 | 4 | 18094 | 48 |
CTNNA2,ABLIM1,MACF1,NEBL |
2.414e-03 | -6.03 | hairy_cell_leukaemia | COSMIC cancer mutations | hairy_cell_leukaemia | 1440 | 11 | 16828 | 49 |
RYR3,NEBL,PREX2,CDH20,PTPRZ1,MACF1,LIFR,CTNND2,NRXN1,FGFR3,FMN2 |
2.414e-03 | -6.03 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-hairy_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-hairy_cell_leukaemia | 1440 | 11 | 16828 | 49 |
RYR3,NEBL,PREX2,CDH20,MACF1,PTPRZ1,LIFR,CTNND2,NRXN1,FMN2,FGFR3 |
2.455e-03 | -6.01 | NTRK3 (neurotrophic receptor tyrosine kinase 3) | protein interactions | 4916 | 367 | 5 | 19454 | 50 |
TNIK,GLUD1,AHCYL2,ABLIM1,NTRK2 |
2.504e-03 | -5.99 | skin-trunk-malignant_melanoma | COSMIC cancer mutations | skin-trunk-malignant_melanoma | 2647 | 16 | 16828 | 49 |
ATP1A2,LIFR,ATP13A4,PCDH9,PREX2,LSAMP,NRXN1,SLC1A3,CTNND2,MAML2,CDH20,TRPS1,PTPRZ1,NEBL,RYR3,SOX5 |
2.512e-03 | -5.99 | cell differentiation | biological process | GO:0030154 | 3645 | 19 | 18204 | 50 |
CTNNA2,NFIA,NHSL1,TNIK,FGFR3,CTNND2,NEBL,PTPRZ1,NTRK2,SOX5,BMPR1B,GPM6A,NRXN1,MSI2,RORA,SLC1A3,FMN2,NTM,PREX2 |
2.537e-03 | -5.98 | cellular developmental process | biological process | GO:0048869 | 3648 | 19 | 18204 | 50 |
SLC1A3,RORA,MSI2,NRXN1,GPM6A,PREX2,NTM,FMN2,TNIK,NHSL1,NFIA,CTNNA2,BMPR1B,SOX5,NTRK2,PTPRZ1,NEBL,CTNND2,FGFR3 |
2.570e-03 | -5.96 | fgf3.L (fibroblast growth factor 3 L homeolog) | protein interactions | 373669 | 1 | 1 | 19454 | 50 |
FGFR3 |
2.570e-03 | -5.96 | Agtrap (angiotensin II, type I receptor-associated protein) | protein interactions | 11610 | 1 | 1 | 19454 | 50 |
PITPNC1 |
2.570e-03 | -5.96 | Sytl1 (synaptotagmin-like 1) | protein interactions | 269589 | 1 | 1 | 19454 | 50 |
NRXN1 |
2.570e-03 | -5.96 | 1700006A11Rik (RIKEN cDNA 1700006A11 gene) | protein interactions | 71824 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.570e-03 | -5.96 | Bdnf (brain derived neurotrophic factor) | protein interactions | 12064 | 1 | 1 | 19454 | 50 |
NTRK2 |
2.570e-03 | -5.96 | Hipk3 (homeodomain interacting protein kinase 3) | protein interactions | 15259 | 1 | 1 | 19454 | 50 |
GLIS3 |
2.570e-03 | -5.96 | Dcaf7 (DDB1 and CUL4 associated factor 7) | protein interactions | 71833 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.570e-03 | -5.96 | Sh2b1 (SH2B adaptor protein 1) | protein interactions | 20399 | 1 | 1 | 19454 | 50 |
FGFR3 |
2.570e-03 | -5.96 | Lztr1 (leucine-zipper-like transcriptional regulator, 1) | protein interactions | 66863 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.570e-03 | -5.96 | Isl1 (ISL1 transcription factor, LIM/homeodomain) | protein interactions | 16392 | 1 | 1 | 19454 | 50 |
GLIS3 |
2.570e-03 | -5.96 | Dynlt1 (dynein light chain Tctex-type 1) | protein interactions | 83462 | 1 | 1 | 19454 | 50 |
NTRK2 |
2.593e-03 | -5.95 | Calcium-transporting ATPase, transmembrane domain | gene3d domains | 1.20.1110.10 | 25 | 2 | 14470 | 44 |
ATP1A2,ATP13A4 |
2.602e-03 | -5.95 | inorganic molecular entity transmembrane transporter activity | molecular function | GO:0015318 | 714 | 7 | 18094 | 48 |
ITPR2,SLC1A3,RYR3,ATP1A2,SLC4A4,GPM6A,SLC1A2 |
2.614e-03 | -5.95 | response to alkaloid | biological process | GO:0043279 | 100 | 3 | 18204 | 50 |
SLC1A3,SLC1A2,RYR3 |
2.645e-03 | -5.93 | KLF3 (KLF transcription factor 3) | protein interactions | 51274 | 225 | 4 | 19454 | 50 |
TRPS1,NFIA,GLUD1,SOX5 |
2.653e-03 | -5.93 | brain-derived neurotrophic factor receptor activity | molecular function | GO:0060175 | 1 | 1 | 18094 | 48 |
NTRK2 |
2.673e-03 | -5.92 | ligand-gated calcium channel activity | molecular function | GO:0099604 | 29 | 2 | 18094 | 48 |
ITPR2,RYR3 |
2.673e-03 | -5.92 | amino acid:monoatomic cation symporter activity | molecular function | GO:0005416 | 29 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
2.698e-03 | -5.92 | EN1 (engrailed homeobox 1) | protein interactions | 2019 | 108 | 3 | 19454 | 50 |
TRPS1,NFIA,AHCYL2 |
2.700e-03 | -5.91 | Rex2_DEP_1 | interpro domains | IPR037367 | 1 | 1 | 18521 | 50 |
PREX2 |
2.700e-03 | -5.91 | NTRK2 | interpro domains | IPR020455 | 1 | 1 | 18521 | 50 |
NTRK2 |
2.700e-03 | -5.91 | M14_CPE_CPD | interpro domains | IPR034232 | 1 | 1 | 18521 | 50 |
CPE |
2.700e-03 | -5.91 | LIFR_N | interpro domains | IPR040901 | 1 | 1 | 18521 | 50 |
LIFR |
2.700e-03 | -5.91 | Nebulette_SH3 | interpro domains | IPR035631 | 1 | 1 | 18521 | 50 |
NEBL |
2.700e-03 | -5.91 | TRPS1 | interpro domains | IPR028440 | 1 | 1 | 18521 | 50 |
TRPS1 |
2.700e-03 | -5.91 | SPARC-like_p1 | interpro domains | IPR016359 | 1 | 1 | 18521 | 50 |
SPARCL1 |
2.700e-03 | -5.91 | MAML2_TAD | interpro domains | IPR048452 | 1 | 1 | 18521 | 50 |
MAML2 |
2.709e-03 | -5.91 | large_intestine-caecum-carcinoma-adenocarcinoma | COSMIC cancer mutations | large_intestine-caecum-carcinoma-adenocarcinoma | 14236 | 48 | 16828 | 49 |
ATP13A4,GLUD1,NTM,NHSL1,MACF1,NKAIN3,NFIA,SLC1A2,SOX5,NRXN1,PCDH9,PREX2,NPAS3,ABLIM1,ITPR2,NTRK2,CPE,RORA,TNIK,CDH20,TRPS1,GPM6A,FBXL7,PTGDS,AHCYL2,SPARCL1,LIFR,DTNA,BMPR1B,RYR3,CST3,ZBTB20,HIF3A,LSAMP,GLIS3,ATP1A2,PARD3B,FGFR3,SFXN5,PITPNC1,SLC4A4,NEBL,CTNND2,SLC1A3,GPC5,MAML2,FMN2,PTPRZ1 |
2.747e-03 | -5.90 | negative regulation of elastin catabolic process | biological process | GO:0060311 | 1 | 1 | 18204 | 50 |
CST3 |
2.747e-03 | -5.90 | negative regulation of collagen catabolic process | biological process | GO:0010711 | 1 | 1 | 18204 | 50 |
CST3 |
2.747e-03 | -5.90 | trans-synaptic signaling by neuropeptide | biological process | GO:0099540 | 1 | 1 | 18204 | 50 |
NTRK2 |
2.747e-03 | -5.90 | trans-synaptic signaling by neuropeptide, modulating synaptic transmission | biological process | GO:0099551 | 1 | 1 | 18204 | 50 |
NTRK2 |
2.747e-03 | -5.90 | negative regulation of calcium:sodium antiporter activity | biological process | GO:1903280 | 1 | 1 | 18204 | 50 |
ATP1A2 |
2.747e-03 | -5.90 | olfactory cortex development | biological process | GO:0021989 | 1 | 1 | 18204 | 50 |
ATP1A2 |
2.747e-03 | -5.90 | homologous chromosome movement towards spindle pole in meiosis I anaphase | biological process | GO:0051758 | 1 | 1 | 18204 | 50 |
FMN2 |
2.809e-03 | -5.87 | caecum | COSMIC cancer mutations | caecum | 14248 | 48 | 16828 | 49 |
NPAS3,PCDH9,PREX2,ABLIM1,ITPR2,NTRK2,RORA,CPE,TNIK,GPM6A,TRPS1,CDH20,ATP13A4,NTM,GLUD1,NHSL1,MACF1,NKAIN3,NFIA,SOX5,SLC1A2,NRXN1,CST3,ZBTB20,GLIS3,LSAMP,HIF3A,FGFR3,PARD3B,ATP1A2,SLC4A4,PITPNC1,SFXN5,NEBL,GPC5,MAML2,FMN2,SLC1A3,CTNND2,PTPRZ1,PTGDS,FBXL7,AHCYL2,SPARCL1,LIFR,DTNA,RYR3,BMPR1B |
2.810e-03 | -5.87 | FGFR3_TM | pfam domains | PF21165 | 1 | 1 | 17795 | 50 |
FGFR3 |
2.810e-03 | -5.87 | MAML2_TAD | pfam domains | PF20804 | 1 | 1 | 17795 | 50 |
MAML2 |
2.810e-03 | -5.87 | LIFR_N | pfam domains | PF18207 | 1 | 1 | 17795 | 50 |
LIFR |
2.820e-03 | -5.87 | t(4;14) translocations of FGFR3 | REACTOME pathways | R-HSA-2033515 | 1 | 1 | 10285 | 29 |
FGFR3 |
2.857e-03 | -5.86 | catenin complex | cellular component | GO:0016342 | 31 | 2 | 19108 | 49 |
CDH20,CTNNA2 |
2.862e-03 | -5.86 | ACTB (actin beta) | protein interactions | 60 | 958 | 8 | 19454 | 50 |
ABLIM1,AHCYL2,DTNA,FMN2,NEBL,NHSL1,MACF1,SFXN5 |
2.870e-03 | -5.85 | SH2B1 (SH2B adaptor protein 1) | protein interactions | 25970 | 31 | 2 | 19454 | 50 |
FGFR3,NTRK2 |
2.991e-03 | -5.81 | TBR1 (T-box brain transcription factor 1) | protein interactions | 10716 | 112 | 3 | 19454 | 50 |
TRPS1,SOX5,NFIA |
3.002e-03 | -5.81 | neural precursor cell proliferation | biological process | GO:0061351 | 105 | 3 | 18204 | 50 |
SOX5,RORA,NFIA |
3.041e-03 | -5.80 | - | gene3d domains | 6.10.250.1740 | 1 | 1 | 14470 | 44 |
FGFR3 |
3.051e-03 | -5.79 | intracellularly ligand-gated monoatomic ion channel activity | molecular function | GO:0005217 | 31 | 2 | 18094 | 48 |
RYR3,ITPR2 |
3.057e-03 | -5.79 | NXPH2 (neurexophilin 2) | protein interactions | 11249 | 32 | 2 | 19454 | 50 |
PCDH9,NRXN1 |
3.062e-03 | -5.79 | L-glutamate import | biological process | GO:0051938 | 30 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
3.072e-03 | -5.79 | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | 1485 | 11 | 16828 | 49 |
PTPRZ1,MACF1,PARD3B,FGFR3,GPC5,FMN2,RYR3,PREX2,DTNA,PCDH9,NPAS3 |
3.104e-03 | -5.78 | upper_aerodigestive_tract | COSMIC cancer mutations | upper_aerodigestive_tract | 13181 | 46 | 16828 | 49 |
DTNA,RYR3,BMPR1B,LIFR,FBXL7,PTGDS,AHCYL2,SLC1A3,CTNND2,MAML2,FMN2,GPC5,PTPRZ1,MSI2,NEBL,PARD3B,ATP1A2,FGFR3,SFXN5,SLC4A4,PITPNC1,CST3,ZBTB20,HIF3A,GLIS3,LSAMP,NRXN1,NKAIN3,NFIA,SOX5,SLC1A2,NHSL1,MACF1,ATP13A4,NTM,TNIK,CDH20,GPM6A,TRPS1,NTRK2,RORA,ABLIM1,ITPR2,PREX2,PCDH9,NPAS3 |
3.144e-03 | -5.76 | ORF3b (ORF3b protein) | protein interactions | 1489670 | 114 | 3 | 19454 | 50 |
MACF1,PCDH9,ZBTB20 |
3.234e-03 | -5.73 | cell junction organization | biological process | GO:0034330 | 532 | 6 | 18204 | 50 |
CDH20,CTNND2,SPARCL1,GPM6A,NRXN1,NFIA |
3.305e-03 | -5.71 | Pancreatic secretion | KEGG pathways | hsa04972 | 95 | 3 | 7161 | 23 |
ATP1A2,SLC4A4,ITPR2 |
3.305e-03 | -5.71 | Pancreatic secretion | KEGG pathways | ko04972 | 95 | 3 | 7161 | 23 |
ITPR2,SLC4A4,ATP1A2 |
3.349e-03 | -5.70 | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | 3531 | 19 | 16828 | 49 |
NHSL1,ATP1A2,ABLIM1,SPARCL1,MACF1,SLC4A4,PCDH9,PREX2,ZBTB20,CTNND2,GPC5,MAML2,TNIK,FMN2,GPM6A,PTPRZ1,RYR3,SOX5,NEBL |
3.371e-03 | -5.69 | middle_third | COSMIC cancer mutations | middle_third | 3533 | 19 | 16828 | 49 |
NEBL,RYR3,SOX5,GPC5,FMN2,TNIK,MAML2,CTNND2,PTPRZ1,GPM6A,ZBTB20,PREX2,PCDH9,ABLIM1,SPARCL1,ATP1A2,NHSL1,SLC4A4,MACF1 |
3.415e-03 | -5.68 | E1-E2_ATPase | pfam domains | PF00122 | 31 | 2 | 17795 | 50 |
ATP13A4,ATP1A2 |
3.430e-03 | -5.68 | lentigo_maligna | COSMIC cancer mutations | lentigo_maligna | 30 | 2 | 16828 | 49 |
PREX2,FGFR3 |
3.430e-03 | -5.68 | skin-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-malignant_melanoma-acral_lentiginous | 30 | 2 | 16828 | 49 |
FGFR3,PREX2 |
3.445e-03 | -5.67 | brain development | biological process | GO:0007420 | 724 | 7 | 18204 | 50 |
RORA,SLC1A2,PCDH9,CTNNA2,ATP1A2,NTRK2,GLUD1 |
3.479e-03 | -5.66 | positive regulation of ATP metabolic process | biological process | GO:1903580 | 32 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
3.479e-03 | -5.66 | positive regulation of cartilage development | biological process | GO:0061036 | 32 | 2 | 18204 | 50 |
SOX5,BMPR1B |
3.479e-03 | -5.66 | transepithelial transport | biological process | GO:0070633 | 32 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
3.637e-03 | -5.62 | Cation_ATPase | pfam domains | PF13246 | 32 | 2 | 17795 | 50 |
ATP13A4,ATP1A2 |
3.649e-03 | -5.61 | TPRA1 (transmembrane protein adipocyte associated 1) | protein interactions | 131601 | 35 | 2 | 19454 | 50 |
ITPR2,BMPR1B |
3.674e-03 | -5.61 | cell-cell adhesion | biological process | GO:0098609 | 546 | 6 | 18204 | 50 |
CTNNA2,PCDH9,NRXN1,CTNND2,CDH20,SPARCL1 |
3.688e-03 | -5.60 | calcium channel activity | molecular function | GO:0005262 | 117 | 3 | 18094 | 48 |
GPM6A,RYR3,ITPR2 |
3.688e-03 | -5.60 | solute:monoatomic cation symporter activity | molecular function | GO:0015294 | 117 | 3 | 18094 | 48 |
SLC1A2,SLC4A4,SLC1A3 |
3.692e-03 | -5.60 | dendrite development | biological process | GO:0016358 | 113 | 3 | 18204 | 50 |
CTNNA2,PREX2,CTNND2 |
3.724e-03 | -5.59 | bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 107 | 3 | 16828 | 49 |
HIF3A,NEBL,PARD3B |
3.741e-03 | -5.59 | connective tissue development | biological process | GO:0061448 | 232 | 4 | 18204 | 50 |
SOX5,BMPR1B,FGFR3,NFIA |
3.758e-03 | -5.58 | plasma membrane bounded cell projection organization | biological process | GO:0120036 | 1152 | 9 | 18204 | 50 |
ABLIM1,TNIK,CTNNA2,GPM6A,NRXN1,BMPR1B,PREX2,PTPRZ1,CTNND2 |
3.792e-03 | -5.57 | PAS-like_dom_sf | interpro domains | IPR035965 | 34 | 2 | 18521 | 50 |
NPAS3,HIF3A |
3.792e-03 | -5.57 | PAS | interpro domains | IPR000014 | 34 | 2 | 18521 | 50 |
NPAS3,HIF3A |
3.858e-03 | -5.56 | receptor complex | cellular component | GO:0043235 | 409 | 5 | 19108 | 49 |
BMPR1B,FGFR3,LIFR,NTRK2,ITPR2 |
3.878e-03 | -5.55 | organic acid:sodium symporter activity | molecular function | GO:0005343 | 35 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
3.908e-03 | -5.54 | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 891 | 8 | 16828 | 49 |
ITPR2,PTPRZ1,ATP1A2,FGFR3,ABLIM1,SPARCL1,NPAS3,PTGDS |
3.912e-03 | -5.54 | Ig_sub2 | interpro domains | IPR003598 | 239 | 4 | 18521 | 50 |
NTM,LSAMP,FGFR3,NTRK2 |
3.978e-03 | -5.53 | eye-uveal_tract-malignant_melanoma-spindle | COSMIC cancer mutations | eye-uveal_tract-malignant_melanoma-spindle | 363 | 5 | 16828 | 49 |
MACF1,CPE,PREX2,CTNND2,PCDH9 |
4.071e-03 | -5.50 | HPCA (hippocalcin) | protein interactions | 3208 | 37 | 2 | 19454 | 50 |
CST3,GPM6A |
4.116e-03 | -5.49 | DELLA | smart domains | SM01129 | 1 | 1 | 9717 | 40 |
MACF1 |
4.238e-03 | -5.46 | extraskeletal | COSMIC cancer mutations | extraskeletal | 903 | 8 | 16828 | 49 |
ITPR2,PTPRZ1,ATP1A2,FGFR3,SPARCL1,ABLIM1,PTGDS,NPAS3 |
4.244e-03 | -5.46 | P_typ_ATPase | interpro domains | IPR001757 | 36 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.244e-03 | -5.46 | ATPase_P-typ_P_site | interpro domains | IPR018303 | 36 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.244e-03 | -5.46 | ATPase_P-typ_cyto_dom_N | interpro domains | IPR023299 | 36 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.244e-03 | -5.46 | ATPase_P-typ_transduc_dom_A_sf | interpro domains | IPR008250 | 36 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.244e-03 | -5.46 | P_typ_ATPase_HD_dom | interpro domains | IPR044492 | 36 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.258e-03 | -5.46 | EPB41L4A (erythrocyte membrane protein band 4.1 like 4A) | protein interactions | 64097 | 127 | 3 | 19454 | 50 |
MACF1,ABLIM1,DTNA |
4.370e-03 | -5.43 | striated muscle contraction | biological process | GO:0006941 | 120 | 3 | 18204 | 50 |
ATP1A2,DTNA,RYR3 |
4.400e-03 | -5.43 | NTKRECEPTOR2 | prints domains | PR01941 | 1 | 1 | 5227 | 23 |
NTRK2 |
4.448e-03 | -5.42 | Lima1 (LIM domain and actin binding 1) | protein interactions | 65970 | 129 | 3 | 19454 | 50 |
ITPR2,ABLIM1,ZBTB20 |
4.478e-03 | -5.41 | ATPase_P-typ_TM_dom_sf | interpro domains | IPR023298 | 37 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.602e-03 | -5.38 | FGFR1 (fibroblast growth factor receptor 1) | protein interactions | 2260 | 611 | 6 | 19454 | 50 |
TNIK,AHCYL2,ABLIM1,DTNA,FGFR3,NHSL1 |
4.603e-03 | -5.38 | organic anion transport | biological process | GO:0015711 | 398 | 5 | 18204 | 50 |
SLC4A4,SLC1A3,SLC1A2,SFXN5,NTRK2 |
4.605e-03 | -5.38 | regulation of synapse organization | biological process | GO:0050807 | 246 | 4 | 18204 | 50 |
GPM6A,CTNNA2,NRXN1,NTRK2 |
4.607e-03 | -5.38 | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | 6040 | 27 | 16828 | 49 |
NRXN1,NFIA,DTNA,SPARCL1,MACF1,ATP13A4,FMN2,GPC5,SLC1A3,TRPS1,PTPRZ1,GPM6A,CDH20,NTRK2,NEBL,FGFR3,ABLIM1,ATP1A2,PARD3B,ITPR2,SLC4A4,SFXN5,ZBTB20,PCDH9,PREX2,GLIS3,HIF3A |
4.631e-03 | -5.38 | positive regulation of purine nucleotide metabolic process | biological process | GO:1900544 | 37 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
4.631e-03 | -5.38 | positive regulation of nucleotide metabolic process | biological process | GO:0045981 | 37 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
4.631e-03 | -5.37 | transitional_cell_carcinoma | COSMIC cancer mutations | transitional_cell_carcinoma | 6042 | 27 | 16828 | 49 |
NEBL,NTRK2,TRPS1,GPM6A,PTPRZ1,CDH20,GPC5,FMN2,SLC1A3,GLIS3,HIF3A,ZBTB20,PCDH9,PREX2,ITPR2,SLC4A4,SFXN5,FGFR3,ABLIM1,ATP1A2,PARD3B,NFIA,DTNA,NRXN1,ATP13A4,MACF1,SPARCL1 |
4.632e-03 | -5.37 | prostate-carcinoma-adenocarcinoma | COSMIC cancer mutations | prostate-carcinoma-adenocarcinoma | 12379 | 44 | 16828 | 49 |
CDH20,TRPS1,GPM6A,PTPRZ1,SLC1A3,CTNND2,TNIK,GPC5,FMN2,MAML2,NEBL,CPE,RORA,NTRK2,SFXN5,PITPNC1,ITPR2,ATP1A2,PARD3B,FGFR3,ABLIM1,HIF3A,LSAMP,GLIS3,PCDH9,PREX2,NPAS3,ZBTB20,NRXN1,SLC1A2,BMPR1B,SOX5,RYR3,NFIA,NKAIN3,LIFR,MACF1,NHSL1,SPARCL1,GLUD1,AHCYL2,NTM,ATP13A4,FBXL7 |
4.669e-03 | -5.37 | PAS | smart domains | SM00091 | 25 | 2 | 9717 | 40 |
HIF3A,NPAS3 |
4.691e-03 | -5.36 | monoatomic cation transport | biological process | GO:0006812 | 766 | 7 | 18204 | 50 |
ATP1A2,SLC4A4,ATP13A4,RYR3,SLC1A3,GPM6A,ITPR2 |
4.705e-03 | -5.36 | plasma membrane region | cellular component | GO:0098590 | 1278 | 9 | 19108 | 49 |
NRXN1,SLC1A3,PARD3B,ATP1A2,GPM6A,TNIK,MACF1,SLC4A4,SLC1A2 |
4.753e-03 | -5.35 | endoplasmic reticulum | cellular component | GO:0005783 | 2051 | 12 | 19108 | 49 |
FMN2,AHCYL2,GLUD1,ITPR2,ATP13A4,RYR3,NRXN1,FGFR3,SPARCL1,ATP1A2,PTGDS,CST3 |
4.816e-03 | -5.34 | gallbladder | COSMIC cancer mutations | gallbladder | 2821 | 16 | 16828 | 49 |
TRPS1,PTPRZ1,CTNND2,FMN2,TNIK,RYR3,NKAIN3,ITPR2,PITPNC1,SLC4A4,MACF1,NHSL1,FGFR3,SPARCL1,PREX2,PCDH9 |
4.816e-03 | -5.34 | biliary_tract-gallbladder-carcinoma-adenocarcinoma | COSMIC cancer mutations | biliary_tract-gallbladder-carcinoma-adenocarcinoma | 2821 | 16 | 16828 | 49 |
FGFR3,SPARCL1,NHSL1,ITPR2,PITPNC1,SLC4A4,MACF1,PCDH9,PREX2,TNIK,FMN2,CTNND2,TRPS1,PTPRZ1,NKAIN3,RYR3 |
4.880e-03 | -5.32 | amino acid import across plasma membrane | biological process | GO:0089718 | 38 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
4.915e-03 | -5.32 | cell projection organization | biological process | GO:0030030 | 1200 | 9 | 18204 | 50 |
ABLIM1,TNIK,NRXN1,GPM6A,CTNNA2,BMPR1B,PTPRZ1,PREX2,CTNND2 |
4.945e-03 | -5.31 | NUFIP1 (nuclear FMR1 interacting protein 1) | protein interactions | 26747 | 134 | 3 | 19454 | 50 |
NTM,GPM6A,CPE |
4.963e-03 | -5.31 | head development | biological process | GO:0060322 | 774 | 7 | 18204 | 50 |
RORA,SLC1A2,CTNNA2,PCDH9,ATP1A2,NTRK2,GLUD1 |
4.969e-03 | -5.30 | intracellular chemical homeostasis | biological process | GO:0055082 | 581 | 6 | 18204 | 50 |
RYR3,SLC1A3,ATP13A4,ZBTB20,ATP1A2,SLC4A4 |
4.980e-03 | -5.30 | TAFA2 (TAFA chemokine like family member 2) | protein interactions | 338811 | 41 | 2 | 19454 | 50 |
CPE,LIFR |
4.988e-03 | -5.30 | upper_aerodigestive_tract-lymph_node-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-lymph_node-carcinoma-adenoid_cystic_carcinoma | 383 | 5 | 16828 | 49 |
MAML2,FGFR3,NTRK2,TNIK,LIFR |
4.988e-03 | -5.30 | upper_aerodigestive_tract-mouth-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-adenoid_cystic_carcinoma | 383 | 5 | 16828 | 49 |
FGFR3,TNIK,NTRK2,MAML2,LIFR |
4.988e-03 | -5.30 | upper_aerodigestive_tract-carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-carcinoma | 383 | 5 | 16828 | 49 |
NTRK2,MAML2,FGFR3,TNIK,LIFR |
4.988e-03 | -5.30 | upper_aerodigestive_tract-head_neck-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-head_neck-carcinoma-adenoid_cystic_carcinoma | 383 | 5 | 16828 | 49 |
MAML2,FGFR3,NTRK2,TNIK,LIFR |
4.988e-03 | -5.30 | salivary_gland-carcinoma | COSMIC cancer mutations | salivary_gland-carcinoma | 383 | 5 | 16828 | 49 |
LIFR,FGFR3,TNIK,MAML2,NTRK2 |
5.014e-03 | -5.30 | regulation of synapse structure or activity | biological process | GO:0050803 | 252 | 4 | 18204 | 50 |
GPM6A,CTNNA2,NRXN1,NTRK2 |
5.042e-03 | -5.29 | testis | COSMIC cancer mutations | testis | 733 | 7 | 16828 | 49 |
PREX2,NTRK2,TNIK,FGFR3,BMPR1B,MACF1,TRPS1 |
5.049e-03 | -5.29 | NTRK2 (neurotrophic receptor tyrosine kinase 2) | protein interactions | 4915 | 135 | 3 | 19454 | 50 |
DTNA,ABLIM1,NTRK2 |
5.049e-03 | -5.29 | Myo1c (myosin IC) | protein interactions | 17913 | 135 | 3 | 19454 | 50 |
ABLIM1,ITPR2,TRPS1 |
5.127e-03 | -5.27 | EF-hand-dom_pair | interpro domains | IPR011992 | 258 | 4 | 18521 | 50 |
DTNA,MACF1,SPARCL1,RYR3 |
5.134e-03 | -5.27 | Mknk2 (MAP kinase-interacting serine/threonine kinase 2) | protein interactions | 17347 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Fkbp1a (FK506 binding protein 1a) | protein interactions | 14225 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Sh3kbp1 (SH3-domain kinase binding protein 1) | protein interactions | 58194 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Fbxo34 (F-box protein 34) | protein interactions | 78938 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Bcr (BCR activator of RhoGEF and GTPase) | protein interactions | 110279 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Zmym2 (zinc finger, MYM-type 2) | protein interactions | 76007 | 2 | 1 | 19454 | 50 |
GLIS3 |
5.134e-03 | -5.27 | Bmpr2 (bone morphogenetic protein receptor type 2) | protein interactions | 12168 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Fkbp1b (FK506 binding protein 1b) | protein interactions | 14226 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Irf7 (interferon regulatory factor 7) | protein interactions | 54123 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Ppp3cc (protein phosphatase 3, catalytic subunit, gamma isoform) | protein interactions | 19057 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Kdm4c (lysine (K)-specific demethylase 4C) | protein interactions | 76804 | 2 | 1 | 19454 | 50 |
GLIS3 |
5.134e-03 | -5.27 | Klhl1 (kelch-like 1) | protein interactions | 93688 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | sodium ion homeostasis | biological process | GO:0055078 | 39 | 2 | 18204 | 50 |
SLC1A3,ATP1A2 |
5.135e-03 | -5.27 | prostate | COSMIC cancer mutations | prostate | 13883 | 47 | 16828 | 49 |
ATP1A2,PARD3B,FGFR3,SFXN5,PITPNC1,SLC4A4,ZBTB20,HIF3A,GLIS3,LSAMP,SLC1A3,CTNND2,GPC5,FMN2,MAML2,PTPRZ1,MSI2,NEBL,SPARCL1,LIFR,FBXL7,AHCYL2,DTNA,BMPR1B,RYR3,ABLIM1,ITPR2,PREX2,PCDH9,NPAS3,TNIK,CDH20,TRPS1,GPM6A,NTRK2,CPE,RORA,NHSL1,MACF1,ATP13A4,GLUD1,NTM,NRXN1,NKAIN3,NFIA,SLC1A2,SOX5 |
5.157e-03 | -5.27 | ovary-carcinoma | COSMIC cancer mutations | ovary-carcinoma | 933 | 8 | 16828 | 49 |
ATP1A2,TNIK,FGFR3,MACF1,ITPR2,PREX2,NTRK2,BMPR1B |
5.198e-03 | -5.26 | RDX (radixin) | protein interactions | 5962 | 272 | 4 | 19454 | 50 |
FGFR3,ABLIM1,NEBL,MACF1 |
5.198e-03 | -5.26 | PAS | prosite domains | PS50112 | 30 | 2 | 12186 | 44 |
HIF3A,NPAS3 |
5.251e-03 | -5.25 | oligoastrocytoma_Grade_II | COSMIC cancer mutations | oligoastrocytoma_Grade_II | 121 | 3 | 16828 | 49 |
CDH20,DTNA,FGFR3 |
5.299e-03 | -5.24 | glutamate dehydrogenase (NADP+) activity | molecular function | GO:0004354 | 2 | 1 | 18094 | 48 |
GLUD1 |
5.299e-03 | -5.24 | glutamate dehydrogenase [NAD(P)+] activity | molecular function | GO:0004353 | 2 | 1 | 18094 | 48 |
GLUD1 |
5.299e-03 | -5.24 | glutamate dehydrogenase (NAD+) activity | molecular function | GO:0004352 | 2 | 1 | 18094 | 48 |
GLUD1 |
5.299e-03 | -5.24 | leukemia inhibitory factor receptor activity | molecular function | GO:0004923 | 2 | 1 | 18094 | 48 |
LIFR |
5.299e-03 | -5.24 | oxidoreductase activity, acting on the CH-NH2 group of donors, NAD or NADP as acceptor | molecular function | GO:0016639 | 2 | 1 | 18094 | 48 |
GLUD1 |
5.331e-03 | -5.23 | Calcium-transporting ATPase, cytoplasmic domain N | gene3d domains | 3.40.1110.10 | 36 | 2 | 14470 | 44 |
ATP1A2,ATP13A4 |
5.331e-03 | -5.23 | Calcium-transporting ATPase, cytoplasmic transduction domain A | gene3d domains | 2.70.150.10 | 36 | 2 | 14470 | 44 |
ATP13A4,ATP1A2 |
5.366e-03 | -5.23 | NFIB (nuclear factor I B) | protein interactions | 4781 | 138 | 3 | 19454 | 50 |
TRPS1,NFIA,SOX5 |
5.377e-03 | -5.23 | somatodendritic compartment | cellular component | GO:0036477 | 842 | 7 | 19108 | 49 |
NTRK2,BMPR1B,GPM6A,ATP1A2,CTNND2,SLC1A3,NRXN1 |
5.386e-03 | -5.22 | membrane | cellular component | GO:0016020 | 9220 | 33 | 19108 | 49 |
HIF3A,PTGDS,CTNND2,SFXN5,CTNNA2,MACF1,NKAIN3,CPE,RYR3,SLC1A3,LSAMP,GPM6A,GPC5,SLC4A4,SLC1A2,PTPRZ1,CST3,PCDH9,CDH20,ATP1A2,PREX2,FGFR3,NTRK2,NRXN1,LIFR,PARD3B,ATP13A4,TNIK,ITPR2,DTNA,BMPR1B,NTM,FMN2 |
5.392e-03 | -5.22 | Glu/Leu/Phe/Val/Trp_DH_dimer | interpro domains | IPR006097 | 2 | 1 | 18521 | 50 |
GLUD1 |
5.392e-03 | -5.22 | Osteonectin_CS | interpro domains | IPR001999 | 2 | 1 | 18521 | 50 |
SPARCL1 |
5.392e-03 | -5.22 | Glu/Leu/Phe/Val/Trp_DH_C | interpro domains | IPR006096 | 2 | 1 | 18521 | 50 |
GLUD1 |
5.392e-03 | -5.22 | Par3/HAL_N | interpro domains | IPR021922 | 2 | 1 | 18521 | 50 |
PARD3B |
5.392e-03 | -5.22 | Glu/Leu/Phe/Val/Trp_DH | interpro domains | IPR006095 | 2 | 1 | 18521 | 50 |
GLUD1 |
5.392e-03 | -5.22 | Distrobrevin | interpro domains | IPR017432 | 2 | 1 | 18521 | 50 |
DTNA |
5.392e-03 | -5.22 | Alpha_CARP_receptor-type | interpro domains | IPR041887 | 2 | 1 | 18521 | 50 |
PTPRZ1 |
5.392e-03 | -5.22 | LIFR_D2 | interpro domains | IPR040817 | 2 | 1 | 18521 | 50 |
LIFR |
5.392e-03 | -5.22 | LIF-R-like_Ig-like | interpro domains | IPR048497 | 2 | 1 | 18521 | 50 |
LIFR |
5.392e-03 | -5.22 | MSI_RRM2 | interpro domains | IPR034126 | 2 | 1 | 18521 | 50 |
MSI2 |
5.392e-03 | -5.22 | NAD_bind_Glu_DH | interpro domains | IPR033922 | 2 | 1 | 18521 | 50 |
GLUD1 |
5.392e-03 | -5.22 | Formin_Cappuccino_subfam | interpro domains | IPR001265 | 2 | 1 | 18521 | 50 |
FMN2 |
5.392e-03 | -5.22 | Glu/Leu/Phe/Val_DH_AS | interpro domains | IPR033524 | 2 | 1 | 18521 | 50 |
GLUD1 |
5.440e-03 | -5.21 | sarcoplasmic reticulum membrane | cellular component | GO:0033017 | 43 | 2 | 19108 | 49 |
ITPR2,RYR3 |
5.486e-03 | -5.21 | regulation of elastin catabolic process | biological process | GO:0060310 | 2 | 1 | 18204 | 50 |
CST3 |
5.486e-03 | -5.21 | fibroblast growth factor receptor apoptotic signaling pathway | biological process | GO:1902178 | 2 | 1 | 18204 | 50 |
FGFR3 |
5.486e-03 | -5.21 | negative regulation of blood vessel remodeling | biological process | GO:0060313 | 2 | 1 | 18204 | 50 |
CST3 |
5.492e-03 | -5.20 | organic anion transmembrane transporter activity | molecular function | GO:0008514 | 268 | 4 | 18094 | 48 |
SLC1A3,SLC1A2,SFXN5,SLC4A4 |
5.517e-03 | -5.20 | Glutamatergic synapse | KEGG pathways | ko04724 | 114 | 3 | 7161 | 23 |
SLC1A3,ITPR2,SLC1A2 |
5.517e-03 | -5.20 | Glutamatergic synapse | KEGG pathways | hsa04724 | 114 | 3 | 7161 | 23 |
SLC1A3,ITPR2,SLC1A2 |
5.535e-03 | -5.20 | salivary_gland-parotid-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | salivary_gland-parotid-carcinoma-adenoid_cystic_carcinoma | 561 | 6 | 16828 | 49 |
FGFR3,TNIK,MAML2,LIFR,NTRK2,RYR3 |
5.545e-03 | -5.19 | neutral L-amino acid transmembrane transporter activity | molecular function | GO:0015175 | 42 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
5.547e-03 | -5.19 | Ser-Thr/Tyr_kinase_cat_dom | interpro domains | IPR001245 | 133 | 3 | 18521 | 50 |
FGFR3,NTRK2,BMPR1B |
5.612e-03 | -5.18 | LIF-R_Ig-like | pfam domains | PF21177 | 2 | 1 | 17795 | 50 |
LIFR |
5.612e-03 | -5.18 | LIFR_D2 | pfam domains | PF17971 | 2 | 1 | 17795 | 50 |
LIFR |
5.612e-03 | -5.18 | ELFV_dehydrog_N | pfam domains | PF02812 | 2 | 1 | 17795 | 50 |
GLUD1 |
5.612e-03 | -5.18 | ELFV_dehydrog | pfam domains | PF00208 | 2 | 1 | 17795 | 50 |
GLUD1 |
5.612e-03 | -5.18 | Par3_HAL_N_term | pfam domains | PF12053 | 2 | 1 | 17795 | 50 |
PARD3B |
5.612e-03 | -5.18 | calcium ion transmembrane transporter activity | molecular function | GO:0015085 | 136 | 3 | 18094 | 48 |
GPM6A,ITPR2,RYR3 |
5.612e-03 | -5.18 | growth factor binding | molecular function | GO:0019838 | 136 | 3 | 18094 | 48 |
NTRK2,LIFR,FGFR3 |
5.692e-03 | -5.17 | actin binding | molecular function | GO:0003779 | 434 | 5 | 18094 | 48 |
NEBL,FMN2,ABLIM1,MACF1,CTNNA2 |
5.752e-03 | -5.16 | middle_lobe | COSMIC cancer mutations | middle_lobe | 1382 | 10 | 16828 | 49 |
RYR3,CPE,ATP13A4,PCDH9,ITPR2,MACF1,ATP1A2,PARD3B,CTNND2,FGFR3 |
5.755e-03 | -5.16 | clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | clear_cell_renal_cell_carcinoma | 13924 | 47 | 16828 | 49 |
LIFR,SPARCL1,AHCYL2,PTGDS,FBXL7,BMPR1B,RYR3,DTNA,PITPNC1,SLC4A4,SFXN5,FGFR3,ATP1A2,PARD3B,LSAMP,GLIS3,HIF3A,ZBTB20,PTPRZ1,MAML2,FMN2,GPC5,CTNND2,SLC1A3,NEBL,MSI2,MACF1,NHSL1,GLUD1,ATP13A4,NRXN1,SLC1A2,SOX5,NFIA,NKAIN3,ITPR2,ABLIM1,NPAS3,PCDH9,PREX2,TRPS1,GPM6A,CDH20,TNIK,CPE,RORA,NTRK2 |
5.755e-03 | -5.16 | kidney-carcinoma-clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-clear_cell_renal_cell_carcinoma | 13924 | 47 | 16828 | 49 |
SLC1A2,SOX5,NFIA,NKAIN3,NRXN1,GLUD1,ATP13A4,MACF1,NHSL1,CPE,RORA,NTRK2,CDH20,TRPS1,GPM6A,TNIK,PCDH9,PREX2,NPAS3,ITPR2,ABLIM1,BMPR1B,RYR3,DTNA,AHCYL2,FBXL7,PTGDS,LIFR,SPARCL1,NEBL,MSI2,PTPRZ1,SLC1A3,CTNND2,MAML2,FMN2,GPC5,HIF3A,LSAMP,GLIS3,ZBTB20,SFXN5,PITPNC1,SLC4A4,ATP1A2,PARD3B,FGFR3 |
5.767e-03 | -5.16 | sarcolemma | cellular component | GO:0042383 | 142 | 3 | 19108 | 49 |
RYR3,DTNA,ATP1A2 |
5.802e-03 | -5.15 | mast_cell_neoplasm | COSMIC cancer mutations | mast_cell_neoplasm | 248 | 4 | 16828 | 49 |
NPAS3,GPC5,NFIA,PCDH9 |
5.802e-03 | -5.15 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | 248 | 4 | 16828 | 49 |
PCDH9,NFIA,GPC5,NPAS3 |
5.813e-03 | -5.15 | PK_Tyr_Ser-Thr | pfam domains | PF07714 | 130 | 3 | 17795 | 50 |
BMPR1B,NTRK2,FGFR3 |
5.817e-03 | -5.15 | regulation of sequestering of calcium ion | biological process | GO:0051282 | 133 | 3 | 18204 | 50 |
ITPR2,RYR3,ATP1A2 |
5.885e-03 | -5.14 | central_nervous_system-brain-glioma-oligodendroglioma_Grade_III | COSMIC cancer mutations | central_nervous_system-brain-glioma-oligodendroglioma_Grade_III | 249 | 4 | 16828 | 49 |
MACF1,PTPRZ1,GLIS3,FGFR3 |
6.037e-03 | -5.11 | Calml3 (calmodulin-like 3) | protein interactions | 70405 | 144 | 3 | 19454 | 50 |
MACF1,ZBTB20,ABLIM1 |
6.073e-03 | -5.10 | - | gene3d domains | 6.20.350.10 | 2 | 1 | 14470 | 44 |
RYR3 |
6.073e-03 | -5.10 | - | gene3d domains | 1.10.287.140 | 2 | 1 | 14470 | 44 |
GLUD1 |
6.073e-03 | -5.10 | Vinculin, Vh2 four-helix bundle | gene3d domains | 1.20.120.810 | 2 | 1 | 14470 | 44 |
CTNNA2 |
6.107e-03 | -5.10 | axon | cellular component | GO:0030424 | 650 | 6 | 19108 | 49 |
SLC1A2,NTRK2,PCDH9,DTNA,GPM6A,CTNNA2 |
6.237e-03 | -5.08 | intracellular monoatomic cation homeostasis | biological process | GO:0030003 | 428 | 5 | 18204 | 50 |
SLC4A4,ATP1A2,ATP13A4,RYR3,SLC1A3 |
6.257e-03 | -5.07 | active transmembrane transporter activity | molecular function | GO:0022804 | 444 | 5 | 18094 | 48 |
SLC4A4,SLC1A2,ATP13A4,ATP1A2,SLC1A3 |
6.372e-03 | -5.06 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | 10418 | 39 | 16828 | 49 |
AHCYL2,NTM,ATP13A4,FBXL7,LIFR,MACF1,NHSL1,SPARCL1,SLC1A2,RYR3,SOX5,NKAIN3,NFIA,NRXN1,HIF3A,LSAMP,GLIS3,PCDH9,PREX2,NPAS3,SFXN5,ITPR2,SLC4A4,ATP1A2,PARD3B,ABLIM1,NEBL,CPE,RORA,MSI2,NTRK2,CDH20,PTPRZ1,CTNND2,SLC1A3,MAML2,GPC5,TNIK,FMN2 |
6.372e-03 | -5.06 | acute_myeloid_leukaemia | COSMIC cancer mutations | acute_myeloid_leukaemia | 10418 | 39 | 16828 | 49 |
ATP1A2,PARD3B,ABLIM1,SFXN5,ITPR2,SLC4A4,PCDH9,PREX2,NPAS3,HIF3A,GLIS3,LSAMP,CTNND2,SLC1A3,TNIK,GPC5,MAML2,FMN2,CDH20,PTPRZ1,MSI2,NTRK2,NEBL,CPE,RORA,NHSL1,SPARCL1,LIFR,MACF1,ATP13A4,FBXL7,AHCYL2,NTM,NRXN1,NKAIN3,NFIA,SLC1A2,RYR3,SOX5 |
6.384e-03 | -5.05 | parotid | COSMIC cancer mutations | parotid | 578 | 6 | 16828 | 49 |
NTRK2,RYR3,FGFR3,TNIK,MAML2,LIFR |
6.420e-03 | -5.05 | trans-synaptic signaling | biological process | GO:0099537 | 431 | 5 | 18204 | 50 |
NRXN1,NTRK2,DTNA,SLC1A2,SLC1A3 |
6.429e-03 | -5.05 | extremity | COSMIC cancer mutations | extremity | 1876 | 12 | 16828 | 49 |
FMN2,FGFR3,CDH20,PTPRZ1,PITPNC1,PCDH9,ATP13A4,FBXL7,PREX2,NTRK2,RYR3,NEBL |
6.500e-03 | -5.04 | CNTN1 (contactin 1) | protein interactions | 1272 | 47 | 2 | 19454 | 50 |
PTPRZ1,GPM6A |
6.500e-03 | -5.04 | BDNF (brain derived neurotrophic factor) | protein interactions | 627 | 47 | 2 | 19454 | 50 |
CPE,NTRK2 |
6.550e-03 | -5.03 | PAS domain | gene3d domains | 3.30.450.20 | 40 | 2 | 14470 | 44 |
HIF3A,NPAS3 |
6.597e-03 | -5.02 | upper_arm | COSMIC cancer mutations | upper_arm | 582 | 6 | 16828 | 49 |
PREX2,SLC4A4,ITPR2,PARD3B,FGFR3,FMN2 |
6.634e-03 | -5.02 | GSE1 (Gse1 coiled-coil protein) | protein interactions | 23199 | 149 | 3 | 19454 | 50 |
NFIA,SOX5,TNIK |
6.634e-03 | -5.02 | vascular process in circulatory system | biological process | GO:0003018 | 273 | 4 | 18204 | 50 |
SLC1A3,SLC1A2,ATP1A2,SLC4A4 |
6.660e-03 | -5.01 | skin-leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-leg-malignant_melanoma-nodular | 258 | 4 | 16828 | 49 |
ATP13A4,FMN2,SLC4A4,PTPRZ1 |
6.676e-03 | -5.01 | inorganic cation transmembrane transport | biological process | GO:0098662 | 618 | 6 | 18204 | 50 |
ATP1A2,SLC4A4,RYR3,SLC1A3,GPM6A,ITPR2 |
6.798e-03 | -4.99 | intracellular monoatomic ion homeostasis | biological process | GO:0006873 | 437 | 5 | 18204 | 50 |
ATP1A2,ATP13A4,RYR3,SLC1A3,SLC4A4 |
6.853e-03 | -4.98 | cell-cell signaling | biological process | GO:0007267 | 822 | 7 | 18204 | 50 |
NRXN1,SLC1A3,SLC1A2,DTNA,FGFR3,CPE,NTRK2 |
6.870e-03 | -4.98 | uveal_tract | COSMIC cancer mutations | uveal_tract | 587 | 6 | 16828 | 49 |
MACF1,CPE,FGFR3,PREX2,CTNND2,PCDH9 |
6.875e-03 | -4.98 | transmembrane transport | biological process | GO:0055085 | 1264 | 9 | 18204 | 50 |
SFXN5,ATP1A2,SLC4A4,ATP13A4,SLC1A3,SLC1A2,RYR3,ITPR2,GPM6A |
6.890e-03 | -4.98 | learning or memory | biological process | GO:0007611 | 276 | 4 | 18204 | 50 |
NTRK2,ATP1A2,PTPRZ1,NRXN1 |
6.939e-03 | -4.97 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | 981 | 8 | 16828 | 49 |
ITPR2,GPC5,CTNND2,RORA,LSAMP,SOX5,NKAIN3,PCDH9 |
6.969e-03 | -4.97 | monoatomic anion transmembrane transport | biological process | GO:0098656 | 142 | 3 | 18204 | 50 |
SLC1A2,SLC1A3,SLC4A4 |
7.064e-03 | -4.95 | SP7 (Sp7 transcription factor) | protein interactions | 121340 | 297 | 4 | 19454 | 50 |
SOX5,NFIA,GLUD1,TRPS1 |
7.087e-03 | -4.95 | symporter activity | molecular function | GO:0015293 | 148 | 3 | 18094 | 48 |
SLC4A4,SLC1A2,SLC1A3 |
7.135e-03 | -4.94 | SOX6 (SRY-box transcription factor 6) | protein interactions | 55553 | 153 | 3 | 19454 | 50 |
NFIA,SOX5,TRPS1 |
7.203e-03 | -4.93 | SFN (stratifin) | protein interactions | 2810 | 671 | 6 | 19454 | 50 |
FMN2,PARD3B,MACF1,ABLIM1,NFIA,TNIK |
7.209e-03 | -4.93 | OSTEONECTIN_1 | prosite domains | PS00612 | 2 | 1 | 12186 | 44 |
SPARCL1 |
7.209e-03 | -4.93 | GLFV_DEHYDROGENASE | prosite domains | PS00074 | 2 | 1 | 12186 | 44 |
GLUD1 |
7.209e-03 | -4.93 | OSTEONECTIN_2 | prosite domains | PS00613 | 2 | 1 | 12186 | 44 |
SPARCL1 |
7.240e-03 | -4.93 | Cardiac conduction | REACTOME pathways | R-HSA-5576891 | 142 | 3 | 10285 | 29 |
ATP1A2,ITPR2,RYR3 |
7.272e-03 | -4.92 | Ig_3 | pfam domains | PF13927 | 141 | 3 | 17795 | 50 |
FGFR3,LSAMP,NTM |
7.312e-03 | -4.92 | metal ion transport | biological process | GO:0030001 | 630 | 6 | 18204 | 50 |
SLC4A4,ATP1A2,ITPR2,GPM6A,RYR3,SLC1A3 |
7.404e-03 | -4.91 | large_intestine-adenoma | COSMIC cancer mutations | large_intestine-adenoma | 266 | 4 | 16828 | 49 |
LIFR,SOX5,RYR3,CDH20 |
7.426e-03 | -4.90 | ATPASE_E1_E2 | prosite domains | PS00154 | 36 | 2 | 12186 | 44 |
ATP1A2,ATP13A4 |
7.456e-03 | -4.90 | follicular_lymphoma | COSMIC cancer mutations | follicular_lymphoma | 1209 | 9 | 16828 | 49 |
CTNND2,TNIK,GPC5,ITPR2,PCDH9,NKAIN3,SOX5,LSAMP,RORA |
7.515e-03 | -4.89 | Wnt signaling pathway | biological process | GO:0016055 | 283 | 4 | 18204 | 50 |
CPE,TNIK,MACF1,CTNND2 |
7.617e-03 | -4.88 | Ndc80 (NDC80 kinetochore complex component) | protein interactions | 67052 | 51 | 2 | 19454 | 50 |
MACF1,NHSL1 |
7.631e-03 | -4.88 | human chr8q23.3 | chromosome location | human chr8q23.3 | 4 | 1 | 26134 | 50 |
TRPS1 |
7.691e-03 | -4.87 | Plekhb1 (pleckstrin homology domain containing, family B (evectins) member 1) | protein interactions | 27276 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Rap2a (RAS related protein 2a) | protein interactions | 76108 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Usp45 (ubiquitin specific petidase 45) | protein interactions | 77593 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Stk35 (serine/threonine kinase 35) | protein interactions | 67333 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Spop (speckle-type BTB/POZ protein) | protein interactions | 20747 | 3 | 1 | 19454 | 50 |
GLIS3 |
7.691e-03 | -4.87 | IL34 (interleukin 34) | protein interactions | 146433 | 3 | 1 | 19454 | 50 |
PTPRZ1 |
7.691e-03 | -4.87 | Chn1 (chimerin 1) | protein interactions | 108699 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Smad6 (SMAD family member 6) | protein interactions | 17130 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Fbxw5 (F-box and WD-40 domain protein 5) | protein interactions | 30839 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Hk2 (hexokinase 2) | protein interactions | 25059 | 3 | 1 | 19454 | 50 |
PTGDS |
7.691e-03 | -4.87 | Atg16l1 (autophagy related 16 like 1) | protein interactions | 77040 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | BCO1 (beta-carotene oxygenase 1) | protein interactions | 53630 | 3 | 1 | 19454 | 50 |
ABLIM1 |
7.691e-03 | -4.87 | TULP1 (TUB like protein 1) | protein interactions | 7287 | 3 | 1 | 19454 | 50 |
NRXN1 |
7.691e-03 | -4.87 | QRFPR (pyroglutamylated RFamide peptide receptor) | protein interactions | 84109 | 3 | 1 | 19454 | 50 |
NTM |
7.702e-03 | -4.87 | animal organ development | biological process | GO:0048513 | 2846 | 15 | 18204 | 50 |
GLUD1,CPE,ATP1A2,RORA,PCDH9,GPM6A,BMPR1B,SOX5,NTRK2,NEBL,FGFR3,ABLIM1,SLC1A2,NFIA,CTNNA2 |
7.761e-03 | -4.86 | C20 prostanoid biosynthesis | BIOCYC pathways | META_PWY66-374 | 7 | 1 | 902 | 1 |
PTGDS |
7.761e-03 | -4.86 | C20 prostanoid biosynthesis | BIOCYC pathways | HUMAN_PWY66-374 | 7 | 1 | 902 | 1 |
PTGDS |
7.762e-03 | -4.86 | anchoring junction | cellular component | GO:0070161 | 902 | 7 | 19108 | 49 |
CTNND2,CDH20,ATP1A2,PARD3B,PCDH9,CTNNA2,FGFR3 |
7.832e-03 | -4.85 | response to organic cyclic compound | biological process | GO:0014070 | 843 | 7 | 18204 | 50 |
ATP1A2,RORA,SLC1A2,RYR3,SLC1A3,PTGDS,ITPR2 |
7.938e-03 | -4.84 | cysteine transmembrane transporter activity | molecular function | GO:0033229 | 3 | 1 | 18094 | 48 |
SLC1A2 |
7.938e-03 | -4.84 | adenosylhomocysteinase activity | molecular function | GO:0004013 | 3 | 1 | 18094 | 48 |
AHCYL2 |
7.938e-03 | -4.84 | inositol 1,4,5-trisphosphate-gated calcium channel activity | molecular function | GO:0005220 | 3 | 1 | 18094 | 48 |
ITPR2 |
7.938e-03 | -4.84 | oncostatin-M receptor activity | molecular function | GO:0004924 | 3 | 1 | 18094 | 48 |
LIFR |
7.938e-03 | -4.84 | prostaglandin-D synthase activity | molecular function | GO:0004667 | 3 | 1 | 18094 | 48 |
PTGDS |
7.938e-03 | -4.84 | hydrolase activity, acting on carbon-sulfur bonds | molecular function | GO:0046508 | 3 | 1 | 18094 | 48 |
AHCYL2 |
7.952e-03 | -4.83 | neuromuscular process | biological process | GO:0050905 | 149 | 3 | 18204 | 50 |
SLC1A3,NRXN1,CTNNA2 |
7.984e-03 | -4.83 | eye | COSMIC cancer mutations | eye | 606 | 6 | 16828 | 49 |
CPE,PREX2,PCDH9,MACF1,FGFR3,CTNND2 |
8.065e-03 | -4.82 | SOX5 (SRY-box transcription factor 5) | protein interactions | 6660 | 160 | 3 | 19454 | 50 |
SOX5,NFIA,TRPS1 |
8.078e-03 | -4.82 | Ado_hCys_hydrolase_NAD-bd | interpro domains | IPR015878 | 3 | 1 | 18521 | 50 |
AHCYL2 |
8.078e-03 | -4.82 | Adenosylhomocysteinase-like | interpro domains | IPR000043 | 3 | 1 | 18521 | 50 |
AHCYL2 |
8.078e-03 | -4.82 | Myelin_PLP | interpro domains | IPR001614 | 3 | 1 | 18521 | 50 |
GPM6A |
8.078e-03 | -4.82 | NR_DBD_ROR | interpro domains | IPR044101 | 3 | 1 | 18521 | 50 |
RORA |
8.078e-03 | -4.82 | ROR_rcpt | interpro domains | IPR003079 | 3 | 1 | 18521 | 50 |
RORA |
8.078e-03 | -4.82 | Myelin_PLP_CS | interpro domains | IPR018237 | 3 | 1 | 18521 | 50 |
GPM6A |
8.078e-03 | -4.82 | Ryan_recept | interpro domains | IPR013333 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Vinculin_CS | interpro domains | IPR000633 | 3 | 1 | 18521 | 50 |
CTNNA2 |
8.078e-03 | -4.82 | SPRY2_RyR | interpro domains | IPR035764 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | InsP3_rcpt | interpro domains | IPR000493 | 3 | 1 | 18521 | 50 |
ITPR2 |
8.078e-03 | -4.82 | RYDR_Jsol | interpro domains | IPR048581 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | HIF_alpha-like | interpro domains | IPR021537 | 3 | 1 | 18521 | 50 |
HIF3A |
8.078e-03 | -4.82 | SPRY3_RyR | interpro domains | IPR035762 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Ryanodine_rcpt | interpro domains | IPR003032 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | S-Ado-L-homoCys_hydrolase_CS | interpro domains | IPR020082 | 3 | 1 | 18521 | 50 |
AHCYL2 |
8.078e-03 | -4.82 | Ryanrecept_TM4-6 | interpro domains | IPR009460 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | NTRK | interpro domains | IPR020777 | 3 | 1 | 18521 | 50 |
NTRK2 |
8.078e-03 | -4.82 | MAML1-3 | interpro domains | IPR046369 | 3 | 1 | 18521 | 50 |
MAML2 |
8.078e-03 | -4.82 | Mastermind-like_N | interpro domains | IPR019082 | 3 | 1 | 18521 | 50 |
MAML2 |
8.078e-03 | -4.82 | NTRK_LRRCT | interpro domains | IPR031635 | 3 | 1 | 18521 | 50 |
NTRK2 |
8.078e-03 | -4.82 | Adenosylhomocyst_ase-like_sf | interpro domains | IPR042172 | 3 | 1 | 18521 | 50 |
AHCYL2 |
8.078e-03 | -4.82 | MAML_N_sf | interpro domains | IPR046370 | 3 | 1 | 18521 | 50 |
MAML2 |
8.078e-03 | -4.82 | SPRY1_RyR | interpro domains | IPR035761 | 3 | 1 | 18521 | 50 |
RYR3 |
8.085e-03 | -4.82 | signaling | biological process | GO:0023052 | 4968 | 22 | 18204 | 50 |
TNIK,SLC1A2,FGFR3,BMPR1B,NTRK2,NRXN1,LIFR,RYR3,SLC1A3,PREX2,FMN2,ATP1A2,CPE,NFIA,PITPNC1,DTNA,CTNND2,SPARCL1,ITPR2,MAML2,RORA,MACF1 |
8.088e-03 | -4.82 | amino acid binding | molecular function | GO:0016597 | 51 | 2 | 18094 | 48 |
GLUD1,SLC1A3 |
8.136e-03 | -4.81 | SLC-mediated transmembrane transport | REACTOME pathways | R-HSA-425407 | 287 | 4 | 10285 | 29 |
SLC1A3,AHCYL2,SLC1A2,SLC4A4 |
8.206e-03 | -4.80 | FOXF2 (forkhead box F2) | protein interactions | 2295 | 53 | 2 | 19454 | 50 |
ZBTB20,AHCYL2 |
8.216e-03 | -4.80 | ELFV_dehydrog | smart domains | SM00839 | 2 | 1 | 9717 | 40 |
GLUD1 |
8.218e-03 | -4.80 | cysteine transmembrane transport | biological process | GO:1903712 | 3 | 1 | 18204 | 50 |
SLC1A2 |
8.218e-03 | -4.80 | regulation of calcium:sodium antiporter activity | biological process | GO:1903279 | 3 | 1 | 18204 | 50 |
ATP1A2 |
8.218e-03 | -4.80 | formin-nucleated actin cable organization | biological process | GO:0110009 | 3 | 1 | 18204 | 50 |
FMN2 |
8.218e-03 | -4.80 | trans-synaptic signaling by BDNF, modulating synaptic transmission | biological process | GO:0099183 | 3 | 1 | 18204 | 50 |
NTRK2 |
8.218e-03 | -4.80 | neuroligin clustering involved in postsynaptic membrane assembly | biological process | GO:0097118 | 3 | 1 | 18204 | 50 |
NRXN1 |
8.218e-03 | -4.80 | cysteine transport | biological process | GO:0042883 | 3 | 1 | 18204 | 50 |
SLC1A2 |
8.218e-03 | -4.80 | cardiac muscle thin filament assembly | biological process | GO:0071691 | 3 | 1 | 18204 | 50 |
NEBL |
8.218e-03 | -4.80 | formin-nucleated actin cable assembly | biological process | GO:0070649 | 3 | 1 | 18204 | 50 |
FMN2 |
8.218e-03 | -4.80 | meiotic chromosome movement towards spindle pole | biological process | GO:0016344 | 3 | 1 | 18204 | 50 |
FMN2 |
8.218e-03 | -4.80 | radial glia guided migration of Purkinje cell | biological process | GO:0021942 | 3 | 1 | 18204 | 50 |
CTNNA2 |
8.317e-03 | -4.79 | synaptic signaling | biological process | GO:0099536 | 459 | 5 | 18204 | 50 |
NRXN1,NTRK2,DTNA,SLC1A2,SLC1A3 |
8.406e-03 | -4.78 | RYDR_Jsol | pfam domains | PF21119 | 3 | 1 | 17795 | 50 |
RYR3 |
8.406e-03 | -4.78 | LRRCT_2 | pfam domains | PF16920 | 3 | 1 | 17795 | 50 |
NTRK2 |
8.406e-03 | -4.78 | Myelin_PLP | pfam domains | PF01275 | 3 | 1 | 17795 | 50 |
GPM6A |
8.406e-03 | -4.78 | SR_plectin_7 | pfam domains | PF21097 | 3 | 1 | 17795 | 50 |
MACF1 |
8.406e-03 | -4.78 | AdoHcyase | pfam domains | PF05221 | 3 | 1 | 17795 | 50 |
AHCYL2 |
8.406e-03 | -4.78 | HIF-1 | pfam domains | PF11413 | 3 | 1 | 17795 | 50 |
HIF3A |
8.406e-03 | -4.78 | RR_TM4-6 | pfam domains | PF06459 | 3 | 1 | 17795 | 50 |
RYR3 |
8.406e-03 | -4.78 | RyR | pfam domains | PF02026 | 3 | 1 | 17795 | 50 |
RYR3 |
8.406e-03 | -4.78 | MamL-1 | pfam domains | PF09596 | 3 | 1 | 17795 | 50 |
MAML2 |
8.406e-03 | -4.78 | AdoHcyase_NAD | pfam domains | PF00670 | 3 | 1 | 17795 | 50 |
AHCYL2 |
8.436e-03 | -4.78 | protein binding | molecular function | GO:0005515 | 13983 | 44 | 18094 | 48 |
PITPNC1,MSI2,SLC1A2,GLIS3,NTRK2,SOX5,GPC5,GLUD1,CPE,CDH20,LSAMP,TNIK,FGFR3,MAML2,FBXL7,RORA,PTPRZ1,BMPR1B,HIF3A,ATP1A2,ITPR2,PARD3B,RYR3,NRXN1,GPM6A,NPAS3,SLC1A3,ABLIM1,LIFR,NTM,SLC4A4,SFXN5,FMN2,SPARCL1,DTNA,CTNND2,CTNNA2,NFIA,PTGDS,AHCYL2,MACF1,TRPS1,CST3,NEBL |
8.507e-03 | -4.77 | TAFA4 (TAFA chemokine like family member 4) | protein interactions | 151647 | 54 | 2 | 19454 | 50 |
LIFR,ITPR2 |
8.546e-03 | -4.76 | acute_lymphoblastic_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_leukaemia | 2197 | 13 | 16828 | 49 |
TNIK,TRPS1,PTPRZ1,NTRK2,NFIA,DTNA,BMPR1B,SOX5,FGFR3,ATP1A2,PARD3B,SLC4A4,PREX2 |
8.651e-03 | -4.75 | neuromuscular process controlling balance | biological process | GO:0050885 | 51 | 2 | 18204 | 50 |
NRXN1,SLC1A3 |
8.702e-03 | -4.74 | learning | biological process | GO:0007612 | 154 | 3 | 18204 | 50 |
NRXN1,ATP1A2,NTRK2 |
8.702e-03 | -4.74 | calcium-mediated signaling | biological process | GO:0019722 | 154 | 3 | 18204 | 50 |
ITPR2,ATP1A2,RYR3 |
8.711e-03 | -4.74 | urinary_tract-bladder-papilloma | COSMIC cancer mutations | urinary_tract-bladder-papilloma | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-leg-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-leg-other-seborrhoeic_keratosis | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-trunk-lentigo | COSMIC cancer mutations | skin-trunk-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-lentigo | COSMIC cancer mutations | skin-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-face-lentigo | COSMIC cancer mutations | skin-face-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-forearm-lentigo | COSMIC cancer mutations | skin-forearm-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-trunk-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-trunk-other-seborrhoeic_keratosis | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-hand-lentigo | COSMIC cancer mutations | skin-hand-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-leg-lentigo | COSMIC cancer mutations | skin-leg-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | lentigo | COSMIC cancer mutations | lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.712e-03 | -4.74 | ATPase-coupled monoatomic cation transmembrane transporter activity | molecular function | GO:0019829 | 53 | 2 | 18094 | 48 |
ATP13A4,ATP1A2 |
8.736e-03 | -4.74 | Amyotrophic lateral sclerosis (ALS) | WikiPathways | WP2447 | 38 | 2 | 5310 | 20 |
CST3,SLC1A2 |
8.771e-03 | -4.74 | EGR2 (early growth response 2) | protein interactions | 1959 | 165 | 3 | 19454 | 50 |
NFIA,SOX5,TRPS1 |
8.771e-03 | -4.74 | positive regulation of nervous system development | biological process | GO:0051962 | 296 | 4 | 18204 | 50 |
NTRK2,MACF1,PTPRZ1,NRXN1 |
8.782e-03 | -4.74 | FORMIN | prints domains | PR00828 | 2 | 1 | 5227 | 23 |
FMN2 |
8.782e-03 | -4.74 | GLFDHDRGNASE | prints domains | PR00082 | 2 | 1 | 5227 | 23 |
GLUD1 |
8.873e-03 | -4.72 | carboxylic acid transport | biological process | GO:0046942 | 297 | 4 | 18204 | 50 |
SFXN5,NTRK2,SLC1A3,SLC1A2 |
8.917e-03 | -4.72 | SCLT1 (sodium channel and clathrin linker 1) | protein interactions | 132320 | 166 | 3 | 19454 | 50 |
ATP1A2,NEBL,ABLIM1 |
8.976e-03 | -4.71 | organic acid transport | biological process | GO:0015849 | 298 | 4 | 18204 | 50 |
SLC1A2,SLC1A3,NTRK2,SFXN5 |
8.978e-03 | -4.71 | cell communication | biological process | GO:0007154 | 5010 | 22 | 18204 | 50 |
BMPR1B,NTRK2,FGFR3,SLC1A2,TNIK,CPE,ATP1A2,PREX2,FMN2,RYR3,SLC1A3,NRXN1,LIFR,SPARCL1,CTNND2,DTNA,NFIA,PITPNC1,MACF1,MAML2,RORA,ITPR2 |
8.982e-03 | -4.71 | regulation of purine nucleotide catabolic process | biological process | GO:0033121 | 52 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
8.982e-03 | -4.71 | regulation of glycolytic process | biological process | GO:0006110 | 52 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
8.982e-03 | -4.71 | regulation of nucleotide catabolic process | biological process | GO:0030811 | 52 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
8.986e-03 | -4.71 | Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-112310 | 51 | 2 | 10285 | 29 |
SLC1A3,SLC1A2 |
9.015e-03 | -4.71 | calcium ion binding | molecular function | GO:0005509 | 683 | 6 | 18094 | 48 |
RYR3,PCDH9,NRXN1,ITPR2,SPARCL1,MACF1 |
9.095e-03 | -4.70 | Adenosylhomocysteinase-like | gene3d domains | 3.40.50.1480 | 3 | 1 | 14470 | 44 |
AHCYL2 |
9.095e-03 | -4.70 | - | gene3d domains | 6.10.250.970 | 3 | 1 | 14470 | 44 |
MAML2 |
9.095e-03 | -4.70 | - | gene3d domains | 1.10.490.160 | 3 | 1 | 14470 | 44 |
RYR3 |
9.095e-03 | -4.70 | - | gene3d domains | 6.10.250.2510 | 3 | 1 | 14470 | 44 |
CTNNA2 |
9.147e-03 | -4.69 | presynaptic membrane | cellular component | GO:0042734 | 168 | 3 | 19108 | 49 |
SLC1A2,NRXN1,GPM6A |
9.171e-03 | -4.69 | positive regulation of synaptic transmission | biological process | GO:0050806 | 157 | 3 | 18204 | 50 |
NRXN1,NTRK2,SLC1A3 |
9.191e-03 | -4.69 | EF-hand | gene3d domains | 1.10.238.10 | 272 | 4 | 14470 | 44 |
DTNA,MACF1,SPARCL1,RYR3 |
9.212e-03 | -4.69 | POU2F1 (POU class 2 homeobox 1) | protein interactions | 5451 | 168 | 3 | 19454 | 50 |
SOX5,GPC5,LIFR |
9.318e-03 | -4.68 | neutral amino acid transport | biological process | GO:0015804 | 53 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
9.442e-03 | -4.66 | NXPH3 (neurexophilin 3) | protein interactions | 11248 | 57 | 2 | 19454 | 50 |
CTNNA2,NRXN1 |
9.492e-03 | -4.66 | monoatomic anion transport | biological process | GO:0006820 | 159 | 3 | 18204 | 50 |
SLC1A2,SLC1A3,SLC4A4 |
9.538e-03 | -4.65 | Signaling pathways regulating pluripotency of stem cells | KEGG pathways | hsa04550 | 139 | 3 | 7161 | 23 |
BMPR1B,LIFR,FGFR3 |
9.538e-03 | -4.65 | Signaling pathways regulating pluripotency of stem cells | KEGG pathways | ko04550 | 139 | 3 | 7161 | 23 |
BMPR1B,LIFR,FGFR3 |
9.616e-03 | -4.64 | lung-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-squamous_cell_carcinoma | 14664 | 48 | 16828 | 49 |
NEBL,MSI2,PTPRZ1,FMN2,GPC5,MAML2,CTNND2,SLC1A3,GLIS3,LSAMP,HIF3A,ZBTB20,SLC4A4,PITPNC1,SFXN5,FGFR3,PARD3B,ATP1A2,RYR3,BMPR1B,DTNA,AHCYL2,PTGDS,FBXL7,LIFR,SPARCL1,RORA,CPE,NTRK2,GPM6A,TRPS1,CDH20,TNIK,NPAS3,PCDH9,PREX2,ITPR2,ABLIM1,SOX5,SLC1A2,NFIA,NKAIN3,NRXN1,NTM,GLUD1,ATP13A4,MACF1,NHSL1 |
9.634e-03 | -4.64 | biliary_tract | COSMIC cancer mutations | biliary_tract | 15309 | 49 | 16828 | 49 |
MSI2,NEBL,CTNND2,SLC1A3,MAML2,FMN2,GPC5,PTPRZ1,CST3,ZBTB20,HIF3A,LSAMP,GLIS3,PARD3B,ATP1A2,FGFR3,SFXN5,SLC4A4,PITPNC1,DTNA,RYR3,BMPR1B,FBXL7,PTGDS,AHCYL2,SPARCL1,LIFR,NTRK2,RORA,CPE,TNIK,CDH20,GPM6A,TRPS1,PREX2,PCDH9,NPAS3,ABLIM1,ITPR2,NKAIN3,NFIA,SOX5,SLC1A2,NRXN1,ATP13A4,GLUD1,NTM,NHSL1,MACF1 |
9.709e-03 | -4.63 | HNRNPL (heterogeneous nuclear ribonucleoprotein L) | protein interactions | 3191 | 1958 | 11 | 19454 | 50 |
DTNA,ZBTB20,ABLIM1,AHCYL2,BMPR1B,PARD3B,MACF1,TRPS1,NFIA,FGFR3,MSI2 |
9.751e-03 | -4.63 | dendritic spine | cellular component | GO:0043197 | 172 | 3 | 19108 | 49 |
ATP1A2,NTRK2,GPM6A |
9.858e-03 | -4.62 | skin-scalp-malignant_melanoma | COSMIC cancer mutations | skin-scalp-malignant_melanoma | 634 | 6 | 16828 | 49 |
NFIA,FMN2,PREX2,PTPRZ1,NTM,NEBL |
9.950e-03 | -4.61 | CAV1 (caveolin 1) | protein interactions | 857 | 719 | 6 | 19454 | 50 |
TNIK,DTNA,AHCYL2,MACF1,FMN2,SLC1A3 |
1.001e-02 | -4.60 | response to cocaine | biological process | GO:0042220 | 55 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
1.002e-02 | -4.60 | Znf_NHR/GATA | interpro domains | IPR013088 | 56 | 2 | 18521 | 50 |
RORA,TRPS1 |
1.006e-02 | -4.60 | neuron spine | cellular component | GO:0044309 | 174 | 3 | 19108 | 49 |
ATP1A2,NTRK2,GPM6A |
1.009e-02 | -4.60 | CATATPASE | prints domains | PR00119 | 35 | 2 | 5227 | 23 |
ATP13A4,ATP1A2 |
1.022e-02 | -4.58 | extrinsic component of membrane | cellular component | GO:0019898 | 175 | 3 | 19108 | 49 |
CDH20,DTNA,CTNNA2 |
1.024e-02 | -4.58 | Nkiras1 (NFKB inhibitor interacting Ras-like protein 1) | protein interactions | 69721 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Ilkap (integrin-linked kinase-associated serine/threonine phosphatase 2C) | protein interactions | 67444 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Srgap1 (SLIT-ROBO Rho GTPase activating protein 1) | protein interactions | 117600 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Nme2 (NME/NM23 nucleoside diphosphate kinase 2) | protein interactions | 18103 | 4 | 1 | 19454 | 50 |
RORA |
1.024e-02 | -4.58 | Rhebl1 (Ras homolog enriched in brain like 1) | protein interactions | 69159 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Arhgef6 (Rac/Cdc42 guanine nucleotide exchange factor 6) | protein interactions | 73341 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Naa20 (N(alpha)-acetyltransferase 20, NatB catalytic subunit) | protein interactions | 67877 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Dnaja1 (DnaJ heat shock protein family (Hsp40) member A1) | protein interactions | 15502 | 4 | 1 | 19454 | 50 |
GLIS3 |
1.024e-02 | -4.58 | CCDC126 (coiled-coil domain containing 126) | protein interactions | 90693 | 4 | 1 | 19454 | 50 |
GPM6A |
1.024e-02 | -4.58 | Cdk14 (cyclin dependent kinase 14) | protein interactions | 18647 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Ctbp2 (C-terminal binding protein 2) | protein interactions | 13017 | 4 | 1 | 19454 | 50 |
TRPS1 |
1.029e-02 | -4.58 | LHX3 (LIM homeobox 3) | protein interactions | 8022 | 175 | 3 | 19454 | 50 |
SOX5,NFIA,TRPS1 |
1.036e-02 | -4.57 | release of sequestered calcium ion into cytosol | biological process | GO:0051209 | 56 | 2 | 18204 | 50 |
RYR3,ITPR2 |
1.042e-02 | -4.56 | SNTB1 (syntrophin beta 1) | protein interactions | 6641 | 60 | 2 | 19454 | 50 |
FGFR3,DTNA |
1.043e-02 | -4.56 | actin cytoskeleton | cellular component | GO:0015629 | 520 | 5 | 19108 | 49 |
FMN2,MACF1,CTNNA2,ABLIM1,NEBL |
1.049e-02 | -4.56 | import across plasma membrane | biological process | GO:0098739 | 165 | 3 | 18204 | 50 |
SLC1A2,SLC1A3,ATP1A2 |
1.057e-02 | -4.55 | ciliary neurotrophic factor receptor activity | molecular function | GO:0004897 | 4 | 1 | 18094 | 48 |
LIFR |
1.057e-02 | -4.55 | citrate transmembrane transporter activity | molecular function | GO:0015137 | 4 | 1 | 18094 | 48 |
SFXN5 |
1.057e-02 | -4.55 | tricarboxylic acid transmembrane transporter activity | molecular function | GO:0015142 | 4 | 1 | 18094 | 48 |
SFXN5 |
1.057e-02 | -4.55 | brain-derived neurotrophic factor binding | molecular function | GO:0048403 | 4 | 1 | 18094 | 48 |
NTRK2 |
1.057e-02 | -4.55 | ryanodine-sensitive calcium-release channel activity | molecular function | GO:0005219 | 4 | 1 | 18094 | 48 |
RYR3 |
1.072e-02 | -4.54 | visual behavior | biological process | GO:0007632 | 57 | 2 | 18204 | 50 |
SLC1A2,ATP1A2 |
1.072e-02 | -4.54 | negative regulation of sequestering of calcium ion | biological process | GO:0051283 | 57 | 2 | 18204 | 50 |
ITPR2,RYR3 |
1.076e-02 | -4.53 | CTF/NFI_DNA-bd-dom | interpro domains | IPR020604 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | CTF/NFI_DNA-bd_N | interpro domains | IPR019548 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | P5A-ATPase_N | interpro domains | IPR047819 | 4 | 1 | 18521 | 50 |
ATP13A4 |
1.076e-02 | -4.53 | P5B-type_ATPase | interpro domains | IPR047821 | 4 | 1 | 18521 | 50 |
ATP13A4 |
1.076e-02 | -4.53 | Na/K-Atpase_Interacting | interpro domains | IPR008516 | 4 | 1 | 18521 | 50 |
NKAIN3 |
1.076e-02 | -4.53 | Nebulin_repeat | interpro domains | IPR000900 | 4 | 1 | 18521 | 50 |
NEBL |
1.076e-02 | -4.53 | AbLIM_anchor | interpro domains | IPR032402 | 4 | 1 | 18521 | 50 |
ABLIM1 |
1.076e-02 | -4.53 | CTF/NFI_DNA-bd_CS | interpro domains | IPR019739 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | NHS-like | interpro domains | IPR024845 | 4 | 1 | 18521 | 50 |
NHSL1 |
1.076e-02 | -4.53 | Desmoplakin_Spectrin-like | interpro domains | IPR041573 | 4 | 1 | 18521 | 50 |
MACF1 |
1.076e-02 | -4.53 | Alpha_catenin | interpro domains | IPR001033 | 4 | 1 | 18521 | 50 |
CTNNA2 |
1.076e-02 | -4.53 | PCN-like_spectrin-like_rpt | interpro domains | IPR049538 | 4 | 1 | 18521 | 50 |
MACF1 |
1.076e-02 | -4.53 | FGF_rcpt_fam | interpro domains | IPR016248 | 4 | 1 | 18521 | 50 |
FGFR3 |
1.076e-02 | -4.53 | CTF/NFI | interpro domains | IPR000647 | 4 | 1 | 18521 | 50 |
NFIA |
1.079e-02 | -4.53 | ADOHCYASE_1 | prosite domains | PS00738 | 3 | 1 | 12186 | 44 |
AHCYL2 |
1.079e-02 | -4.53 | MYELIN_PLP_1 | prosite domains | PS00575 | 3 | 1 | 12186 | 44 |
GPM6A |
1.079e-02 | -4.53 | ADOHCYASE_2 | prosite domains | PS00739 | 3 | 1 | 12186 | 44 |
AHCYL2 |
1.079e-02 | -4.53 | MYELIN_PLP_2 | prosite domains | PS01004 | 3 | 1 | 12186 | 44 |
GPM6A |
1.079e-02 | -4.53 | VINCULIN_1 | prosite domains | PS00663 | 3 | 1 | 12186 | 44 |
CTNNA2 |
1.090e-02 | -4.52 | testis-germ_cell_tumour-seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-seminoma | 648 | 6 | 16828 | 49 |
FGFR3,TNIK,NTRK2,PREX2,TRPS1,BMPR1B |
1.094e-02 | -4.52 | response to glycoside | biological process | GO:1903416 | 4 | 1 | 18204 | 50 |
ATP1A2 |
1.094e-02 | -4.52 | negative regulation of germ cell proliferation | biological process | GO:1905937 | 4 | 1 | 18204 | 50 |
PTGDS |
1.094e-02 | -4.52 | brain-derived neurotrophic factor receptor signaling pathway | biological process | GO:0031547 | 4 | 1 | 18204 | 50 |
NTRK2 |
1.094e-02 | -4.52 | oncostatin-M-mediated signaling pathway | biological process | GO:0038165 | 4 | 1 | 18204 | 50 |
LIFR |
1.094e-02 | -4.52 | regulation of amino acid uptake involved in synaptic transmission | biological process | GO:0051941 | 4 | 1 | 18204 | 50 |
ATP1A2 |
1.094e-02 | -4.52 | regulation of glutamate uptake involved in transmission of nerve impulse | biological process | GO:0051946 | 4 | 1 | 18204 | 50 |
ATP1A2 |
1.094e-02 | -4.52 | ovarian cumulus expansion | biological process | GO:0001550 | 4 | 1 | 18204 | 50 |
BMPR1B |
1.094e-02 | -4.52 | regulation of collagen catabolic process | biological process | GO:0010710 | 4 | 1 | 18204 | 50 |
CST3 |
1.094e-02 | -4.52 | protein localization to secretory granule | biological process | GO:0033366 | 4 | 1 | 18204 | 50 |
CPE |
1.094e-02 | -4.52 | leukemia inhibitory factor signaling pathway | biological process | GO:0048861 | 4 | 1 | 18204 | 50 |
LIFR |
1.094e-02 | -4.52 | trans-synaptic signaling by BDNF | biological process | GO:0099191 | 4 | 1 | 18204 | 50 |
NTRK2 |
1.094e-02 | -4.52 | glutamate biosynthetic process | biological process | GO:0006537 | 4 | 1 | 18204 | 50 |
GLUD1 |
1.094e-02 | -4.52 | negative regulation of male germ cell proliferation | biological process | GO:2000255 | 4 | 1 | 18204 | 50 |
PTGDS |
1.094e-02 | -4.52 | positive regulation of mesenchymal stem cell differentiation | biological process | GO:2000741 | 4 | 1 | 18204 | 50 |
SOX5 |
1.098e-02 | -4.51 | primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | primitive_neuroectodermal_tumour-medulloblastoma | 15350 | 49 | 16828 | 49 |
DTNA,RYR3,BMPR1B,SPARCL1,LIFR,FBXL7,PTGDS,AHCYL2,SLC1A3,CTNND2,MAML2,GPC5,FMN2,PTPRZ1,MSI2,NEBL,PARD3B,ATP1A2,FGFR3,SFXN5,SLC4A4,PITPNC1,ZBTB20,CST3,HIF3A,LSAMP,GLIS3,NRXN1,NFIA,NKAIN3,SOX5,SLC1A2,NHSL1,MACF1,ATP13A4,GLUD1,NTM,TNIK,CDH20,GPM6A,TRPS1,NTRK2,RORA,CPE,ABLIM1,ITPR2,PCDH9,PREX2,NPAS3 |
1.110e-02 | -4.50 | cellular homeostasis | biological process | GO:0019725 | 689 | 6 | 18204 | 50 |
ATP13A4,RYR3,SLC1A3,ZBTB20,ATP1A2,SLC4A4 |
1.110e-02 | -4.50 | MYOD1 (myogenic differentiation 1) | protein interactions | 4654 | 180 | 3 | 19454 | 50 |
TRPS1,RORA,NFIA |
1.110e-02 | -4.50 | EPHA4 (EPH receptor A4) | protein interactions | 2043 | 180 | 3 | 19454 | 50 |
FGFR3,AHCYL2,CTNNA2 |
1.118e-02 | -4.49 | parathyroid-carcinoma | COSMIC cancer mutations | parathyroid-carcinoma | 300 | 4 | 16828 | 49 |
GPC5,MACF1,TRPS1,RYR3 |
1.119e-02 | -4.49 | P5-ATPase | pfam domains | PF12409 | 4 | 1 | 17795 | 50 |
ATP13A4 |
1.119e-02 | -4.49 | NKAIN | pfam domains | PF05640 | 4 | 1 | 17795 | 50 |
NKAIN3 |
1.119e-02 | -4.49 | CTF_NFI | pfam domains | PF00859 | 4 | 1 | 17795 | 50 |
NFIA |
1.119e-02 | -4.49 | NfI_DNAbd_pre-N | pfam domains | PF10524 | 4 | 1 | 17795 | 50 |
NFIA |
1.119e-02 | -4.49 | Spectrin_2 | pfam domains | PF18373 | 4 | 1 | 17795 | 50 |
MACF1 |
1.119e-02 | -4.49 | Spectrin_4 | pfam domains | PF21020 | 4 | 1 | 17795 | 50 |
MACF1 |
1.119e-02 | -4.49 | AbLIM_anchor | pfam domains | PF16182 | 4 | 1 | 17795 | 50 |
ABLIM1 |
1.119e-02 | -4.49 | NHS | pfam domains | PF15273 | 4 | 1 | 17795 | 50 |
NHSL1 |
1.119e-02 | -4.49 | Nebulin | pfam domains | PF00880 | 4 | 1 | 17795 | 50 |
NEBL |
1.119e-02 | -4.49 | Spectrin_3 | pfam domains | PF21019 | 4 | 1 | 17795 | 50 |
MACF1 |
1.120e-02 | -4.49 | cellular response to growth factor stimulus | biological process | GO:0071363 | 494 | 5 | 18204 | 50 |
FGFR3,NFIA,NTRK2,SOX5,BMPR1B |
1.132e-02 | -4.48 | cognition | biological process | GO:0050890 | 319 | 4 | 18204 | 50 |
NRXN1,PTPRZ1,NTRK2,ATP1A2 |
1.143e-02 | -4.47 | human chr4q34.2 | chromosome location | human chr4q34.2 | 6 | 1 | 26134 | 50 |
GPM6A |
1.143e-02 | -4.47 | human chr14q13.1 | chromosome location | human chr14q13.1 | 6 | 1 | 26134 | 50 |
NPAS3 |
1.145e-02 | -4.47 | endochondral bone morphogenesis | biological process | GO:0060350 | 59 | 2 | 18204 | 50 |
FGFR3,BMPR1B |
1.151e-02 | -4.46 | Ion transport by P-type ATPases | REACTOME pathways | R-HSA-936837 | 58 | 2 | 10285 | 29 |
ATP13A4,ATP1A2 |
1.156e-02 | -4.46 | oligodendroglioma_Grade_III | COSMIC cancer mutations | oligodendroglioma_Grade_III | 303 | 4 | 16828 | 49 |
FGFR3,GLIS3,PTPRZ1,MACF1 |
1.160e-02 | -4.46 | skin-lower_leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-lower_leg-malignant_melanoma-nodular | 4 | 1 | 16828 | 49 |
PREX2 |
1.160e-02 | -4.46 | urinary_tract-bladder-papilloma-inverted | COSMIC cancer mutations | urinary_tract-bladder-papilloma-inverted | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | inverted | COSMIC cancer mutations | inverted | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | skin-face-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-face-malignant_melanoma-superficial_spreading | 4 | 1 | 16828 | 49 |
PREX2 |
1.160e-02 | -4.46 | skin-benign_melanocytic_nevus-junctional | COSMIC cancer mutations | skin-benign_melanocytic_nevus-junctional | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | urinary_tract-bladder-other-normal | COSMIC cancer mutations | urinary_tract-bladder-other-normal | 4 | 1 | 16828 | 49 |
FGFR3 |
1.166e-02 | -4.45 | ion binding | molecular function | GO:0043167 | 6007 | 24 | 18094 | 48 |
CPE,GLUD1,SLC1A2,ABLIM1,PITPNC1,SLC1A3,NTRK2,GLIS3,TRPS1,MACF1,ZBTB20,ITPR2,ATP1A2,NRXN1,RYR3,PCDH9,ATP13A4,FGFR3,DTNA,TNIK,SPARCL1,RORA,BMPR1B,PTGDS |
1.167e-02 | -4.45 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-peripheral_T_cell_lymphoma_unspecified | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-peripheral_T_cell_lymphoma_unspecified | 162 | 3 | 16828 | 49 |
RYR3,ITPR2,MACF1 |
1.175e-02 | -4.44 | skeletal system development | biological process | GO:0001501 | 500 | 5 | 18204 | 50 |
NFIA,FGFR3,TRPS1,BMPR1B,SOX5 |
1.178e-02 | -4.44 | transmembrane receptor protein tyrosine kinase activity | molecular function | GO:0004714 | 62 | 2 | 18094 | 48 |
FGFR3,NTRK2 |
1.178e-02 | -4.44 | cation binding | molecular function | GO:0043169 | 4341 | 19 | 18094 | 48 |
ATP13A4,SLC1A2,ABLIM1,SLC1A3,DTNA,SPARCL1,BMPR1B,RORA,GLIS3,CPE,TRPS1,ZBTB20,GLUD1,MACF1,ITPR2,ATP1A2,NRXN1,RYR3,PCDH9 |
1.179e-02 | -4.44 | EVA1C (eva-1 homolog C) | protein interactions | 59271 | 64 | 2 | 19454 | 50 |
PCDH9,BMPR1B |
1.179e-02 | -4.44 | VSX1 (visual system homeobox 1) | protein interactions | 30813 | 64 | 2 | 19454 | 50 |
NFIA,TRPS1 |
1.179e-02 | -4.44 | SYNC (syncoilin, intermediate filament protein) | protein interactions | 81493 | 64 | 2 | 19454 | 50 |
MAML2,DTNA |
1.182e-02 | -4.44 | transmission of nerve impulse | biological process | GO:0019226 | 60 | 2 | 18204 | 50 |
NTRK2,ATP1A2 |
1.182e-02 | -4.44 | export across plasma membrane | biological process | GO:0140115 | 60 | 2 | 18204 | 50 |
ATP1A2,SLC4A4 |
1.184e-02 | -4.44 | cadherin binding | molecular function | GO:0045296 | 335 | 4 | 18094 | 48 |
MACF1,CTNNA2,CTNND2,CDH20 |
1.184e-02 | -4.44 | upper_aerodigestive_tract-mouth-carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma | 6426 | 27 | 16828 | 49 |
PREX2,NPAS3,ZBTB20,HIF3A,PARD3B,FGFR3,ABLIM1,SFXN5,PITPNC1,SLC4A4,RORA,SLC1A3,CTNND2,FMN2,GPC5,MAML2,CDH20,TRPS1,GPM6A,FBXL7,NTM,NHSL1,LIFR,MACF1,SLC1A2,RYR3,SOX5 |
1.192e-02 | -4.43 | chemical homeostasis | biological process | GO:0048878 | 914 | 7 | 18204 | 50 |
ZBTB20,RORA,ATP13A4,SLC1A3,RYR3,SLC4A4,ATP1A2 |
1.211e-02 | -4.41 | - | gene3d domains | 1.20.58.1060 | 4 | 1 | 14470 | 44 |
MACF1 |
1.216e-02 | -4.41 | parathyroid | COSMIC cancer mutations | parathyroid | 476 | 5 | 16828 | 49 |
RYR3,GPM6A,MACF1,TRPS1,GPC5 |
1.221e-02 | -4.41 | germ_cell_tumour | COSMIC cancer mutations | germ_cell_tumour | 867 | 7 | 16828 | 49 |
TNIK,FGFR3,TRPS1,MACF1,PREX2,NTRK2,BMPR1B |
1.223e-02 | -4.40 | monoatomic cation homeostasis | biological process | GO:0055080 | 505 | 5 | 18204 | 50 |
ATP13A4,ATP1A2,RYR3,SLC1A3,SLC4A4 |
1.228e-02 | -4.40 | ovary-carcinoma-clear_cell_carcinoma | COSMIC cancer mutations | ovary-carcinoma-clear_cell_carcinoma | 665 | 6 | 16828 | 49 |
SPARCL1,FGFR3,NTRK2,TNIK,BMPR1B,LIFR |
1.230e-02 | -4.40 | MamL-1 | smart domains | SM01275 | 3 | 1 | 9717 | 40 |
MAML2 |
1.230e-02 | -4.40 | AdoHcyase_NAD | smart domains | SM00997 | 3 | 1 | 9717 | 40 |
AHCYL2 |
1.230e-02 | -4.40 | AdoHcyase | smart domains | SM00996 | 3 | 1 | 9717 | 40 |
AHCYL2 |
1.230e-02 | -4.40 | PLP | smart domains | SM00002 | 3 | 1 | 9717 | 40 |
GPM6A |
1.248e-02 | -4.38 | HNF1B (HNF1 homeobox B) | protein interactions | 6928 | 188 | 3 | 19454 | 50 |
TRPS1,NFIA,SOX5 |
1.249e-02 | -4.38 | central nervous system neuron differentiation | biological process | GO:0021953 | 176 | 3 | 18204 | 50 |
BMPR1B,NTRK2,RORA |
1.249e-02 | -4.38 | back | COSMIC cancer mutations | back | 310 | 4 | 16828 | 49 |
PREX2,ATP1A2,FGFR3,TNIK |
1.250e-02 | -4.38 | ORM1 (orosomucoid 1) | protein interactions | 5004 | 66 | 2 | 19454 | 50 |
PTGDS,GLUD1 |
1.250e-02 | -4.38 | MAML1 (mastermind like transcriptional coactivator 1) | protein interactions | 9794 | 66 | 2 | 19454 | 50 |
MAML2,NFIA |
1.254e-02 | -4.38 | Erythroid Transcription Factor GATA-1, subunit A | gene3d domains | 3.30.50.10 | 56 | 2 | 14470 | 44 |
RORA,TRPS1 |
1.259e-02 | -4.38 | regulation of carbohydrate catabolic process | biological process | GO:0043470 | 62 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
1.261e-02 | -4.37 | CDH1 (cadherin 1) | protein interactions | 999 | 757 | 6 | 19454 | 50 |
ABLIM1,NEBL,NHSL1,CTNND2,CTNNA2,MACF1 |
1.262e-02 | -4.37 | clear_cell_carcinoma | COSMIC cancer mutations | clear_cell_carcinoma | 669 | 6 | 16828 | 49 |
SPARCL1,NTRK2,FGFR3,TNIK,LIFR,BMPR1B |
1.262e-02 | -4.37 | Ig-like_fold | interpro domains | IPR013783 | 721 | 6 | 18521 | 50 |
LIFR,NTM,LSAMP,FGFR3,PTPRZ1,NTRK2 |
1.266e-02 | -4.37 | peripheral_T_cell_lymphoma_unspecified | COSMIC cancer mutations | peripheral_T_cell_lymphoma_unspecified | 167 | 3 | 16828 | 49 |
RYR3,ITPR2,MACF1 |
1.279e-02 | -4.36 | Wwp2 (WW domain containing E3 ubiquitin protein ligase 2) | protein interactions | 66894 | 5 | 1 | 19454 | 50 |
GLIS3 |
1.279e-02 | -4.36 | Cdk4 (cyclin dependent kinase 4) | protein interactions | 12567 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | PTGER2 (prostaglandin E receptor 2) | protein interactions | 5732 | 5 | 1 | 19454 | 50 |
PTGDS |
1.279e-02 | -4.36 | Rab6b (RAB6B, member RAS oncogene family) | protein interactions | 270192 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | TRH (thyrotropin releasing hormone) | protein interactions | 7200 | 5 | 1 | 19454 | 50 |
CPE |
1.279e-02 | -4.36 | ARSI (arylsulfatase family member I) | protein interactions | 340075 | 5 | 1 | 19454 | 50 |
AHCYL2 |
1.279e-02 | -4.36 | Rhoj (ras homolog family member J) | protein interactions | 80837 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Hk3 (hexokinase 3) | protein interactions | 25060 | 5 | 1 | 19454 | 50 |
PTGDS |
1.279e-02 | -4.36 | SYT13 (synaptotagmin 13) | protein interactions | 57586 | 5 | 1 | 19454 | 50 |
NRXN1 |
1.279e-02 | -4.36 | Rhobtb1 (Rho-related BTB domain containing 1) | protein interactions | 69288 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Rras2 (related RAS viral (r-ras) oncogene 2) | protein interactions | 66922 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Rab38 (RAB38, member RAS oncogene family) | protein interactions | 72433 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | D-Glutamine and D-glutamate metabolism | KEGG pathways | hsa00471 | 4 | 1 | 7161 | 23 |
GLUD1 |
1.279e-02 | -4.36 | D-Glutamine and D-glutamate metabolism | KEGG pathways | ko00471 | 4 | 1 | 7161 | 23 |
GLUD1 |
1.302e-02 | -4.34 | pancreas-carcinoma | COSMIC cancer mutations | pancreas-carcinoma | 14770 | 48 | 16828 | 49 |
MACF1,NHSL1,NTM,GLUD1,ATP13A4,NRXN1,SOX5,SLC1A2,NKAIN3,NFIA,ITPR2,ABLIM1,NPAS3,PCDH9,PREX2,GPM6A,TRPS1,CDH20,TNIK,RORA,CPE,NTRK2,LIFR,SPARCL1,AHCYL2,PTGDS,FBXL7,RYR3,BMPR1B,SLC4A4,PITPNC1,SFXN5,FGFR3,PARD3B,ATP1A2,LSAMP,GLIS3,HIF3A,CST3,ZBTB20,PTPRZ1,FMN2,GPC5,MAML2,SLC1A3,CTNND2,NEBL,MSI2 |
1.310e-02 | -4.34 | medullomyoblastoma | COSMIC cancer mutations | medullomyoblastoma | 485 | 5 | 16828 | 49 |
ATP13A4,PCDH9,SLC4A4,LSAMP,RYR3 |
1.310e-02 | -4.34 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-medullomyoblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-medullomyoblastoma | 485 | 5 | 16828 | 49 |
PCDH9,ATP13A4,RYR3,SLC4A4,LSAMP |
1.314e-02 | -4.33 | inorganic ion transmembrane transport | biological process | GO:0098660 | 715 | 6 | 18204 | 50 |
RYR3,SLC1A3,GPM6A,ITPR2,ATP1A2,SLC4A4 |
1.315e-02 | -4.33 | MYELINPLP | prints domains | PR00214 | 3 | 1 | 5227 | 23 |
GPM6A |
1.315e-02 | -4.33 | NTKRECEPTOR | prints domains | PR01939 | 3 | 1 | 5227 | 23 |
NTRK2 |
1.315e-02 | -4.33 | PGNDSYNTHASE | prints domains | PR01254 | 3 | 1 | 5227 | 23 |
PTGDS |
1.315e-02 | -4.33 | INSP3RECEPTR | prints domains | PR00779 | 3 | 1 | 5227 | 23 |
ITPR2 |
1.315e-02 | -4.33 | RORNUCRECPTR | prints domains | PR01293 | 3 | 1 | 5227 | 23 |
RORA |
1.315e-02 | -4.33 | RYANODINER | prints domains | PR00795 | 3 | 1 | 5227 | 23 |
RYR3 |
1.317e-02 | -4.33 | carboxylic acid transmembrane transporter activity | molecular function | GO:0046943 | 186 | 3 | 18094 | 48 |
SFXN5,SLC1A2,SLC1A3 |
1.317e-02 | -4.33 | upper_leg | COSMIC cancer mutations | upper_leg | 880 | 7 | 16828 | 49 |
FGFR3,FMN2,HIF3A,GLIS3,PCDH9,PREX2,NFIA |
1.320e-02 | -4.33 | fibroblast growth factor receptor activity | molecular function | GO:0005007 | 5 | 1 | 18094 | 48 |
FGFR3 |
1.320e-02 | -4.33 | transforming growth factor beta receptor activity, type I | molecular function | GO:0005025 | 5 | 1 | 18094 | 48 |
BMPR1B |
1.320e-02 | -4.33 | neurotrophin receptor activity | molecular function | GO:0005030 | 5 | 1 | 18094 | 48 |
NTRK2 |
1.320e-02 | -4.33 | neuroligin family protein binding | molecular function | GO:0097109 | 5 | 1 | 18094 | 48 |
NRXN1 |
1.321e-02 | -4.33 | non_small_cell_carcinoma | COSMIC cancer mutations | non_small_cell_carcinoma | 5198 | 23 | 16828 | 49 |
SPARCL1,LIFR,FBXL7,ATP13A4,BMPR1B,SOX5,FGFR3,ABLIM1,PITPNC1,ITPR2,PREX2,NPAS3,HIF3A,LSAMP,CTNND2,SLC1A3,MAML2,TNIK,TRPS1,PTPRZ1,MSI2,NTRK2,RORA |
1.321e-02 | -4.33 | lung-carcinoma-non_small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-non_small_cell_carcinoma | 5198 | 23 | 16828 | 49 |
MSI2,NTRK2,SOX5,BMPR1B,RORA,CTNND2,SLC1A3,TNIK,MAML2,PTPRZ1,TRPS1,ATP13A4,PREX2,FBXL7,NPAS3,HIF3A,LSAMP,ABLIM1,SPARCL1,FGFR3,ITPR2,PITPNC1,LIFR |
1.322e-02 | -4.33 | monoatomic ion homeostasis | biological process | GO:0050801 | 515 | 5 | 18204 | 50 |
SLC1A3,RYR3,ATP1A2,ATP13A4,SLC4A4 |
1.327e-02 | -4.32 | L-amino acid transmembrane transporter activity | molecular function | GO:0015179 | 66 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
1.332e-02 | -4.32 | testis-germ_cell_tumour-non_seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-non_seminoma | 487 | 5 | 16828 | 49 |
BMPR1B,MACF1,FGFR3,NTRK2,TNIK |
1.332e-02 | -4.32 | human chr8q13.2 | chromosome location | human chr8q13.2 | 7 | 1 | 26134 | 50 |
PREX2 |
1.332e-02 | -4.32 | human chr13q21.32 | chromosome location | human chr13q21.32 | 7 | 1 | 26134 | 50 |
PCDH9 |
1.335e-02 | -4.32 | camera-type eye development | biological process | GO:0043010 | 335 | 4 | 18204 | 50 |
NTRK2,BMPR1B,GPM6A,NFIA |
1.336e-02 | -4.32 | organic acid transmembrane transporter activity | molecular function | GO:0005342 | 187 | 3 | 18094 | 48 |
SFXN5,SLC1A2,SLC1A3 |
1.343e-02 | -4.31 | Protocadherin | interpro domains | IPR013585 | 5 | 1 | 18521 | 50 |
PCDH9 |
1.343e-02 | -4.31 | Follistatin/Osteonectin_EGF | interpro domains | IPR015369 | 5 | 1 | 18521 | 50 |
SPARCL1 |
1.343e-02 | -4.31 | PI_transfer | interpro domains | IPR001666 | 5 | 1 | 18521 | 50 |
PITPNC1 |
1.343e-02 | -4.31 | Vinculin/catenin | interpro domains | IPR006077 | 5 | 1 | 18521 | 50 |
CTNNA2 |
1.343e-02 | -4.31 | Mtc | interpro domains | IPR004686 | 5 | 1 | 18521 | 50 |
SFXN5 |
1.343e-02 | -4.31 | Na/HCO3_transpt | interpro domains | IPR003024 | 5 | 1 | 18521 | 50 |
SLC4A4 |
1.343e-02 | -4.31 | P-type_TPase_V | interpro domains | IPR006544 | 5 | 1 | 18521 | 50 |
ATP13A4 |
1.356e-02 | -4.30 | arm | COSMIC cancer mutations | arm | 1331 | 9 | 16828 | 49 |
MACF1,SLC4A4,TRPS1,PARD3B,ATP1A2,FGFR3,NTM,ZBTB20,NPAS3 |
1.366e-02 | -4.29 | citrate transport | biological process | GO:0015746 | 5 | 1 | 18204 | 50 |
SFXN5 |
1.366e-02 | -4.29 | amygdala development | biological process | GO:0021764 | 5 | 1 | 18204 | 50 |
ATP1A2 |
1.366e-02 | -4.29 | synaptic signaling via neuropeptide | biological process | GO:0099538 | 5 | 1 | 18204 | 50 |
NTRK2 |
1.366e-02 | -4.29 | tricarboxylic acid transport | biological process | GO:0006842 | 5 | 1 | 18204 | 50 |
SFXN5 |
1.366e-02 | -4.29 | polar body extrusion after meiotic divisions | biological process | GO:0040038 | 5 | 1 | 18204 | 50 |
FMN2 |
1.366e-02 | -4.29 | ciliary neurotrophic factor-mediated signaling pathway | biological process | GO:0070120 | 5 | 1 | 18204 | 50 |
LIFR |
1.366e-02 | -4.29 | negative regulation of chondrocyte proliferation | biological process | GO:1902731 | 5 | 1 | 18204 | 50 |
BMPR1B |
1.366e-02 | -4.29 | gephyrin clustering involved in postsynaptic density assembly | biological process | GO:0097116 | 5 | 1 | 18204 | 50 |
NRXN1 |
1.367e-02 | -4.29 | neoplasm | COSMIC cancer mutations | neoplasm | 14787 | 48 | 16828 | 49 |
LIFR,MACF1,NHSL1,SPARCL1,GLUD1,AHCYL2,NTM,FBXL7,ATP13A4,PTGDS,NRXN1,SLC1A2,BMPR1B,SOX5,RYR3,DTNA,NFIA,NKAIN3,SFXN5,ITPR2,SLC4A4,ATP1A2,PARD3B,FGFR3,ABLIM1,HIF3A,LSAMP,GLIS3,PREX2,PCDH9,ZBTB20,CST3,NPAS3,CDH20,TRPS1,PTPRZ1,GPM6A,SLC1A3,CTNND2,TNIK,GPC5,MAML2,FMN2,NEBL,CPE,RORA,MSI2,NTRK2 |
1.377e-02 | -4.29 | positive regulation of synapse assembly | biological process | GO:0051965 | 65 | 2 | 18204 | 50 |
NTRK2,NRXN1 |
1.386e-02 | -4.28 | regulation of carbohydrate metabolic process | biological process | GO:0006109 | 183 | 3 | 18204 | 50 |
RORA,ZBTB20,SLC4A4 |
1.387e-02 | -4.28 | non_seminoma | COSMIC cancer mutations | non_seminoma | 492 | 5 | 16828 | 49 |
NTRK2,TNIK,FGFR3,MACF1,BMPR1B |
1.397e-02 | -4.27 | Vinculin | pfam domains | PF01044 | 5 | 1 | 17795 | 50 |
CTNNA2 |
1.397e-02 | -4.27 | IP_trans | pfam domains | PF02121 | 5 | 1 | 17795 | 50 |
PITPNC1 |
1.397e-02 | -4.27 | SFXNs | pfam domains | PF03820 | 5 | 1 | 17795 | 50 |
SFXN5 |
1.397e-02 | -4.27 | Protocadherin | pfam domains | PF08374 | 5 | 1 | 17795 | 50 |
PCDH9 |
1.397e-02 | -4.27 | FOLN | pfam domains | PF09289 | 5 | 1 | 17795 | 50 |
SPARCL1 |
1.398e-02 | -4.27 | skin-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-carcinoma-squamous_cell_carcinoma | 493 | 5 | 16828 | 49 |
PREX2,FGFR3,MAML2,NTRK2,LIFR |
1.402e-02 | -4.27 | NGF-independant TRKA activation | REACTOME pathways | R-HSA-187024 | 5 | 1 | 10285 | 29 |
NTRK2 |
1.406e-02 | -4.26 | superficial_spreading | COSMIC cancer mutations | superficial_spreading | 1110 | 8 | 16828 | 49 |
CTNND2,FGFR3,SLC4A4,MACF1,LIFR,ATP13A4,PREX2,NTM |
1.407e-02 | -4.26 | RAB35 (RAB35, member RAS oncogene family) | protein interactions | 11021 | 559 | 5 | 19454 | 50 |
FMN2,MACF1,SLC1A3,AHCYL2,DTNA |
1.418e-02 | -4.26 | liver-carcinoma-hepatocellular_carcinoma | COSMIC cancer mutations | liver-carcinoma-hepatocellular_carcinoma | 14800 | 48 | 16828 | 49 |
NTRK2,CPE,RORA,TNIK,TRPS1,GPM6A,CDH20,NPAS3,PCDH9,PREX2,ABLIM1,ITPR2,NKAIN3,NFIA,SLC1A2,SOX5,NRXN1,ATP13A4,NTM,GLUD1,NHSL1,MACF1,NEBL,GPC5,MAML2,FMN2,CTNND2,SLC1A3,PTPRZ1,ZBTB20,CST3,LSAMP,GLIS3,HIF3A,FGFR3,ATP1A2,PARD3B,PITPNC1,SLC4A4,SFXN5,DTNA,BMPR1B,RYR3,PTGDS,FBXL7,AHCYL2,SPARCL1,LIFR |
1.418e-02 | -4.26 | hepatocellular_carcinoma | COSMIC cancer mutations | hepatocellular_carcinoma | 14800 | 48 | 16828 | 49 |
DTNA,RYR3,BMPR1B,SPARCL1,LIFR,FBXL7,PTGDS,AHCYL2,SLC1A3,CTNND2,MAML2,GPC5,FMN2,PTPRZ1,NEBL,PARD3B,ATP1A2,FGFR3,SFXN5,SLC4A4,PITPNC1,ZBTB20,CST3,HIF3A,GLIS3,LSAMP,NRXN1,NKAIN3,NFIA,SOX5,SLC1A2,NHSL1,MACF1,ATP13A4,GLUD1,NTM,TNIK,CDH20,GPM6A,TRPS1,NTRK2,RORA,CPE,ABLIM1,ITPR2,PREX2,PCDH9,NPAS3 |
1.418e-02 | -4.26 | L-alpha-amino acid transmembrane transport | biological process | GO:1902475 | 66 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
1.427e-02 | -4.25 | response to growth factor | biological process | GO:0070848 | 525 | 5 | 18204 | 50 |
NFIA,FGFR3,BMPR1B,NTRK2,SOX5 |
1.429e-02 | -4.25 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | 2081 | 12 | 16828 | 49 |
SLC4A4,ATP1A2,FGFR3,PREX2,PTPRZ1,TRPS1,TNIK,SOX5,BMPR1B,DTNA,NTRK2,NFIA |
1.433e-02 | -4.25 | NFIX (nuclear factor I X) | protein interactions | 4784 | 198 | 3 | 19454 | 50 |
NFIA,SOX5,TRPS1 |
1.437e-02 | -4.24 | CTF_NFI_2 | prosite domains | PS51080 | 4 | 1 | 12186 | 44 |
NFIA |
1.437e-02 | -4.24 | NEBULIN | prosite domains | PS51216 | 4 | 1 | 12186 | 44 |
NEBL |
1.437e-02 | -4.24 | CTF_NFI_1 | prosite domains | PS00349 | 4 | 1 | 12186 | 44 |
NFIA |
1.437e-02 | -4.24 | ANK2 (ankyrin 2) | protein interactions | 287 | 71 | 2 | 19454 | 50 |
GPM6A,TNIK |
1.448e-02 | -4.24 | skin-face-other-nevus_sebaceous | COSMIC cancer mutations | skin-face-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-ear-other-nevus_sebaceous | COSMIC cancer mutations | skin-ear-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-breast-other-lichenoid_keratosis | COSMIC cancer mutations | skin-breast-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-upper_back-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_back-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | monoclonal_gammopathy_of_undetermined_significance | COSMIC cancer mutations | monoclonal_gammopathy_of_undetermined_significance | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-face-other-lichenoid_keratosis | COSMIC cancer mutations | skin-face-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-breast-other-nevus_sebaceous | COSMIC cancer mutations | skin-breast-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-hip-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-hip-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-chest-other-lichenoid_keratosis | COSMIC cancer mutations | skin-chest-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_back-other-lichenoid_keratosis | COSMIC cancer mutations | skin-lower_back-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-adnexal_tumour-syringocystadenoma_papilliferum | COSMIC cancer mutations | skin-adnexal_tumour-syringocystadenoma_papilliferum | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-scalp-other-nevus_sebaceous | COSMIC cancer mutations | skin-scalp-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-forearm-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-forearm-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-upper_arm-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_arm-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-shoulder-other-nevus_sebaceous | COSMIC cancer mutations | skin-shoulder-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-flank-other-lichenoid_keratosis | COSMIC cancer mutations | skin-flank-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | syringocystadenoma_papilliferum | COSMIC cancer mutations | syringocystadenoma_papilliferum | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-forearm-other-lichenoid_keratosis | COSMIC cancer mutations | skin-forearm-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-shoulder-other-lichenoid_keratosis | COSMIC cancer mutations | skin-shoulder-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_back-other-nevus_sebaceous | COSMIC cancer mutations | skin-lower_back-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-arm-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-arm-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-hand-other-lichenoid_keratosis | COSMIC cancer mutations | skin-hand-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-other-lichenoid_keratosis | COSMIC cancer mutations | skin-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-monoclonal_gammopathy_of_undetermined_significance | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-monoclonal_gammopathy_of_undetermined_significance | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-neck-other-nevus_sebaceous | COSMIC cancer mutations | skin-neck-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-neck-other-lichenoid_keratosis | COSMIC cancer mutations | skin-neck-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_leg-other-lichenoid_keratosis | COSMIC cancer mutations | skin-lower_leg-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-lower_leg-malignant_melanoma-superficial_spreading | 5 | 1 | 16828 | 49 |
PREX2 |
1.448e-02 | -4.24 | lichenoid_keratosis | COSMIC cancer mutations | lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-upper_leg-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_leg-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.476e-02 | -4.22 | DPYSL3 (dihydropyrimidinase like 3) | protein interactions | 1809 | 72 | 2 | 19454 | 50 |
TNIK,GPM6A |
1.476e-02 | -4.22 | PPP3CC (protein phosphatase 3 catalytic subunit gamma) | protein interactions | 5533 | 72 | 2 | 19454 | 50 |
BMPR1B,PARD3B |
1.493e-02 | -4.20 | presynapse | cellular component | GO:0098793 | 569 | 5 | 19108 | 49 |
NTRK2,SLC1A2,NRXN1,GPM6A,TNIK |
1.493e-02 | -4.20 | meninges-meningioma | COSMIC cancer mutations | meninges-meningioma | 327 | 4 | 16828 | 49 |
ITPR2,NFIA,FMN2,FGFR3 |
1.494e-02 | -4.20 | carboxylic acid binding | molecular function | GO:0031406 | 195 | 3 | 18094 | 48 |
SLC1A3,PTGDS,GLUD1 |
1.500e-02 | -4.20 | adenoid_cystic_carcinoma | COSMIC cancer mutations | adenoid_cystic_carcinoma | 1123 | 8 | 16828 | 49 |
RYR3,RORA,NTRK2,LIFR,CTNND2,TNIK,FGFR3,MAML2 |
1.508e-02 | -4.19 | upper_back | COSMIC cancer mutations | upper_back | 328 | 4 | 16828 | 49 |
MACF1,FGFR3,GPC5,PARD3B |
1.512e-02 | -4.19 | FEV (FEV transcription factor, ETS family member) | protein interactions | 54738 | 202 | 3 | 19454 | 50 |
TRPS1,NFIA,SOX5 |
1.517e-02 | -4.19 | breast-carcinoma-ductal_carcinoma | COSMIC cancer mutations | breast-carcinoma-ductal_carcinoma | 14824 | 48 | 16828 | 49 |
ABLIM1,ITPR2,PREX2,PCDH9,NPAS3,TNIK,CDH20,TRPS1,GPM6A,NTRK2,CPE,RORA,MACF1,ATP13A4,GLUD1,NTM,NRXN1,NFIA,NKAIN3,SLC1A2,SOX5,ATP1A2,PARD3B,FGFR3,SFXN5,PITPNC1,SLC4A4,ZBTB20,CST3,HIF3A,GLIS3,LSAMP,CTNND2,SLC1A3,GPC5,MAML2,FMN2,PTPRZ1,MSI2,NEBL,SPARCL1,LIFR,FBXL7,PTGDS,AHCYL2,DTNA,BMPR1B,RYR3 |
1.526e-02 | -4.18 | positive regulation of multicellular organismal process | biological process | GO:0051240 | 1691 | 10 | 18204 | 50 |
RORA,NRXN1,ZBTB20,BMPR1B,NTRK2,SFXN5,ATP1A2,SOX5,PTPRZ1,MACF1 |
1.532e-02 | -4.18 | GDF6 (growth differentiation factor 6) | protein interactions | 392255 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | FGF18 (fibroblast growth factor 18) | protein interactions | 8817 | 6 | 1 | 19454 | 50 |
FGFR3 |
1.532e-02 | -4.18 | SYTL3 (synaptotagmin like 3) | protein interactions | 94120 | 6 | 1 | 19454 | 50 |
NRXN1 |
1.532e-02 | -4.18 | FGF6 (fibroblast growth factor 6) | protein interactions | 2251 | 6 | 1 | 19454 | 50 |
FGFR3 |
1.532e-02 | -4.18 | CYRIA (CYFIP related Rac1 interactor A) | protein interactions | 81553 | 6 | 1 | 19454 | 50 |
GPM6A |
1.532e-02 | -4.18 | Fancl (Fanconi anemia, complementation group L) | protein interactions | 67030 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | DRP2 (dystrophin related protein 2) | protein interactions | 1821 | 6 | 1 | 19454 | 50 |
DTNA |
1.532e-02 | -4.18 | SOX11 (SRY-box transcription factor 11) | protein interactions | 6664 | 6 | 1 | 19454 | 50 |
SOX5 |
1.532e-02 | -4.18 | Klhl22 (kelch-like 22) | protein interactions | 224023 | 6 | 1 | 19454 | 50 |
GLUD1 |
1.532e-02 | -4.18 | FGF23 (fibroblast growth factor 23) | protein interactions | 8074 | 6 | 1 | 19454 | 50 |
FGFR3 |
1.532e-02 | -4.18 | Itch (itchy, E3 ubiquitin protein ligase) | protein interactions | 16396 | 6 | 1 | 19454 | 50 |
GLIS3 |
1.532e-02 | -4.18 | Tiam2 (T cell lymphoma invasion and metastasis 2) | protein interactions | 24001 | 6 | 1 | 19454 | 50 |
DTNA |
1.532e-02 | -4.18 | SLC12A5 (solute carrier family 12 member 5) | protein interactions | 57468 | 6 | 1 | 19454 | 50 |
GPM6A |
1.532e-02 | -4.18 | Rhod (ras homolog family member D) | protein interactions | 11854 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | LIF (LIF interleukin 6 family cytokine) | protein interactions | 3976 | 6 | 1 | 19454 | 50 |
LIFR |
1.532e-02 | -4.18 | SOX1 (SRY-box transcription factor 1) | protein interactions | 6656 | 6 | 1 | 19454 | 50 |
SOX5 |
1.532e-02 | -4.18 | Map2k3 (mitogen-activated protein kinase kinase 3) | protein interactions | 26397 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.541e-02 | -4.17 | GJA1 (gap junction protein alpha 1) | protein interactions | 2697 | 572 | 5 | 19454 | 50 |
TNIK,DTNA,MACF1,PCDH9,ITPR2 |
1.547e-02 | -4.17 | cell-cell contact zone | cellular component | GO:0044291 | 74 | 2 | 19108 | 49 |
ATP1A2,PCDH9 |
1.549e-02 | -4.17 | skin-ear-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-ear-carcinoma-squamous_cell_carcinoma | 506 | 5 | 16828 | 49 |
FGFR3,NPAS3,SPARCL1,ZBTB20,LIFR |
1.549e-02 | -4.17 | seminoma | COSMIC cancer mutations | seminoma | 700 | 6 | 16828 | 49 |
BMPR1B,NTRK2,PREX2,TRPS1,TNIK,FGFR3 |
1.552e-02 | -4.17 | NFIC (nuclear factor I C) | protein interactions | 4782 | 204 | 3 | 19454 | 50 |
NFIA,SOX5,TRPS1 |
1.576e-02 | -4.15 | Znf_LIM | interpro domains | IPR001781 | 71 | 2 | 18521 | 50 |
NEBL,ABLIM1 |
1.581e-02 | -4.15 | calcium-induced calcium release activity | molecular function | GO:0048763 | 6 | 1 | 18094 | 48 |
RYR3 |
1.581e-02 | -4.15 | ciliary neurotrophic factor receptor binding | molecular function | GO:0005127 | 6 | 1 | 18094 | 48 |
LIFR |
1.581e-02 | -4.15 | sodium:bicarbonate symporter activity | molecular function | GO:0008510 | 6 | 1 | 18094 | 48 |
SLC4A4 |
1.581e-02 | -4.15 | steroid hormone binding | molecular function | GO:1990239 | 6 | 1 | 18094 | 48 |
ATP1A2 |
1.592e-02 | -4.14 | cellular process | biological process | GO:0009987 | 14996 | 47 | 18204 | 50 |
SOX5,FGFR3,GLIS3,NHSL1,PARD3B,CPE,ATP1A2,SFXN5,CDH20,LSAMP,GPC5,GPM6A,NRXN1,SPARCL1,NEBL,DTNA,ABLIM1,CTNNA2,PITPNC1,GLUD1,SLC4A4,AHCYL2,MSI2,NTRK2,BMPR1B,TNIK,SLC1A2,ZBTB20,FMN2,PREX2,ATP13A4,CST3,RYR3,SLC1A3,PCDH9,LIFR,PTPRZ1,CTNND2,FBXL7,HIF3A,NFIA,NTM,MACF1,RORA,PTGDS,MAML2,ITPR2 |
1.597e-02 | -4.14 | Synaptic Vesicle Pathway | WikiPathways | WP2267 | 52 | 2 | 5310 | 20 |
SLC1A3,ATP1A2 |
1.600e-02 | -4.13 | lung-middle_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-middle_lobe-carcinoma-adenocarcinoma | 1368 | 9 | 16828 | 49 |
ATP13A4,PCDH9,CPE,RYR3,ATP1A2,CTNND2,PARD3B,ITPR2,MACF1 |
1.600e-02 | -4.13 | other | COSMIC cancer mutations | other | 14843 | 48 | 16828 | 49 |
AHCYL2,FBXL7,PTGDS,LIFR,SPARCL1,BMPR1B,RYR3,DTNA,HIF3A,LSAMP,GLIS3,CST3,ZBTB20,SFXN5,SLC4A4,ATP1A2,PARD3B,FGFR3,NEBL,MSI2,PTPRZ1,SLC1A3,CTNND2,FMN2,GPC5,MAML2,GLUD1,NTM,ATP13A4,MACF1,NHSL1,SLC1A2,SOX5,NFIA,NKAIN3,NRXN1,PREX2,PCDH9,NPAS3,ITPR2,ABLIM1,CPE,RORA,NTRK2,CDH20,TRPS1,GPM6A,TNIK |
1.609e-02 | -4.13 | GLI-like | interpro domains | IPR043359 | 6 | 1 | 18521 | 50 |
GLIS3 |
1.609e-02 | -4.13 | Glypican_CS | interpro domains | IPR019803 | 6 | 1 | 18521 | 50 |
GPC5 |
1.609e-02 | -4.13 | Syndecan/Neurexin_dom | interpro domains | IPR027789 | 6 | 1 | 18521 | 50 |
NRXN1 |
1.609e-02 | -4.13 | EF-hand_dom_typ2 | interpro domains | IPR015154 | 6 | 1 | 18521 | 50 |
DTNA |
1.609e-02 | -4.13 | Glypican | interpro domains | IPR001863 | 6 | 1 | 18521 | 50 |
GPC5 |
1.609e-02 | -4.13 | EF-hand_dom_typ1 | interpro domains | IPR015153 | 6 | 1 | 18521 | 50 |
DTNA |
1.609e-02 | -4.13 | GAR_dom | interpro domains | IPR003108 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | Desmoplakin_SH3 | interpro domains | IPR041615 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | GAR_dom_sf | interpro domains | IPR036534 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | P-type_ATPase_IIC | interpro domains | IPR005775 | 6 | 1 | 18521 | 50 |
ATP1A2 |
1.610e-02 | -4.13 | LIM | pfam domains | PF00412 | 69 | 2 | 17795 | 50 |
NEBL,ABLIM1 |
1.616e-02 | -4.13 | bone-femur-other-chondroblastoma | COSMIC cancer mutations | bone-femur-other-chondroblastoma | 183 | 3 | 16828 | 49 |
PCDH9,GPC5,RYR3 |
1.622e-02 | -4.12 | salivary_gland | COSMIC cancer mutations | salivary_gland | 1139 | 8 | 16828 | 49 |
RORA,RYR3,NTRK2,LIFR,MAML2,FGFR3,TNIK,CTNND2 |
1.627e-02 | -4.12 | sarcoplasmic reticulum | cellular component | GO:0016529 | 76 | 2 | 19108 | 49 |
RYR3,ITPR2 |
1.630e-02 | -4.12 | IGc2 | smart domains | SM00408 | 239 | 4 | 9717 | 40 |
NTM,LSAMP,NTRK2,FGFR3 |
1.637e-02 | -4.11 | NEBU | smart domains | SM00227 | 4 | 1 | 9717 | 40 |
NEBL |
1.637e-02 | -4.11 | vocal learning | biological process | GO:0042297 | 6 | 1 | 18204 | 50 |
NRXN1 |
1.637e-02 | -4.11 | negative regulation of extracellular matrix disassembly | biological process | GO:0010716 | 6 | 1 | 18204 | 50 |
CST3 |
1.637e-02 | -4.11 | imitative learning | biological process | GO:0098596 | 6 | 1 | 18204 | 50 |
NRXN1 |
1.637e-02 | -4.11 | postsynaptic density protein 95 clustering | biological process | GO:0097119 | 6 | 1 | 18204 | 50 |
NRXN1 |
1.637e-02 | -4.11 | fused antrum stage | biological process | GO:0048165 | 6 | 1 | 18204 | 50 |
BMPR1B |
1.637e-02 | -4.11 | asymmetric neuroblast division | biological process | GO:0055059 | 6 | 1 | 18204 | 50 |
SOX5 |
1.637e-02 | -4.11 | establishment of meiotic spindle localization | biological process | GO:0051295 | 6 | 1 | 18204 | 50 |
FMN2 |
1.637e-02 | -4.11 | gamma-aminobutyric acid biosynthetic process | biological process | GO:0009449 | 6 | 1 | 18204 | 50 |
SLC1A3 |
1.647e-02 | -4.11 | meninges | COSMIC cancer mutations | meninges | 514 | 5 | 16828 | 49 |
FMN2,NFIA,FGFR3,RYR3,ITPR2 |
1.647e-02 | -4.11 | meningioma | COSMIC cancer mutations | meningioma | 514 | 5 | 16828 | 49 |
ITPR2,RYR3,NFIA,FMN2,FGFR3 |
1.672e-02 | -4.09 | regulation of ATP metabolic process | biological process | GO:1903578 | 72 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
1.674e-02 | -4.09 | SH3_10 | pfam domains | PF17902 | 6 | 1 | 17795 | 50 |
MACF1 |
1.674e-02 | -4.09 | Glypican | pfam domains | PF01153 | 6 | 1 | 17795 | 50 |
GPC5 |
1.674e-02 | -4.09 | EF-hand_3 | pfam domains | PF09069 | 6 | 1 | 17795 | 50 |
DTNA |
1.674e-02 | -4.09 | Syndecan | pfam domains | PF01034 | 6 | 1 | 17795 | 50 |
NRXN1 |
1.674e-02 | -4.09 | Plectin | pfam domains | PF00681 | 6 | 1 | 17795 | 50 |
MACF1 |
1.674e-02 | -4.09 | EF-hand_2 | pfam domains | PF09068 | 6 | 1 | 17795 | 50 |
DTNA |
1.674e-02 | -4.09 | GAS2 | pfam domains | PF02187 | 6 | 1 | 17795 | 50 |
MACF1 |
1.680e-02 | -4.09 | embryonal | COSMIC cancer mutations | embryonal | 2659 | 14 | 16828 | 49 |
MACF1,SPARCL1,FGFR3,PARD3B,GLIS3,NPAS3,PREX2,PTPRZ1,FMN2,MAML2,CTNND2,RORA,RYR3,NFIA |
1.680e-02 | -4.09 | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | 2659 | 14 | 16828 | 49 |
CTNND2,FMN2,MAML2,PTPRZ1,NFIA,RYR3,RORA,PARD3B,FGFR3,SPARCL1,MACF1,PREX2,NPAS3,GLIS3 |
1.680e-02 | -4.09 | Activation of TRKA receptors | REACTOME pathways | R-HSA-187015 | 6 | 1 | 10285 | 29 |
NTRK2 |
1.705e-02 | -4.07 | HAD_sf | interpro domains | IPR023214 | 74 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
1.709e-02 | -4.07 | skin-extremity-malignant_melanoma | COSMIC cancer mutations | skin-extremity-malignant_melanoma | 1875 | 11 | 16828 | 49 |
NTRK2,NEBL,RYR3,FMN2,PTPRZ1,CDH20,PREX2,FBXL7,PCDH9,ATP13A4,PITPNC1 |
1.709e-02 | -4.07 | human chr4q22.3 | chromosome location | human chr4q22.3 | 9 | 1 | 26134 | 50 |
BMPR1B |
1.716e-02 | -4.07 | peptide metabolic process | biological process | GO:0006518 | 73 | 2 | 18204 | 50 |
CPE,SLC1A2 |
1.716e-02 | -4.07 | MARCKS (myristoylated alanine rich protein kinase C substrate) | protein interactions | 4082 | 588 | 5 | 19454 | 50 |
DTNA,AHCYL2,ABLIM1,SLC1A3,MACF1 |
1.717e-02 | -4.06 | Nedd4 (NEDD4 E3 ubiquitin protein ligase) | protein interactions | 25489 | 78 | 2 | 19454 | 50 |
NTRK2,BMPR1B |
1.717e-02 | -4.06 | ANKRD40 (ankyrin repeat domain 40) | protein interactions | 91369 | 78 | 2 | 19454 | 50 |
MSI2,SOX5 |
1.718e-02 | -4.06 | DNAJC2 (DnaJ heat shock protein family (Hsp40) member C2) | protein interactions | 27000 | 212 | 3 | 19454 | 50 |
GLUD1,TNIK,MACF1 |
1.735e-02 | -4.05 | skin-head_neck-malignant_melanoma | COSMIC cancer mutations | skin-head_neck-malignant_melanoma | 6 | 1 | 16828 | 49 |
PREX2 |
1.735e-02 | -4.05 | collecting_duct_carcinoma | COSMIC cancer mutations | collecting_duct_carcinoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-upper_leg-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-upper_leg-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-back-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-back-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-in_situ_epithelial_neoplasm-actinic_keratosis | COSMIC cancer mutations | skin-in_situ_epithelial_neoplasm-actinic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-abdomen-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-abdomen-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-in_situ_epithelial_neoplasm-Bowen_disease | COSMIC cancer mutations | skin-in_situ_epithelial_neoplasm-Bowen_disease | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-head_neck-epidermal_nevus | COSMIC cancer mutations | skin-head_neck-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-epidermal_nevus | COSMIC cancer mutations | skin-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-lower_back-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-lower_back-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | kidney-carcinoma-collecting_duct_carcinoma | COSMIC cancer mutations | kidney-carcinoma-collecting_duct_carcinoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-benign_melanocytic_nevus-lentiginous_nevus | COSMIC cancer mutations | skin-benign_melanocytic_nevus-lentiginous_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-arm-epidermal_nevus | COSMIC cancer mutations | skin-arm-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-forearm-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-forearm-malignant_melanoma-superficial_spreading | 6 | 1 | 16828 | 49 |
PREX2 |
1.735e-02 | -4.05 | skin-lower_leg-epidermal_nevus | COSMIC cancer mutations | skin-lower_leg-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-trunk-epidermal_nevus | COSMIC cancer mutations | skin-trunk-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-face-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-face-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-adnexal_tumour-trichoblastoma | COSMIC cancer mutations | skin-adnexal_tumour-trichoblastoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | autonomic_ganglia-paraganglioma-benign | COSMIC cancer mutations | autonomic_ganglia-paraganglioma-benign | 6 | 1 | 16828 | 49 |
NHSL1 |
1.735e-02 | -4.05 | lentiginous_nevus | COSMIC cancer mutations | lentiginous_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-flank-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-flank-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.747e-02 | -4.05 | small molecule binding | molecular function | GO:0036094 | 6197 | 24 | 18094 | 48 |
SLC1A2,ABLIM1,SLC1A3,PITPNC1,NTRK2,GLIS3,CPE,GLUD1,ATP13A4,FGFR3,DTNA,TNIK,SPARCL1,RORA,BMPR1B,PTGDS,TRPS1,MACF1,ZBTB20,ATP1A2,ITPR2,NRXN1,RYR3,PCDH9 |
1.749e-02 | -4.05 | ALPHACATENIN | prints domains | PR00805 | 4 | 1 | 5227 | 23 |
CTNNA2 |
1.750e-02 | -4.05 | organic acid binding | molecular function | GO:0043177 | 207 | 3 | 18094 | 48 |
SLC1A3,PTGDS,GLUD1 |
1.759e-02 | -4.04 | PRDM1 (PR/SET domain 1) | protein interactions | 639 | 79 | 2 | 19454 | 50 |
NFIA,TRPS1 |
1.761e-02 | -4.04 | NCK1 (NCK adaptor protein 1) | protein interactions | 4690 | 214 | 3 | 19454 | 50 |
NTRK2,NHSL1,TNIK |
1.765e-02 | -4.04 | animal organ morphogenesis | biological process | GO:0009887 | 988 | 7 | 18204 | 50 |
CPE,SOX5,NTRK2,ABLIM1,BMPR1B,CTNNA2,FGFR3 |
1.766e-02 | -4.04 | stomach-adenocarcinoma | COSMIC cancer mutations | stomach-adenocarcinoma | 4101 | 19 | 16828 | 49 |
GPC5,FMN2,CTNND2,TRPS1,CDH20,RORA,SLC1A2,NEBL,FGFR3,ABLIM1,ATP1A2,PARD3B,ITPR2,SLC4A4,MACF1,PCDH9,PREX2,ATP13A4,AHCYL2 |
1.786e-02 | -4.03 | RGMB (repulsive guidance molecule BMP co-receptor b) | protein interactions | 285704 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | Fbxo3 (F-box protein 3) | protein interactions | 57443 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | FGF5 (fibroblast growth factor 5) | protein interactions | 2250 | 7 | 1 | 19454 | 50 |
FGFR3 |
1.786e-02 | -4.03 | ABCC12 (ATP binding cassette subfamily C member 12) | protein interactions | 94160 | 7 | 1 | 19454 | 50 |
NPAS3 |
1.786e-02 | -4.03 | Uhmk1 (U2AF homology motif (UHM) kinase 1) | protein interactions | 16589 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | ZBTB45 (zinc finger and BTB domain containing 45) | protein interactions | 84878 | 7 | 1 | 19454 | 50 |
ZBTB20 |
1.786e-02 | -4.03 | SLC16A5 (solute carrier family 16 member 5) | protein interactions | 9121 | 7 | 1 | 19454 | 50 |
PTPRZ1 |
1.786e-02 | -4.03 | Smad7 (SMAD family member 7) | protein interactions | 17131 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | Ahcyl1 (S-adenosylhomocysteine hydrolase-like 1) | protein interactions | 229709 | 7 | 1 | 19454 | 50 |
AHCYL2 |
1.786e-02 | -4.03 | SASH3 (SAM and SH3 domain containing 3) | protein interactions | 54440 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | Smurf1 (SMAD specific E3 ubiquitin protein ligase 1) | protein interactions | 75788 | 7 | 1 | 19454 | 50 |
GLIS3 |
1.790e-02 | -4.02 | axonogenesis | biological process | GO:0007409 | 366 | 4 | 18204 | 50 |
BMPR1B,CTNNA2,PTPRZ1,NRXN1 |
1.806e-02 | -4.01 | amino acid biosynthetic process | biological process | GO:0008652 | 75 | 2 | 18204 | 50 |
SLC1A3,GLUD1 |
1.811e-02 | -4.01 | Plakin repeat | gene3d domains | 3.90.1290.10 | 6 | 1 | 14470 | 44 |
MACF1 |
1.811e-02 | -4.01 | Leucine Dehydrogenase, chain A, domain 1 | gene3d domains | 3.40.50.10860 | 6 | 1 | 14470 | 44 |
GLUD1 |
1.811e-02 | -4.01 | Gas2-like domain | gene3d domains | 3.30.920.20 | 6 | 1 | 14470 | 44 |
MACF1 |
1.815e-02 | -4.01 | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | 2414 | 13 | 16828 | 49 |
MACF1,TRPS1,CDH20,SPARCL1,FGFR3,FMN2,SLC1A3,PARD3B,NHSL1,RYR3,NPAS3,NFIA,PREX2 |
1.815e-02 | -4.01 | alveolar | COSMIC cancer mutations | alveolar | 2414 | 13 | 16828 | 49 |
NFIA,RYR3,FMN2,SLC1A3,TRPS1,CDH20,NPAS3,PREX2,FGFR3,SPARCL1,NHSL1,PARD3B,MACF1 |
1.826e-02 | -4.00 | GFAP (glial fibrillary acidic protein) | protein interactions | 2670 | 217 | 3 | 19454 | 50 |
ABLIM1,NKAIN3,RORA |
1.843e-02 | -3.99 | phosphatidic acid transfer activity | molecular function | GO:1990050 | 7 | 1 | 18094 | 48 |
PITPNC1 |
1.843e-02 | -3.99 | P-type sodium:potassium-exchanging transporter activity | molecular function | GO:0005391 | 7 | 1 | 18094 | 48 |
ATP1A2 |
1.843e-02 | -3.99 | L-leucine binding | molecular function | GO:0070728 | 7 | 1 | 18094 | 48 |
GLUD1 |
1.843e-02 | -3.99 | P-type sodium transporter activity | molecular function | GO:0008554 | 7 | 1 | 18094 | 48 |
ATP1A2 |
1.843e-02 | -3.99 | SOX17 (SRY-box transcription factor 17) | protein interactions | 64321 | 81 | 2 | 19454 | 50 |
TRPS1,NFIA |
1.865e-02 | -3.98 | Protein_kinase_ATP_BS | interpro domains | IPR017441 | 377 | 4 | 18521 | 50 |
TNIK,BMPR1B,NTRK2,FGFR3 |
1.872e-02 | -3.98 | calcium ion transmembrane transport | biological process | GO:0070588 | 205 | 3 | 18204 | 50 |
ITPR2,GPM6A,RYR3 |
1.875e-02 | -3.98 | Plakophilin/d_Catenin | interpro domains | IPR028435 | 7 | 1 | 18521 | 50 |
CTNND2 |
1.875e-02 | -3.98 | GS_dom | interpro domains | IPR003605 | 7 | 1 | 18521 | 50 |
BMPR1B |
1.875e-02 | -3.98 | Alpha-catenin/vinculin-like_sf | interpro domains | IPR036723 | 7 | 1 | 18521 | 50 |
CTNNA2 |
1.875e-02 | -3.98 | Plectin_repeat | interpro domains | IPR001101 | 7 | 1 | 18521 | 50 |
MACF1 |
1.875e-02 | -3.98 | Hematopoietin_rcpt_Gp130_CS | interpro domains | IPR003529 | 7 | 1 | 18521 | 50 |
LIFR |
1.875e-02 | -3.98 | Plakin_repeat_sf | interpro domains | IPR035915 | 7 | 1 | 18521 | 50 |
MACF1 |
1.875e-02 | -3.98 | SPARC/Testican_Ca-bd-dom | interpro domains | IPR019577 | 7 | 1 | 18521 | 50 |
SPARCL1 |
1.882e-02 | -3.97 | HAD-like_sf | interpro domains | IPR036412 | 78 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
1.889e-02 | -3.97 | haematopoietic_and_lymphoid_tissue | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue | 14368 | 47 | 16828 | 49 |
NTM,GLUD1,ATP13A4,MACF1,NHSL1,SOX5,SLC1A2,NFIA,NKAIN3,NRXN1,NPAS3,PCDH9,PREX2,ITPR2,ABLIM1,RORA,CPE,NTRK2,GPM6A,TRPS1,CDH20,TNIK,AHCYL2,FBXL7,LIFR,SPARCL1,RYR3,BMPR1B,DTNA,LSAMP,GLIS3,HIF3A,ZBTB20,SLC4A4,PITPNC1,SFXN5,FGFR3,PARD3B,ATP1A2,NEBL,MSI2,PTPRZ1,GPC5,FMN2,MAML2,SLC1A3,CTNND2 |
1.891e-02 | -3.97 | system process | biological process | GO:0003008 | 2015 | 11 | 18204 | 50 |
ATP1A2,NTRK2,PTPRZ1,SLC4A4,ABLIM1,SLC1A3,RYR3,SLC1A2,DTNA,NRXN1,CTNNA2 |
1.897e-02 | -3.96 | human chr9p24.2 | chromosome location | human chr9p24.2 | 10 | 1 | 26134 | 50 |
GLIS3 |
1.897e-02 | -3.96 | human chr12p11.23 | chromosome location | human chr12p11.23 | 10 | 1 | 26134 | 50 |
ITPR2 |
1.898e-02 | -3.96 | regulation of synaptic transmission, glutamatergic | biological process | GO:0051966 | 77 | 2 | 18204 | 50 |
ATP1A2,NRXN1 |
1.898e-02 | -3.96 | neural retina development | biological process | GO:0003407 | 77 | 2 | 18204 | 50 |
NTRK2,GPM6A |
1.898e-02 | -3.96 | BMP signaling pathway | biological process | GO:0030509 | 77 | 2 | 18204 | 50 |
NFIA,BMPR1B |
1.898e-02 | -3.96 | positive regulation of axonogenesis | biological process | GO:0050772 | 77 | 2 | 18204 | 50 |
NTRK2,MACF1 |
1.907e-02 | -3.96 | cellular response to magnesium ion | biological process | GO:0071286 | 7 | 1 | 18204 | 50 |
RYR3 |
1.907e-02 | -3.96 | S-adenosylmethionine cycle | biological process | GO:0033353 | 7 | 1 | 18204 | 50 |
AHCYL2 |
1.907e-02 | -3.96 | chromosome movement towards spindle pole | biological process | GO:0051305 | 7 | 1 | 18204 | 50 |
FMN2 |
1.907e-02 | -3.96 | positive regulation of transcription of Notch receptor target | biological process | GO:0007221 | 7 | 1 | 18204 | 50 |
MAML2 |
1.907e-02 | -3.96 | regulation of oligodendrocyte progenitor proliferation | biological process | GO:0070445 | 7 | 1 | 18204 | 50 |
PTPRZ1 |
1.907e-02 | -3.96 | regulation of male germ cell proliferation | biological process | GO:2000254 | 7 | 1 | 18204 | 50 |
PTGDS |
1.907e-02 | -3.96 | observational learning | biological process | GO:0098597 | 7 | 1 | 18204 | 50 |
NRXN1 |
1.907e-02 | -3.96 | negative regulation of Arp2/3 complex-mediated actin nucleation | biological process | GO:0034316 | 7 | 1 | 18204 | 50 |
CTNNA2 |
1.907e-02 | -3.96 | glial cell fate specification | biological process | GO:0021780 | 7 | 1 | 18204 | 50 |
NFIA |
1.907e-02 | -3.96 | parallel actin filament bundle assembly | biological process | GO:0030046 | 7 | 1 | 18204 | 50 |
FMN2 |
1.914e-02 | -3.96 | central_nervous_system-brain-glioma-oligodendroglioma_Grade_II | COSMIC cancer mutations | central_nervous_system-brain-glioma-oligodendroglioma_Grade_II | 73 | 2 | 16828 | 49 |
MACF1,FGFR3 |
1.923e-02 | -3.95 | Muscle contraction | REACTOME pathways | R-HSA-397014 | 204 | 3 | 10285 | 29 |
ATP1A2,ITPR2,RYR3 |
1.929e-02 | -3.95 | breast-carcinoma-basal_(triple-negative)_carcinoma | COSMIC cancer mutations | breast-carcinoma-basal_(triple-negative)_carcinoma | 2981 | 15 | 16828 | 49 |
NPAS3,HIF3A,NTM,ATP1A2,SPARCL1,FGFR3,SLC4A4,MACF1,LIFR,MSI2,NTRK2,NEBL,BMPR1B,MAML2,FMN2 |
1.929e-02 | -3.95 | basal_(triple-negative)_carcinoma | COSMIC cancer mutations | basal_(triple-negative)_carcinoma | 2981 | 15 | 16828 | 49 |
ATP1A2,SPARCL1,FGFR3,SLC4A4,MACF1,LIFR,NPAS3,HIF3A,NTM,MAML2,FMN2,MSI2,NTRK2,BMPR1B,NEBL |
1.930e-02 | -3.95 | DNM3 (dynamin 3) | protein interactions | 26052 | 83 | 2 | 19454 | 50 |
GPM6A,FGFR3 |
1.930e-02 | -3.95 | PAX2 (paired box 2) | protein interactions | 5076 | 83 | 2 | 19454 | 50 |
NFIA,TRPS1 |
1.930e-02 | -3.95 | SYT1 (synaptotagmin 1) | protein interactions | 6857 | 83 | 2 | 19454 | 50 |
NRXN1,GPM6A |
1.943e-02 | -3.94 | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 7 | 16828 | 49 |
GPC5,FMN2,MACF1,ITPR2,ATP13A4,PREX2,SLC1A2 |
1.943e-02 | -3.94 | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 7 | 16828 | 49 |
ATP13A4,PREX2,SLC1A2,GPC5,FMN2,ITPR2,MACF1 |
1.944e-02 | -3.94 | positive regulation of carbohydrate metabolic process | biological process | GO:0045913 | 78 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
1.951e-02 | -3.94 | TGF_beta_GS | pfam domains | PF08515 | 7 | 1 | 17795 | 50 |
BMPR1B |
1.951e-02 | -3.94 | SPARC_Ca_bdg | pfam domains | PF10591 | 7 | 1 | 17795 | 50 |
SPARCL1 |
1.958e-02 | -3.93 | FGFR3b ligand binding and activation | REACTOME pathways | R-HSA-190371 | 7 | 1 | 10285 | 29 |
FGFR3 |
1.964e-02 | -3.93 | oligodendroglioma_Grade_II | COSMIC cancer mutations | oligodendroglioma_Grade_II | 74 | 2 | 16828 | 49 |
FGFR3,MACF1 |
1.974e-02 | -3.93 | Tyr_kinase_cat_dom | interpro domains | IPR020635 | 80 | 2 | 18521 | 50 |
NTRK2,FGFR3 |
1.976e-02 | -3.92 | FBXO2 (F-box protein 2) | protein interactions | 26232 | 403 | 4 | 19454 | 50 |
FGFR3,NTM,LIFR,PCDH9 |
1.985e-02 | -3.92 | MAPRE3 (microtubule associated protein RP/EB family member 3) | protein interactions | 22924 | 224 | 3 | 19454 | 50 |
MACF1,GPM6A,ABLIM1 |
2.003e-02 | -3.91 | metal ion binding | molecular function | GO:0046872 | 4239 | 18 | 18094 | 48 |
MACF1,ZBTB20,TRPS1,CPE,ITPR2,ATP1A2,NRXN1,PCDH9,RYR3,ABLIM1,SLC1A2,ATP13A4,SPARCL1,DTNA,SLC1A3,RORA,BMPR1B,GLIS3 |
2.018e-02 | -3.90 | CFAP298 (cilia and flagella associated protein 298) | protein interactions | 56683 | 85 | 2 | 19454 | 50 |
TRPS1,FMN2 |
2.020e-02 | -3.90 | SOX2 (SRY-box transcription factor 2) | protein interactions | 6657 | 1342 | 8 | 19454 | 50 |
ITPR2,MSI2,LSAMP,TRPS1,MACF1,GLIS3,NFIA,SOX5 |
2.021e-02 | -3.90 | skin-benign_melanocytic_nevus-compound | COSMIC cancer mutations | skin-benign_melanocytic_nevus-compound | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-shoulder-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-shoulder-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-face-malignant_melanoma-nodular | COSMIC cancer mutations | skin-face-malignant_melanoma-nodular | 7 | 1 | 16828 | 49 |
PREX2 |
2.021e-02 | -3.90 | nevus_sebaceous | COSMIC cancer mutations | nevus_sebaceous | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-face-adnexal_tumour-malignant_adnexal_tumour | COSMIC cancer mutations | skin-face-adnexal_tumour-malignant_adnexal_tumour | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-benign_melanocytic_nevus-intradermal | COSMIC cancer mutations | skin-benign_melanocytic_nevus-intradermal | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-other-nevus_sebaceous | COSMIC cancer mutations | skin-other-nevus_sebaceous | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-neck-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-neck-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-chest-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-chest-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-adnexal_tumour-trichilemmoma | COSMIC cancer mutations | skin-adnexal_tumour-trichilemmoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-upper_leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma-nodular | 7 | 1 | 16828 | 49 |
PREX2 |
2.021e-02 | -3.90 | trichilemmoma | COSMIC cancer mutations | trichilemmoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | urinary_tract-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-carcinoma-transitional_cell_carcinoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.034e-02 | -3.90 | HFE-transferrin receptor complex | cellular component | GO:1990712 | 8 | 1 | 19108 | 49 |
BMPR1B |
2.038e-02 | -3.89 | CCK (cholecystokinin) | protein interactions | 885 | 8 | 1 | 19454 | 50 |
CPE |
2.038e-02 | -3.89 | PTGER1 (prostaglandin E receptor 1) | protein interactions | 5731 | 8 | 1 | 19454 | 50 |
PTGDS |
2.038e-02 | -3.89 | Rasd2 (RASD family, member 2) | protein interactions | 75141 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.038e-02 | -3.89 | BMP15 (bone morphogenetic protein 15) | protein interactions | 9210 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.038e-02 | -3.89 | LHB (luteinizing hormone subunit beta) | protein interactions | 3972 | 8 | 1 | 19454 | 50 |
NTM |
2.038e-02 | -3.89 | Rps27a (ribosomal protein S27A) | protein interactions | 78294 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.042e-02 | -3.89 | eye development | biological process | GO:0001654 | 381 | 4 | 18204 | 50 |
BMPR1B,NTRK2,NFIA,GPM6A |
2.044e-02 | -3.89 | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 6023 | 25 | 16828 | 49 |
NTRK2,RORA,NEBL,MAML2,CTNND2,SLC1A3,PTPRZ1,ZBTB20,CST3,NPAS3,PREX2,GLIS3,ABLIM1,FGFR3,ATP1A2,SLC4A4,ITPR2,NKAIN3,DTNA,RYR3,SOX5,ATP13A4,SPARCL1,MACF1,LIFR |
2.049e-02 | -3.89 | Ion channel transport | REACTOME pathways | R-HSA-983712 | 209 | 3 | 10285 | 29 |
RYR3,ATP13A4,ATP1A2 |
2.053e-02 | -3.89 | contractile actin filament bundle | cellular component | GO:0097517 | 86 | 2 | 19108 | 49 |
NEBL,ABLIM1 |
2.053e-02 | -3.89 | stress fiber | cellular component | GO:0001725 | 86 | 2 | 19108 | 49 |
NEBL,ABLIM1 |
2.063e-02 | -3.88 | EGLN1 (egl-9 family hypoxia inducible factor 1) | protein interactions | 54583 | 86 | 2 | 19454 | 50 |
FGFR3,HIF3A |
2.067e-02 | -3.88 | kidney-Wilms_tumour | COSMIC cancer mutations | kidney-Wilms_tumour | 545 | 5 | 16828 | 49 |
BMPR1B,FGFR3,NTRK2,FMN2,TNIK |
2.072e-02 | -3.88 | Cysteine Rich Protein | gene3d domains | 2.10.110.10 | 73 | 2 | 14470 | 44 |
NEBL,ABLIM1 |
2.082e-02 | -3.87 | Wilms_tumour | COSMIC cancer mutations | Wilms_tumour | 546 | 5 | 16828 | 49 |
BMPR1B,NTRK2,FMN2,TNIK,FGFR3 |
2.084e-02 | -3.87 | dendrite | cellular component | GO:0030425 | 620 | 5 | 19108 | 49 |
GPM6A,CTNND2,ATP1A2,NTRK2,BMPR1B |
2.087e-02 | -3.87 | adult locomotory behavior | biological process | GO:0008344 | 81 | 2 | 18204 | 50 |
PREX2,ATP1A2 |
2.101e-02 | -3.86 | EF_hand_dom | interpro domains | IPR002048 | 218 | 3 | 18521 | 50 |
SPARCL1,RYR3,MACF1 |
2.103e-02 | -3.86 | P-type potassium transmembrane transporter activity | molecular function | GO:0008556 | 8 | 1 | 18094 | 48 |
ATP1A2 |
2.103e-02 | -3.86 | glutamate binding | molecular function | GO:0016595 | 8 | 1 | 18094 | 48 |
SLC1A3 |
2.103e-02 | -3.86 | sodium ion binding | molecular function | GO:0031402 | 8 | 1 | 18094 | 48 |
ATP1A2 |
2.103e-02 | -3.86 | BMP receptor activity | molecular function | GO:0098821 | 8 | 1 | 18094 | 48 |
BMPR1B |
2.105e-02 | -3.86 | glutamatergic synapse | cellular component | GO:0098978 | 412 | 4 | 19108 | 49 |
SLC1A2,SPARCL1,GPM6A,TNIK |
2.106e-02 | -3.86 | Immunoglobulins | gene3d domains | 2.60.40.10 | 721 | 6 | 14470 | 44 |
LSAMP,NTRK2,LIFR,FGFR3,NTM,PTPRZ1 |
2.108e-02 | -3.86 | Kctd5 (potassium channel tetramerisation domain containing 5) | protein interactions | 69259 | 87 | 2 | 19454 | 50 |
TRPS1,SLC1A3 |
2.108e-02 | -3.86 | ZNF608 (zinc finger protein 608) | protein interactions | 57507 | 87 | 2 | 19454 | 50 |
SOX5,NFIA |
2.108e-02 | -3.86 | NHLH1 (nescient helix-loop-helix 1) | protein interactions | 4807 | 87 | 2 | 19454 | 50 |
TRPS1,NFIA |
2.110e-02 | -3.86 | dendritic tree | cellular component | GO:0097447 | 622 | 5 | 19108 | 49 |
BMPR1B,ATP1A2,NTRK2,CTNND2,GPM6A |
2.113e-02 | -3.86 | visual system development | biological process | GO:0150063 | 385 | 4 | 18204 | 50 |
NFIA,GPM6A,BMPR1B,NTRK2 |
2.118e-02 | -3.85 | papillary_renal_cell_carcinoma | COSMIC cancer mutations | papillary_renal_cell_carcinoma | 6364 | 26 | 16828 | 49 |
ITPR2,PITPNC1,SLC4A4,FGFR3,ABLIM1,ATP1A2,ZBTB20,PREX2,PTPRZ1,FMN2,MAML2,TNIK,GPC5,CTNND2,CPE,RORA,NTRK2,LIFR,MACF1,NTM,ATP13A4,NRXN1,BMPR1B,SOX5,RYR3,NFIA |
2.118e-02 | -3.85 | kidney-carcinoma-papillary_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-papillary_renal_cell_carcinoma | 6364 | 26 | 16828 | 49 |
SLC4A4,ITPR2,PITPNC1,ATP1A2,ABLIM1,FGFR3,PREX2,ZBTB20,PTPRZ1,CTNND2,MAML2,GPC5,FMN2,TNIK,RORA,CPE,NTRK2,MACF1,LIFR,NTM,ATP13A4,NRXN1,RYR3,SOX5,BMPR1B,NFIA |
2.125e-02 | -3.85 | HAD superfamily/HAD-like | gene3d domains | 3.40.50.1000 | 74 | 2 | 14470 | 44 |
ATP1A2,ATP13A4 |
2.127e-02 | -3.85 | DST (dystonin) | protein interactions | 667 | 230 | 3 | 19454 | 50 |
NTRK2,ATP1A2,TNIK |
2.140e-02 | -3.84 | Villin_headpiece | interpro domains | IPR003128 | 8 | 1 | 18521 | 50 |
ABLIM1 |
2.140e-02 | -3.84 | Plakin | interpro domains | IPR043197 | 8 | 1 | 18521 | 50 |
MACF1 |
2.140e-02 | -3.84 | Villin_headpiece_dom_sf | interpro domains | IPR036886 | 8 | 1 | 18521 | 50 |
ABLIM1 |
2.144e-02 | -3.84 | Bile secretion | KEGG pathways | ko04976 | 71 | 2 | 7161 | 23 |
ATP1A2,SLC4A4 |
2.144e-02 | -3.84 | Bile secretion | KEGG pathways | hsa04976 | 71 | 2 | 7161 | 23 |
SLC4A4,ATP1A2 |
2.147e-02 | -3.84 | GAR | prosite domains | PS51460 | 6 | 1 | 12186 | 44 |
MACF1 |
2.147e-02 | -3.84 | GLYPICAN | prosite domains | PS01207 | 6 | 1 | 12186 | 44 |
GPC5 |
2.153e-02 | -3.84 | RAP2A (RAP2A, member of RAS oncogene family) | protein interactions | 5911 | 88 | 2 | 19454 | 50 |
BMPR1B,TNIK |
2.153e-02 | -3.84 | Ig_sub | interpro domains | IPR003599 | 394 | 4 | 18521 | 50 |
NTRK2,FGFR3,NTM,LSAMP |
2.170e-02 | -3.83 | Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways | WikiPathways | WP706 | 162 | 3 | 5310 | 20 |
NTRK2,RORA,SLC1A3 |
2.172e-02 | -3.83 | regulation of cell junction assembly | biological process | GO:1901888 | 217 | 3 | 18204 | 50 |
NTRK2,MACF1,NRXN1 |
2.177e-02 | -3.83 | glutamate catabolic process | biological process | GO:0006538 | 8 | 1 | 18204 | 50 |
GLUD1 |
2.177e-02 | -3.83 | cell proliferation in hindbrain | biological process | GO:0021534 | 8 | 1 | 18204 | 50 |
RORA |
2.177e-02 | -3.83 | cerebellar granule cell precursor proliferation | biological process | GO:0021930 | 8 | 1 | 18204 | 50 |
RORA |
2.177e-02 | -3.83 | meiotic cytokinesis | biological process | GO:0033206 | 8 | 1 | 18204 | 50 |
FMN2 |
2.177e-02 | -3.83 | gamma-aminobutyric acid metabolic process | biological process | GO:0009448 | 8 | 1 | 18204 | 50 |
SLC1A3 |
2.177e-02 | -3.83 | regulation of L-glutamate import across plasma membrane | biological process | GO:0002036 | 8 | 1 | 18204 | 50 |
ATP1A2 |
2.177e-02 | -3.83 | cell proliferation in external granule layer | biological process | GO:0021924 | 8 | 1 | 18204 | 50 |
RORA |
2.177e-02 | -3.83 | insulin processing | biological process | GO:0030070 | 8 | 1 | 18204 | 50 |
CPE |
2.177e-02 | -3.83 | regulation of synapse structural plasticity | biological process | GO:0051823 | 8 | 1 | 18204 | 50 |
CTNNA2 |
2.177e-02 | -3.83 | regulation of germ cell proliferation | biological process | GO:1905936 | 8 | 1 | 18204 | 50 |
PTGDS |
2.182e-02 | -3.83 | NAHCO3TRSPRT | prints domains | PR01232 | 5 | 1 | 5227 | 23 |
SLC4A4 |
2.182e-02 | -3.83 | PITRANSFER | prints domains | PR00391 | 5 | 1 | 5227 | 23 |
PITPNC1 |
2.185e-02 | -3.82 | endometrium-carcinoma-serous_carcinoma | COSMIC cancer mutations | endometrium-carcinoma-serous_carcinoma | 1442 | 9 | 16828 | 49 |
CTNND2,NRXN1,GPC5,FMN2,TNIK,TRPS1,SLC4A4,RYR3,LSAMP |
2.186e-02 | -3.82 | skin-upper_arm-malignant_melanoma | COSMIC cancer mutations | skin-upper_arm-malignant_melanoma | 553 | 5 | 16828 | 49 |
PREX2,PARD3B,FMN2,SLC4A4,ITPR2 |
2.199e-02 | -3.82 | SOX10 (SRY-box transcription factor 10) | protein interactions | 6663 | 89 | 2 | 19454 | 50 |
TRPS1,NFIA |
2.199e-02 | -3.82 | PLEKHA2 (pleckstrin homology domain containing A2) | protein interactions | 59339 | 89 | 2 | 19454 | 50 |
DTNA,AHCYL2 |
2.221e-02 | -3.81 | sensory system development | biological process | GO:0048880 | 391 | 4 | 18204 | 50 |
BMPR1B,NTRK2,NFIA,GPM6A |
2.224e-02 | -3.81 | glial cell differentiation | biological process | GO:0010001 | 219 | 3 | 18204 | 50 |
NFIA,PTPRZ1,NTRK2 |
2.224e-02 | -3.81 | HMG20A (high mobility group 20A) | protein interactions | 10363 | 234 | 3 | 19454 | 50 |
SOX5,NFIA,DTNA |
2.226e-02 | -3.80 | VHP | pfam domains | PF02209 | 8 | 1 | 17795 | 50 |
ABLIM1 |
2.233e-02 | -3.80 | regulation of sodium ion transport | biological process | GO:0002028 | 84 | 2 | 18204 | 50 |
NKAIN3,ATP1A2 |
2.233e-02 | -3.80 | L-amino acid transport | biological process | GO:0015807 | 84 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
2.234e-02 | -3.80 | Release of Hh-Np from the secreting cell | REACTOME pathways | R-HSA-5362798 | 8 | 1 | 10285 | 29 |
GPC5 |
2.246e-02 | -3.80 | CTDSPL (CTD small phosphatase like) | protein interactions | 10217 | 90 | 2 | 19454 | 50 |
FMN2,DTNA |
2.249e-02 | -3.79 | MARK3 (microtubule affinity regulating kinase 3) | protein interactions | 4140 | 235 | 3 | 19454 | 50 |
MACF1,NTRK2,DTNA |
2.250e-02 | -3.79 | response to mechanical stimulus | biological process | GO:0009612 | 220 | 3 | 18204 | 50 |
NRXN1,ATP1A2,SLC1A3 |
2.283e-02 | -3.78 | oligodendrocyte differentiation | biological process | GO:0048709 | 85 | 2 | 18204 | 50 |
NTRK2,PTPRZ1 |
2.285e-02 | -3.78 | platelet dense tubular network membrane | cellular component | GO:0031095 | 9 | 1 | 19108 | 49 |
ITPR2 |
2.290e-02 | -3.78 | NRXN2 (neurexin 2) | protein interactions | 9379 | 9 | 1 | 19454 | 50 |
MACF1 |
2.290e-02 | -3.78 | VEPH1 (ventricular zone expressed PH domain containing 1) | protein interactions | 79674 | 9 | 1 | 19454 | 50 |
BMPR1B |
2.290e-02 | -3.78 | Tyw3 (tRNA-yW synthesizing protein 3 homolog (S. cerevisiae)) | protein interactions | 209584 | 9 | 1 | 19454 | 50 |
CTNNA2 |
2.290e-02 | -3.78 | KLB (klotho beta) | protein interactions | 152831 | 9 | 1 | 19454 | 50 |
FGFR3 |
2.290e-02 | -3.78 | GUSBP1 (GUSB pseudogene 1) | protein interactions | 728411 | 9 | 1 | 19454 | 50 |
FGFR3 |
2.292e-02 | -3.78 | DGUOK (deoxyguanosine kinase) | protein interactions | 1716 | 91 | 2 | 19454 | 50 |
GPM6A,NTM |
2.292e-02 | -3.78 | FOXI1 (forkhead box I1) | protein interactions | 2299 | 91 | 2 | 19454 | 50 |
TRPS1,NFIA |
2.299e-02 | -3.77 | CAMK2A (calcium/calmodulin dependent protein kinase II alpha) | protein interactions | 815 | 237 | 3 | 19454 | 50 |
SOX5,GPM6A,ITPR2 |
2.306e-02 | -3.77 | trichoblastoma | COSMIC cancer mutations | trichoblastoma | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_I | COSMIC cancer mutations | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_I | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | cervical_intraepithelial_neoplasia_Grade_I | COSMIC cancer mutations | cervical_intraepithelial_neoplasia_Grade_I | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | urinary_tract-ureter-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-ureter-carcinoma-transitional_cell_carcinoma | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | skin-chest-malignant_melanoma-nodular | COSMIC cancer mutations | skin-chest-malignant_melanoma-nodular | 8 | 1 | 16828 | 49 |
PREX2 |
2.306e-02 | -3.77 | actinic_keratosis | COSMIC cancer mutations | actinic_keratosis | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | junctional | COSMIC cancer mutations | junctional | 8 | 1 | 16828 | 49 |
FGFR3 |
2.317e-02 | -3.76 | Thyroid hormone synthesis | KEGG pathways | hsa04918 | 74 | 2 | 7161 | 23 |
ATP1A2,ITPR2 |
2.317e-02 | -3.76 | Thyroid hormone synthesis | KEGG pathways | ko04918 | 74 | 2 | 7161 | 23 |
ATP1A2,ITPR2 |
2.318e-02 | -3.76 | skin-leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-leg-malignant_melanoma-superficial_spreading | 210 | 3 | 16828 | 49 |
ATP13A4,NTM,SLC4A4 |
2.325e-02 | -3.76 | forearm | COSMIC cancer mutations | forearm | 81 | 2 | 16828 | 49 |
PREX2,FGFR3 |
2.329e-02 | -3.76 | actomyosin | cellular component | GO:0042641 | 92 | 2 | 19108 | 49 |
ABLIM1,NEBL |
2.339e-02 | -3.76 | POTEI (POTE ankyrin domain family member I) | protein interactions | 653269 | 92 | 2 | 19454 | 50 |
FGFR3,DTNA |
2.339e-02 | -3.76 | SOX9 (SRY-box transcription factor 9) | protein interactions | 6662 | 92 | 2 | 19454 | 50 |
TRPS1,NFIA |
2.339e-02 | -3.76 | FNTA (farnesyltransferase, CAAX box, subunit alpha) | protein interactions | 2339 | 92 | 2 | 19454 | 50 |
TNIK,FGFR3 |
2.376e-02 | -3.74 | Gastric acid secretion | KEGG pathways | ko04971 | 75 | 2 | 7161 | 23 |
ATP1A2,ITPR2 |
2.376e-02 | -3.74 | Gastric acid secretion | KEGG pathways | hsa04971 | 75 | 2 | 7161 | 23 |
ATP1A2,ITPR2 |
2.387e-02 | -3.74 | ARHGEF6 (Rac/Cdc42 guanine nucleotide exchange factor 6) | protein interactions | 9459 | 93 | 2 | 19454 | 50 |
ABLIM1,BMPR1B |
2.401e-02 | -3.73 | - | gene3d domains | 2.80.10.50 | 79 | 2 | 14470 | 44 |
ITPR2,RYR3 |
2.404e-02 | -3.73 | Activin_recp | interpro domains | IPR000472 | 9 | 1 | 18521 | 50 |
BMPR1B |
2.404e-02 | -3.73 | Band3_cytoplasmic_dom | interpro domains | IPR013769 | 9 | 1 | 18521 | 50 |
SLC4A4 |
2.404e-02 | -3.73 | Aminoacid_DH-like_N_sf | interpro domains | IPR046346 | 9 | 1 | 18521 | 50 |
GLUD1 |
2.404e-02 | -3.73 | Prot_inh_cystat_CS | interpro domains | IPR018073 | 9 | 1 | 18521 | 50 |
CST3 |
2.404e-02 | -3.73 | Fol_N | interpro domains | IPR003645 | 9 | 1 | 18521 | 50 |
SPARCL1 |
2.405e-02 | -3.73 | central_nervous_system-brain-atypical_teratoid-rhabdoid_tumour | COSMIC cancer mutations | central_nervous_system-brain-atypical_teratoid-rhabdoid_tumour | 213 | 3 | 16828 | 49 |
PCDH9,FGFR3,FMN2 |
2.405e-02 | -3.73 | atypical_teratoid-rhabdoid_tumour | COSMIC cancer mutations | atypical_teratoid-rhabdoid_tumour | 213 | 3 | 16828 | 49 |
FMN2,FGFR3,PCDH9 |
2.407e-02 | -3.73 | Villin headpiece domain | gene3d domains | 1.10.950.10 | 8 | 1 | 14470 | 44 |
ABLIM1 |
2.433e-02 | -3.72 | Endochondral Ossification | WikiPathways | WP474 | 65 | 2 | 5310 | 20 |
FGFR3,SOX5 |
2.435e-02 | -3.72 | GRIN1 (glutamate ionotropic receptor NMDA type subunit 1) | protein interactions | 2902 | 94 | 2 | 19454 | 50 |
FGFR3,NTRK2 |
2.435e-02 | -3.72 | QSER1 (glutamine and serine rich 1) | protein interactions | 79832 | 94 | 2 | 19454 | 50 |
NFIA,SOX5 |
2.435e-02 | -3.72 | WWC1 (WW and C2 domain containing 1) | protein interactions | 23286 | 94 | 2 | 19454 | 50 |
ABLIM1,TNIK |
2.435e-02 | -3.72 | FOXP4 (forkhead box P4) | protein interactions | 116113 | 94 | 2 | 19454 | 50 |
NFIA,SOX5 |
2.437e-02 | -3.71 | kidney-carcinoma-renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-renal_cell_carcinoma | 4535 | 20 | 16828 | 49 |
LIFR,PITPNC1,ITPR2,MACF1,FGFR3,HIF3A,FBXL7,PREX2,PCDH9,TRPS1,PTPRZ1,NRXN1,CTNND2,TNIK,MAML2,BMPR1B,SOX5,RORA,MSI2,NTRK2 |
2.437e-02 | -3.71 | renal_cell_carcinoma | COSMIC cancer mutations | renal_cell_carcinoma | 4535 | 20 | 16828 | 49 |
TNIK,MAML2,CTNND2,NRXN1,TRPS1,PTPRZ1,NTRK2,MSI2,RORA,BMPR1B,SOX5,FGFR3,LIFR,ITPR2,PITPNC1,MACF1,PREX2,PCDH9,FBXL7,HIF3A |
2.438e-02 | -3.71 | postsynapse | cellular component | GO:0098794 | 646 | 5 | 19108 | 49 |
NTRK2,ATP1A2,GPM6A,TNIK,CTNND2 |
2.445e-02 | -3.71 | GAS2 | smart domains | SM00243 | 6 | 1 | 9717 | 40 |
MACF1 |
2.446e-02 | -3.71 | negative regulation of actin nucleation | biological process | GO:0051126 | 9 | 1 | 18204 | 50 |
CTNNA2 |
2.446e-02 | -3.71 | negative regulation of striated muscle contraction | biological process | GO:0045988 | 9 | 1 | 18204 | 50 |
ATP1A2 |
2.446e-02 | -3.71 | positive regulation of synapse maturation | biological process | GO:0090129 | 9 | 1 | 18204 | 50 |
NRXN1 |
2.446e-02 | -3.71 | release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | biological process | GO:0014808 | 9 | 1 | 18204 | 50 |
RYR3 |
2.446e-02 | -3.71 | cyclooxygenase pathway | biological process | GO:0019371 | 9 | 1 | 18204 | 50 |
PTGDS |
2.446e-02 | -3.71 | hindbrain radial glia guided cell migration | biological process | GO:0021932 | 9 | 1 | 18204 | 50 |
CTNNA2 |
2.446e-02 | -3.71 | polyamine transmembrane transport | biological process | GO:1902047 | 9 | 1 | 18204 | 50 |
ATP13A4 |
2.459e-02 | -3.71 | human chr5p15.1 | chromosome location | human chr5p15.1 | 13 | 1 | 26134 | 50 |
FBXL7 |
2.468e-02 | -3.70 | lung-carcinoma-bronchioloalveolar_adenocarcinoma | COSMIC cancer mutations | lung-carcinoma-bronchioloalveolar_adenocarcinoma | 778 | 6 | 16828 | 49 |
FGFR3,TNIK,CTNND2,NTRK2,SOX5,BMPR1B |
2.468e-02 | -3.70 | bronchioloalveolar_adenocarcinoma | COSMIC cancer mutations | bronchioloalveolar_adenocarcinoma | 778 | 6 | 16828 | 49 |
SOX5,BMPR1B,NTRK2,TNIK,FGFR3,CTNND2 |
2.468e-02 | -3.70 | skeletal system morphogenesis | biological process | GO:0048705 | 228 | 3 | 18204 | 50 |
FGFR3,BMPR1B,SOX5 |
2.484e-02 | -3.70 | vesicle | cellular component | GO:0031982 | 4141 | 17 | 19108 | 49 |
FGFR3,CPE,NTRK2,PTGDS,CST3,ATP1A2,ATP13A4,NEBL,ITPR2,GPM6A,TNIK,SLC4A4,SLC1A2,FMN2,NRXN1,SLC1A3,LIFR |
2.496e-02 | -3.69 | DNA-binding transcription factor activity, RNA polymerase II-specific | molecular function | GO:0000981 | 1355 | 8 | 18094 | 48 |
RORA,NFIA,GLIS3,TRPS1,ZBTB20,HIF3A,SOX5,NPAS3 |
2.501e-02 | -3.69 | GS | prosite domains | PS51256 | 7 | 1 | 12186 | 44 |
BMPR1B |
2.501e-02 | -3.69 | HEMATOPO_REC_L_F2 | prosite domains | PS01353 | 7 | 1 | 12186 | 44 |
LIFR |
2.501e-02 | -3.69 | Band_3_cyto | pfam domains | PF07565 | 9 | 1 | 17795 | 50 |
SLC4A4 |
2.501e-02 | -3.69 | Activin_recp | pfam domains | PF01064 | 9 | 1 | 17795 | 50 |
BMPR1B |
2.521e-02 | -3.68 | actin filament bundle | cellular component | GO:0032432 | 96 | 2 | 19108 | 49 |
NEBL,ABLIM1 |
2.521e-02 | -3.68 | sarcoplasm | cellular component | GO:0016528 | 96 | 2 | 19108 | 49 |
RYR3,ITPR2 |
2.536e-02 | -3.67 | perineuronal net | cellular component | GO:0072534 | 10 | 1 | 19108 | 49 |
PTPRZ1 |
2.539e-02 | -3.67 | regulation of purine nucleotide metabolic process | biological process | GO:1900542 | 90 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
2.541e-02 | -3.67 | CALB2 (calbindin 2) | protein interactions | 794 | 10 | 1 | 19454 | 50 |
GPM6A |
2.541e-02 | -3.67 | Smurf2 (SMAD specific E3 ubiquitin protein ligase 2) | protein interactions | 66313 | 10 | 1 | 19454 | 50 |
GLIS3 |
2.541e-02 | -3.67 | BANK1 (B cell scaffold protein with ankyrin repeats 1) | protein interactions | 55024 | 10 | 1 | 19454 | 50 |
ITPR2 |
2.541e-02 | -3.67 | GSG1 (germ cell associated 1) | protein interactions | 83445 | 10 | 1 | 19454 | 50 |
PITPNC1 |
2.541e-02 | -3.67 | P2rx7 (purinergic receptor P2X 7) | protein interactions | 29665 | 10 | 1 | 19454 | 50 |
PTPRZ1 |
2.541e-02 | -3.67 | SLC8A2 (solute carrier family 8 member A2) | protein interactions | 6543 | 10 | 1 | 19454 | 50 |
GPM6A |
2.541e-02 | -3.67 | SERPINB11 (serpin family B member 11) | protein interactions | 89778 | 10 | 1 | 19454 | 50 |
CPE |
2.541e-02 | -3.67 | Vbp1 (von Hippel-Lindau binding protein 1) | protein interactions | 22327 | 10 | 1 | 19454 | 50 |
ABLIM1 |
2.548e-02 | -3.67 | forebrain development | biological process | GO:0030900 | 408 | 4 | 18204 | 50 |
PCDH9,NTRK2,ATP1A2,SLC1A2 |
2.551e-02 | -3.67 | lipid binding | molecular function | GO:0008289 | 861 | 6 | 18094 | 48 |
PTGDS,RORA,ATP1A2,ITPR2,PITPNC1,PARD3B |
2.585e-02 | -3.66 | NCOR2 (nuclear receptor corepressor 2) | protein interactions | 9612 | 248 | 3 | 19454 | 50 |
SOX5,TNIK,NFIA |
2.589e-02 | -3.65 | shoulder | COSMIC cancer mutations | shoulder | 387 | 4 | 16828 | 49 |
MACF1,CPE,FGFR3,PREX2 |
2.591e-02 | -3.65 | skin-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-other-seborrhoeic_keratosis | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | epidermal_nevus | COSMIC cancer mutations | epidermal_nevus | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-benign_melanocytic_nevus-congenital | COSMIC cancer mutations | skin-benign_melanocytic_nevus-congenital | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | Bowen_disease | COSMIC cancer mutations | Bowen_disease | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-upper_leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma-superficial_spreading | 9 | 1 | 16828 | 49 |
PREX2 |
2.591e-02 | -3.65 | ovary-low_malignant_potential_(borderline)_tumour-Brenner_tumour | COSMIC cancer mutations | ovary-low_malignant_potential_(borderline)_tumour-Brenner_tumour | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-chest-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-chest-malignant_melanoma-superficial_spreading | 9 | 1 | 16828 | 49 |
PREX2 |
2.591e-02 | -3.65 | in_situ_epithelial_neoplasm | COSMIC cancer mutations | in_situ_epithelial_neoplasm | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | compound | COSMIC cancer mutations | compound | 9 | 1 | 16828 | 49 |
FGFR3 |
2.592e-02 | -3.65 | regulation of nucleotide metabolic process | biological process | GO:0006140 | 91 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
2.592e-02 | -3.65 | cellular response to BMP stimulus | biological process | GO:0071773 | 91 | 2 | 18204 | 50 |
BMPR1B,NFIA |
2.592e-02 | -3.65 | response to BMP | biological process | GO:0071772 | 91 | 2 | 18204 | 50 |
NFIA,BMPR1B |
2.613e-02 | -3.64 | ACTIVIN2R | prints domains | PR00653 | 6 | 1 | 5227 | 23 |
BMPR1B |
2.621e-02 | -3.64 | oesophagus-carcinoma-adenocarcinoma | COSMIC cancer mutations | oesophagus-carcinoma-adenocarcinoma | 13112 | 44 | 16828 | 49 |
MACF1,LIFR,NHSL1,SPARCL1,GLUD1,NTM,AHCYL2,ATP13A4,FBXL7,PTGDS,NRXN1,SOX5,RYR3,SLC1A2,BMPR1B,NKAIN3,SFXN5,SLC4A4,ITPR2,PARD3B,ATP1A2,FGFR3,HIF3A,GLIS3,LSAMP,PREX2,PCDH9,NPAS3,ZBTB20,CST3,CDH20,GPM6A,PTPRZ1,TRPS1,CTNND2,SLC1A3,GPC5,TNIK,FMN2,MAML2,NEBL,RORA,CPE,NTRK2 |
2.622e-02 | -3.64 | polyamine transmembrane transporter activity | molecular function | GO:0015203 | 10 | 1 | 18094 | 48 |
ATP13A4 |
2.622e-02 | -3.64 | neurotrophin binding | molecular function | GO:0043121 | 10 | 1 | 18094 | 48 |
NTRK2 |
2.622e-02 | -3.64 | phosphatidylinositol transfer activity | molecular function | GO:0008526 | 10 | 1 | 18094 | 48 |
PITPNC1 |
2.631e-02 | -3.64 | DNAAF2 (dynein axonemal assembly factor 2) | protein interactions | 55172 | 98 | 2 | 19454 | 50 |
LSAMP,GPM6A |
2.631e-02 | -3.64 | FRS2 (fibroblast growth factor receptor substrate 2) | protein interactions | 10818 | 98 | 2 | 19454 | 50 |
NTRK2,FGFR3 |
2.637e-02 | -3.64 | intracellular signaling cassette | biological process | GO:0141124 | 837 | 6 | 18204 | 50 |
PREX2,FGFR3,ITPR2,TNIK,RYR3,ATP1A2 |
2.645e-02 | -3.63 | establishment of localization | biological process | GO:0051234 | 3887 | 17 | 18204 | 50 |
PARD3B,PITPNC1,SLC1A2,NTRK2,GPM6A,ITPR2,NRXN1,ATP13A4,RYR3,SLC1A3,PTGDS,MACF1,SLC4A4,FMN2,ATP1A2,SFXN5,CPE |
2.646e-02 | -3.63 | human chr2p16.3 | chromosome location | human chr2p16.3 | 14 | 1 | 26134 | 50 |
NRXN1 |
2.646e-02 | -3.63 | human chr2p13.2 | chromosome location | human chr2p13.2 | 14 | 1 | 26134 | 50 |
SFXN5 |
2.666e-02 | -3.62 | TCF7L2 (transcription factor 7 like 2) | protein interactions | 6934 | 251 | 3 | 19454 | 50 |
CTNNA2,LIFR,NFIA |
2.668e-02 | -3.62 | PAS_fold_3 | interpro domains | IPR013655 | 10 | 1 | 18521 | 50 |
NPAS3 |
2.668e-02 | -3.62 | PTrfase/Anion_transptr | interpro domains | IPR016152 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | HCO3_transpt-like_TM_dom | interpro domains | IPR011531 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | HCO3_transpt_euk | interpro domains | IPR003020 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.680e-02 | -3.62 | TNKS (tankyrase) | protein interactions | 8658 | 99 | 2 | 19454 | 50 |
PCDH9,TNIK |
2.680e-02 | -3.62 | ZFHX3 (zinc finger homeobox 3) | protein interactions | 463 | 99 | 2 | 19454 | 50 |
TRPS1,SOX5 |
2.683e-02 | -3.62 | ATPase-coupled transmembrane transporter activity | molecular function | GO:0042626 | 96 | 2 | 18094 | 48 |
ATP1A2,ATP13A4 |
2.690e-02 | -3.62 | anterograde trans-synaptic signaling | biological process | GO:0098916 | 415 | 4 | 18204 | 50 |
NRXN1,SLC1A2,SLC1A3,DTNA |
2.690e-02 | -3.62 | chemical synaptic transmission | biological process | GO:0007268 | 415 | 4 | 18204 | 50 |
SLC1A3,SLC1A2,DTNA,NRXN1 |
2.693e-02 | -3.61 | NCK2 (NCK adaptor protein 2) | protein interactions | 8440 | 252 | 3 | 19454 | 50 |
NHSL1,TNIK,NTRK2 |
2.693e-02 | -3.61 | CRX (cone-rod homeobox) | protein interactions | 1406 | 252 | 3 | 19454 | 50 |
TRPS1,NFIA,SOX5 |
2.705e-02 | -3.61 | LIM_DOMAIN_1 | prosite domains | PS00478 | 71 | 2 | 12186 | 44 |
NEBL,ABLIM1 |
2.705e-02 | -3.61 | LIM_DOMAIN_2 | prosite domains | PS50023 | 71 | 2 | 12186 | 44 |
NEBL,ABLIM1 |
2.714e-02 | -3.61 | regulation of mesenchymal stem cell differentiation | biological process | GO:2000739 | 10 | 1 | 18204 | 50 |
SOX5 |
2.714e-02 | -3.61 | learned vocalization behavior or vocal learning | biological process | GO:0098598 | 10 | 1 | 18204 | 50 |
NRXN1 |
2.714e-02 | -3.61 | release of sequestered calcium ion into cytosol by endoplasmic reticulum | biological process | GO:1903514 | 10 | 1 | 18204 | 50 |
RYR3 |
2.714e-02 | -3.61 | postsynaptic density assembly | biological process | GO:0097107 | 10 | 1 | 18204 | 50 |
NRXN1 |
2.714e-02 | -3.61 | postsynaptic membrane assembly | biological process | GO:0097104 | 10 | 1 | 18204 | 50 |
NRXN1 |
2.714e-02 | -3.61 | establishment of centrosome localization | biological process | GO:0051660 | 10 | 1 | 18204 | 50 |
PARD3B |
2.714e-02 | -3.61 | trans-synaptic signaling, modulating synaptic transmission | biological process | GO:0099550 | 10 | 1 | 18204 | 50 |
NTRK2 |
2.714e-02 | -3.61 | cellular response to brain-derived neurotrophic factor stimulus | biological process | GO:1990416 | 10 | 1 | 18204 | 50 |
NTRK2 |
2.714e-02 | -3.61 | retinal rod cell development | biological process | GO:0046548 | 10 | 1 | 18204 | 50 |
NTRK2 |
2.719e-02 | -3.60 | Tyr_kinase_AS | interpro domains | IPR008266 | 95 | 2 | 18521 | 50 |
NTRK2,FGFR3 |
2.731e-02 | -3.60 | APBA1 (amyloid beta precursor protein binding family A member 1) | protein interactions | 320 | 100 | 2 | 19454 | 50 |
ABLIM1,NRXN1 |
2.731e-02 | -3.60 | ATP4A (ATPase H+/K+ transporting subunit alpha) | protein interactions | 495 | 100 | 2 | 19454 | 50 |
GPM6A,ATP1A2 |
2.737e-02 | -3.60 | pancreas-other-adenoma | COSMIC cancer mutations | pancreas-other-adenoma | 224 | 3 | 16828 | 49 |
PCDH9,CTNND2,BMPR1B |
2.748e-02 | -3.59 | Post-translational modification: synthesis of GPI-anchored proteins | REACTOME pathways | R-HSA-163125 | 92 | 2 | 10285 | 29 |
NTM,LSAMP |
2.756e-02 | -3.59 | muscle contraction | biological process | GO:0006936 | 238 | 3 | 18204 | 50 |
ATP1A2,DTNA,RYR3 |
2.775e-02 | -3.58 | PAS_3 | pfam domains | PF08447 | 10 | 1 | 17795 | 50 |
NPAS3 |
2.775e-02 | -3.58 | HCO3_cotransp | pfam domains | PF00955 | 10 | 1 | 17795 | 50 |
SLC4A4 |
2.776e-02 | -3.58 | DYNLL2 (dynein light chain LC8-type 2) | protein interactions | 140735 | 255 | 3 | 19454 | 50 |
TRPS1,NFIA,NHSL1 |
2.781e-02 | -3.58 | CLEC4A (C-type lectin domain family 4 member A) | protein interactions | 50856 | 101 | 2 | 19454 | 50 |
FGFR3,CTNNA2 |
2.785e-02 | -3.58 | Signaling by FGFR3 fusions in cancer | REACTOME pathways | R-HSA-8853334 | 10 | 1 | 10285 | 29 |
FGFR3 |
2.786e-02 | -3.58 | platelet dense tubular network | cellular component | GO:0031094 | 11 | 1 | 19108 | 49 |
ITPR2 |
2.786e-02 | -3.58 | perisynaptic extracellular matrix | cellular component | GO:0098966 | 11 | 1 | 19108 | 49 |
PTPRZ1 |
2.792e-02 | -3.58 | IRAG1 (inositol 1,4,5-triphosphate receptor associated 1) | protein interactions | 10335 | 11 | 1 | 19454 | 50 |
ITPR2 |
2.792e-02 | -3.58 | SYTL1 (synaptotagmin like 1) | protein interactions | 84958 | 11 | 1 | 19454 | 50 |
NRXN1 |
2.792e-02 | -3.58 | CCDC17 (coiled-coil domain containing 17) | protein interactions | 149483 | 11 | 1 | 19454 | 50 |
FGFR3 |
2.792e-02 | -3.58 | PTGDR (prostaglandin D2 receptor) | protein interactions | 5729 | 11 | 1 | 19454 | 50 |
PTGDS |
2.792e-02 | -3.58 | NTS (neurotensin) | protein interactions | 4922 | 11 | 1 | 19454 | 50 |
CPE |
2.792e-02 | -3.58 | Cobll1 (Cobl-like 1) | protein interactions | 319876 | 11 | 1 | 19454 | 50 |
ABLIM1 |
2.792e-02 | -3.58 | Batf3 (basic leucine zipper transcription factor, ATF-like 3) | protein interactions | 381319 | 11 | 1 | 19454 | 50 |
MACF1 |
2.792e-02 | -3.58 | Wipi2 (WD repeat domain, phosphoinositide interacting 2) | protein interactions | 74781 | 11 | 1 | 19454 | 50 |
MACF1 |
2.792e-02 | -3.58 | AQP5 (aquaporin 5) | protein interactions | 362 | 11 | 1 | 19454 | 50 |
ATP1A2 |
2.792e-02 | -3.58 | Gtf2e2 (general transcription factor II E, polypeptide 2 (beta subunit)) | protein interactions | 68153 | 11 | 1 | 19454 | 50 |
NHSL1 |
2.792e-02 | -3.58 | SYN3 (synapsin III) | protein interactions | 8224 | 11 | 1 | 19454 | 50 |
GPM6A |
2.795e-02 | -3.58 | secretion by cell | biological process | GO:0032940 | 420 | 4 | 18204 | 50 |
NRXN1,PTGDS,NTRK2,CPE |
2.795e-02 | -3.58 | axon development | biological process | GO:0061564 | 420 | 4 | 18204 | 50 |
CTNNA2,NRXN1,PTPRZ1,BMPR1B |
2.802e-02 | -3.58 | RNA polymerase II transcription regulatory region sequence-specific DNA binding | molecular function | GO:0000977 | 1385 | 8 | 18094 | 48 |
GLIS3,NFIA,RORA,SOX5,NPAS3,HIF3A,ZBTB20,TRPS1 |
2.807e-02 | -3.57 | calcium ion transmembrane import into cytosol | biological process | GO:0097553 | 95 | 2 | 18204 | 50 |
RYR3,ITPR2 |
2.809e-02 | -3.57 | enzyme-linked receptor protein signaling pathway | biological process | GO:0007167 | 626 | 5 | 18204 | 50 |
NTRK2,BMPR1B,FGFR3,LIFR,NFIA |
2.832e-02 | -3.56 | human chr10p12.31 | chromosome location | human chr10p12.31 | 15 | 1 | 26134 | 50 |
NEBL |
2.832e-02 | -3.56 | human chr8q12.3 | chromosome location | human chr8q12.3 | 15 | 1 | 26134 | 50 |
NKAIN3 |
2.847e-02 | -3.56 | GS | smart domains | SM00467 | 7 | 1 | 9717 | 40 |
BMPR1B |
2.847e-02 | -3.56 | PLEC | smart domains | SM00250 | 7 | 1 | 9717 | 40 |
MACF1 |
2.853e-02 | -3.56 | GATA_ZN_FINGER_1 | prosite domains | PS00344 | 8 | 1 | 12186 | 44 |
TRPS1 |
2.853e-02 | -3.56 | HP | prosite domains | PS51089 | 8 | 1 | 12186 | 44 |
ABLIM1 |
2.860e-02 | -3.55 | PLCG1 (phospholipase C gamma 1) | protein interactions | 5335 | 258 | 3 | 19454 | 50 |
FGFR3,NTRK2,LIFR |
2.862e-02 | -3.55 | pleura | COSMIC cancer mutations | pleura | 4914 | 21 | 16828 | 49 |
FMN2,MAML2,TNIK,CTNND2,TRPS1,PTPRZ1,NTRK2,MSI2,RORA,BMPR1B,NEBL,SOX5,FGFR3,PITPNC1,ITPR2,LIFR,PREX2,FBXL7,ATP13A4,NTM,HIF3A |
2.865e-02 | -3.55 | urinary_tract-bladder-carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma | 14050 | 46 | 16828 | 49 |
FGFR3,ATP1A2,PARD3B,PITPNC1,SLC4A4,SFXN5,ZBTB20,LSAMP,GLIS3,HIF3A,FMN2,GPC5,MAML2,SLC1A3,CTNND2,PTPRZ1,MSI2,NEBL,SPARCL1,LIFR,PTGDS,FBXL7,AHCYL2,DTNA,BMPR1B,RYR3,ABLIM1,ITPR2,NPAS3,PCDH9,PREX2,TNIK,TRPS1,GPM6A,CDH20,NTRK2,CPE,RORA,MACF1,ATP13A4,NTM,GLUD1,NRXN1,NFIA,SLC1A2,SOX5 |
2.875e-02 | -3.55 | intradermal | COSMIC cancer mutations | intradermal | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | lung-carcinoma-pleomorphic_carcinoma | COSMIC cancer mutations | lung-carcinoma-pleomorphic_carcinoma | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | renal_cell_carcinoma_unclassified | COSMIC cancer mutations | renal_cell_carcinoma_unclassified | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | skin-back-malignant_melanoma-nodular | COSMIC cancer mutations | skin-back-malignant_melanoma-nodular | 10 | 1 | 16828 | 49 |
PREX2 |
2.875e-02 | -3.55 | cervical_intraepithelial_neoplasia_Grade_III | COSMIC cancer mutations | cervical_intraepithelial_neoplasia_Grade_III | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | kidney-carcinoma-renal_cell_carcinoma_unclassified | COSMIC cancer mutations | kidney-carcinoma-renal_cell_carcinoma_unclassified | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_III | COSMIC cancer mutations | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_III | 10 | 1 | 16828 | 49 |
FGFR3 |
2.880e-02 | -3.55 | acetylcholine receptor binding | molecular function | GO:0033130 | 11 | 1 | 18094 | 48 |
NRXN1 |
2.880e-02 | -3.55 | sulfur amino acid transmembrane transporter activity | molecular function | GO:0000099 | 11 | 1 | 18094 | 48 |
SLC1A2 |
2.881e-02 | -3.55 | upper_aerodigestive_tract-head_neck-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-head_neck-carcinoma-squamous_cell_carcinoma | 9263 | 34 | 16828 | 49 |
NHSL1,MACF1,LIFR,PTGDS,FBXL7,AHCYL2,NKAIN3,NFIA,RYR3,SOX5,BMPR1B,FGFR3,PARD3B,ATP1A2,SLC4A4,ITPR2,PITPNC1,PCDH9,PREX2,LSAMP,GLIS3,HIF3A,MAML2,TNIK,GPC5,FMN2,CTNND2,PTPRZ1,TRPS1,CDH20,NTRK2,MSI2,RORA,NEBL |
2.881e-02 | -3.55 | transport | biological process | GO:0006810 | 3615 | 16 | 18204 | 50 |
NTRK2,PITPNC1,SLC1A2,FMN2,MACF1,SLC4A4,SFXN5,ATP1A2,CPE,NRXN1,ITPR2,GPM6A,RYR3,SLC1A3,PTGDS,ATP13A4 |
2.884e-02 | -3.55 | RAB6B (RAB6B, member RAS oncogene family) | protein interactions | 51560 | 103 | 2 | 19454 | 50 |
BMPR1B,GPM6A |
2.892e-02 | -3.54 | Bile Acid Indirect Signalling Pathway | SMPDB pathways | SMP0086851 | 8 | 1 | 1369 | 5 |
FGFR3 |
2.892e-02 | -3.54 | Glucose-Alanine Cycle | SMPDB pathways | SMP0000127 | 8 | 1 | 1369 | 5 |
GLUD1 |
2.893e-02 | -3.54 | amino acid transmembrane transporter activity | molecular function | GO:0015171 | 100 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
2.894e-02 | -3.54 | Ig-like_dom | interpro domains | IPR007110 | 432 | 4 | 18521 | 50 |
NTM,LSAMP,FGFR3,NTRK2 |
2.917e-02 | -3.53 | amino acid transmembrane transport | biological process | GO:0003333 | 97 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
2.917e-02 | -3.53 | NS-malignant_melanoma | COSMIC cancer mutations | NS-malignant_melanoma | 3420 | 16 | 16828 | 49 |
GLIS3,PREX2,PCDH9,ATP13A4,PITPNC1,LIFR,ITPR2,MACF1,FGFR3,ATP1A2,NEBL,PTPRZ1,GPC5,FMN2,NRXN1,CTNND2 |
2.920e-02 | -3.53 | LCK (LCK proto-oncogene, Src family tyrosine kinase) | protein interactions | 3932 | 455 | 4 | 19454 | 50 |
DTNA,MACF1,FMN2,CTNND2 |
2.931e-02 | -3.53 | Tyr_kinase_rcpt_2_CS | interpro domains | IPR002011 | 11 | 1 | 18521 | 50 |
NTRK2 |
2.936e-02 | -3.53 | HUNK (hormonally up-regulated Neu-associated kinase) | protein interactions | 30811 | 104 | 2 | 19454 | 50 |
SPARCL1,ABLIM1 |
2.940e-02 | -3.53 | GSK3A (glycogen synthase kinase 3 alpha) | protein interactions | 2931 | 456 | 4 | 19454 | 50 |
MACF1,NHSL1,TNIK,GLUD1 |
2.946e-02 | -3.52 | DIRAS3 (DIRAS family GTPase 3) | protein interactions | 9077 | 261 | 3 | 19454 | 50 |
FMN2,MACF1,DTNA |
2.971e-02 | -3.52 | response to abiotic stimulus | biological process | GO:0009628 | 1100 | 7 | 18204 | 50 |
FMN2,ATP1A2,NRXN1,ITPR2,SLC1A2,SLC1A3,RORA |
2.972e-02 | -3.52 | kidney-carcinoma | COSMIC cancer mutations | kidney-carcinoma | 3720 | 17 | 16828 | 49 |
SOX5,BMPR1B,RORA,MSI2,NTRK2,PTPRZ1,TRPS1,CTNND2,MAML2,TNIK,HIF3A,PREX2,FBXL7,LIFR,ITPR2,PITPNC1,FGFR3 |
2.980e-02 | -3.51 | organic substance transport | biological process | GO:0071702 | 1881 | 10 | 18204 | 50 |
NTRK2,SFXN5,CPE,FMN2,SLC4A4,MACF1,SLC1A2,SLC1A3,ATP13A4,PITPNC1 |
2.981e-02 | -3.51 | polyamine transport | biological process | GO:0015846 | 11 | 1 | 18204 | 50 |
ATP13A4 |
2.981e-02 | -3.51 | establishment or maintenance of transmembrane electrochemical gradient | biological process | GO:0010248 | 11 | 1 | 18204 | 50 |
ATP1A2 |
2.981e-02 | -3.51 | L-ascorbic acid metabolic process | biological process | GO:0019852 | 11 | 1 | 18204 | 50 |
ATP1A2 |
2.981e-02 | -3.51 | lactone metabolic process | biological process | GO:1901334 | 11 | 1 | 18204 | 50 |
ATP1A2 |
2.981e-02 | -3.51 | glutamate secretion | biological process | GO:0014047 | 11 | 1 | 18204 | 50 |
NTRK2 |
2.981e-02 | -3.51 | antral ovarian follicle growth | biological process | GO:0001547 | 11 | 1 | 18204 | 50 |
BMPR1B |
2.981e-02 | -3.51 | cellular response to caffeine | biological process | GO:0071313 | 11 | 1 | 18204 | 50 |
RYR3 |
2.988e-02 | -3.51 | BEND3 (BEN domain containing 3) | protein interactions | 57673 | 105 | 2 | 19454 | 50 |
TRPS1,TNIK |
2.999e-02 | -3.51 | positive regulation of neurogenesis | biological process | GO:0050769 | 246 | 3 | 18204 | 50 |
NTRK2,MACF1,PTPRZ1 |
3.000e-02 | -3.51 | Helical hairpin bin | gene3d domains | 1.10.287.570 | 10 | 1 | 14470 | 44 |
SLC4A4 |
3.028e-02 | -3.50 | bone morphogenesis | biological process | GO:0060349 | 99 | 2 | 18204 | 50 |
FGFR3,BMPR1B |
3.030e-02 | -3.50 | abdomen | COSMIC cancer mutations | abdomen | 603 | 5 | 16828 | 49 |
PREX2,CTNND2,FMN2,FGFR3,ITPR2 |
3.034e-02 | -3.50 | response to wounding | biological process | GO:0009611 | 431 | 4 | 18204 | 50 |
SLC1A2,SLC1A3,MACF1,NFIA |
3.035e-02 | -3.49 | synapse-associated extracellular matrix | cellular component | GO:0099535 | 12 | 1 | 19108 | 49 |
PTPRZ1 |
3.035e-02 | -3.49 | sodium:potassium-exchanging ATPase complex | cellular component | GO:0005890 | 12 | 1 | 19108 | 49 |
ATP1A2 |
3.036e-02 | -3.49 | NRAS (NRAS proto-oncogene, GTPase) | protein interactions | 4893 | 683 | 5 | 19454 | 50 |
SLC1A3,MACF1,PCDH9,FMN2,TNIK |
3.042e-02 | -3.49 | CTF1 (cardiotrophin 1) | protein interactions | 1489 | 12 | 1 | 19454 | 50 |
LIFR |
3.042e-02 | -3.49 | CA4 (carbonic anhydrase 4) | protein interactions | 762 | 12 | 1 | 19454 | 50 |
SLC4A4 |
3.042e-02 | -3.49 | LMP-1 (latent membrane protein LMP-1) | protein interactions | 3783750 | 12 | 1 | 19454 | 50 |
TNIK |
3.042e-02 | -3.49 | NTF4 (neurotrophin 4) | protein interactions | 4909 | 12 | 1 | 19454 | 50 |
NTRK2 |
3.042e-02 | -3.49 | ART4 (ADP-ribosyltransferase 4 (inactive) (Dombrock blood group)) | protein interactions | 420 | 12 | 1 | 19454 | 50 |
GPM6A |
3.042e-02 | -3.49 | BAMBI (BMP and activin membrane bound inhibitor) | protein interactions | 25805 | 12 | 1 | 19454 | 50 |
BMPR1B |
3.042e-02 | -3.49 | PROK2 (prokineticin 2) | protein interactions | 60675 | 12 | 1 | 19454 | 50 |
CPE |
3.049e-02 | -3.49 | PAS_11 | pfam domains | PF14598 | 11 | 1 | 17795 | 50 |
HIF3A |
3.058e-02 | -3.49 | CTNNB1 (catenin beta 1) | protein interactions | 1499 | 926 | 6 | 19454 | 50 |
PTPRZ1,CTNND2,CTNNA2,PARD3B,NHSL1,DTNA |
3.063e-02 | -3.49 | spleen | COSMIC cancer mutations | spleen | 408 | 4 | 16828 | 49 |
PARD3B,TNIK,NTM,PTPRZ1 |
3.067e-02 | -3.48 | PROKAR_LIPOPROTEIN | prosite domains | PS51257 | 76 | 2 | 12186 | 44 |
CPE,GLIS3 |
3.079e-02 | -3.48 | inorganic ion homeostasis | biological process | GO:0098771 | 433 | 4 | 18204 | 50 |
ATP13A4,ATP1A2,RYR3,SLC1A3 |
3.100e-02 | -3.47 | RHOA (ras homolog family member A) | protein interactions | 387 | 1186 | 7 | 19454 | 50 |
FMN2,ITPR2,MACF1,PARD3B,CTNNA2,PREX2,GLUD1 |
3.138e-02 | -3.46 | inositol 1,4,5 trisphosphate binding | molecular function | GO:0070679 | 12 | 1 | 18094 | 48 |
ITPR2 |
3.147e-02 | -3.46 | PAX8 (paired box 8) | protein interactions | 7849 | 108 | 2 | 19454 | 50 |
TRPS1,NFIA |
3.147e-02 | -3.46 | FKBP1A (FKBP prolyl isomerase 1A) | protein interactions | 2280 | 108 | 2 | 19454 | 50 |
MSI2,RYR3 |
3.147e-02 | -3.46 | CAMKV (CaM kinase like vesicle associated) | protein interactions | 79012 | 108 | 2 | 19454 | 50 |
AHCYL2,GPM6A |
3.149e-02 | -3.46 | PFN1 (profilin 1) | protein interactions | 5216 | 466 | 4 | 19454 | 50 |
ABLIM1,NHSL1,MACF1,FMN2 |
3.157e-02 | -3.46 | calcium ion transport | biological process | GO:0006816 | 251 | 3 | 18204 | 50 |
GPM6A,ITPR2,RYR3 |
3.158e-02 | -3.46 | kidney-other-oncocytoma | COSMIC cancer mutations | kidney-other-oncocytoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | skin-scalp-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-basal_cell_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | congenital | COSMIC cancer mutations | congenital | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | pleomorphic_carcinoma | COSMIC cancer mutations | pleomorphic_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | prostate-hyperplasia | COSMIC cancer mutations | prostate-hyperplasia | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | oncocytoma | COSMIC cancer mutations | oncocytoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | skin-hand-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-hand-malignant_melanoma-acral_lentiginous | 11 | 1 | 16828 | 49 |
PREX2 |
3.158e-02 | -3.46 | seborrhoeic_keratosis | COSMIC cancer mutations | seborrhoeic_keratosis | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | skin-back-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-back-malignant_melanoma-superficial_spreading | 11 | 1 | 16828 | 49 |
PREX2 |
3.158e-02 | -3.46 | skin-neck-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-neck-carcinoma-basal_cell_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.168e-02 | -3.45 | Methionine degradation | KEGG pathways | M00035 | 10 | 1 | 7161 | 23 |
AHCYL2 |
3.168e-02 | -3.45 | Methionine degradation | KEGG pathways | hsa_M00035 | 10 | 1 | 7161 | 23 |
AHCYL2 |
3.193e-02 | -3.44 | Lipocalin_CS | interpro domains | IPR022272 | 12 | 1 | 18521 | 50 |
PTGDS |
3.193e-02 | -3.44 | Lipocalin | interpro domains | IPR002345 | 12 | 1 | 18521 | 50 |
PTGDS |
3.193e-02 | -3.44 | TGFB_receptor | interpro domains | IPR000333 | 12 | 1 | 18521 | 50 |
BMPR1B |
3.193e-02 | -3.44 | MAD_homology1_Dwarfin-type | interpro domains | IPR003619 | 12 | 1 | 18521 | 50 |
NFIA |
3.204e-02 | -3.44 | human chr9q21.33 | chromosome location | human chr9q21.33 | 17 | 1 | 26134 | 50 |
NTRK2 |
3.204e-02 | -3.44 | CYSTATIN | prosite domains | PS00287 | 9 | 1 | 12186 | 44 |
CST3 |
3.207e-02 | -3.44 | biliary_tract-bile_duct-carcinoma-adenocarcinoma | COSMIC cancer mutations | biliary_tract-bile_duct-carcinoma-adenocarcinoma | 15095 | 48 | 16828 | 49 |
SPARCL1,NHSL1,LIFR,MACF1,PTGDS,FBXL7,ATP13A4,AHCYL2,NTM,GLUD1,NRXN1,NFIA,DTNA,BMPR1B,SLC1A2,RYR3,SOX5,FGFR3,ABLIM1,ATP1A2,PARD3B,ITPR2,PITPNC1,SLC4A4,SFXN5,NPAS3,ZBTB20,CST3,PCDH9,PREX2,GLIS3,LSAMP,HIF3A,MAML2,TNIK,GPC5,FMN2,SLC1A3,CTNND2,TRPS1,PTPRZ1,GPM6A,CDH20,NTRK2,MSI2,CPE,RORA,NEBL |
3.207e-02 | -3.44 | bile_duct | COSMIC cancer mutations | bile_duct | 15095 | 48 | 16828 | 49 |
NRXN1,NFIA,DTNA,SLC1A2,BMPR1B,SOX5,RYR3,SPARCL1,NHSL1,LIFR,MACF1,PTGDS,ATP13A4,FBXL7,AHCYL2,NTM,GLUD1,FMN2,TNIK,GPC5,MAML2,SLC1A3,CTNND2,TRPS1,PTPRZ1,GPM6A,CDH20,NTRK2,MSI2,CPE,RORA,NEBL,FGFR3,ABLIM1,ATP1A2,PARD3B,ITPR2,PITPNC1,SLC4A4,SFXN5,ZBTB20,NPAS3,CST3,PREX2,PCDH9,GLIS3,LSAMP,HIF3A |
3.247e-02 | -3.43 | VHP | smart domains | SM00153 | 8 | 1 | 9717 | 40 |
ABLIM1 |
3.248e-02 | -3.43 | dicarboxylic acid biosynthetic process | biological process | GO:0043650 | 12 | 1 | 18204 | 50 |
GLUD1 |
3.248e-02 | -3.43 | negative regulation of collagen metabolic process | biological process | GO:0010713 | 12 | 1 | 18204 | 50 |
CST3 |
3.248e-02 | -3.43 | mammalian oogenesis stage | biological process | GO:0022605 | 12 | 1 | 18204 | 50 |
BMPR1B |
3.248e-02 | -3.43 | positive regulation of extrinsic apoptotic signaling pathway via death domain receptors | biological process | GO:1902043 | 12 | 1 | 18204 | 50 |
BMPR1B |
3.248e-02 | -3.43 | regulation of blood vessel remodeling | biological process | GO:0060312 | 12 | 1 | 18204 | 50 |
CST3 |
3.248e-02 | -3.43 | sulfur amino acid transport | biological process | GO:0000101 | 12 | 1 | 18204 | 50 |
SLC1A2 |
3.250e-02 | -3.43 | DNA-binding transcription repressor activity, RNA polymerase II-specific | molecular function | GO:0001227 | 263 | 3 | 18094 | 48 |
GLIS3,ZBTB20,TRPS1 |
3.254e-02 | -3.43 | LZTR1 (leucine zipper like post translational regulator 1) | protein interactions | 8216 | 110 | 2 | 19454 | 50 |
BMPR1B,PARD3B |
3.276e-02 | -3.42 | steroid binding | molecular function | GO:0005496 | 107 | 2 | 18094 | 48 |
ATP1A2,RORA |
3.279e-02 | -3.42 | large_intestine-colon-carcinoma | COSMIC cancer mutations | large_intestine-colon-carcinoma | 2612 | 13 | 16828 | 49 |
ITPR2,MACF1,AHCYL2,PREX2,PCDH9,TRPS1,PTPRZ1,GPC5,FMN2,NRXN1,SLC1A3,CPE,RORA |
3.281e-02 | -3.42 | distal axon | cellular component | GO:0150034 | 273 | 3 | 19108 | 49 |
NTRK2,PCDH9,GPM6A |
3.291e-02 | -3.41 | TBCC (tubulin folding cofactor C) | protein interactions | 6903 | 13 | 1 | 19454 | 50 |
NTM |
3.291e-02 | -3.41 | RAB3C (RAB3C, member RAS oncogene family) | protein interactions | 115827 | 13 | 1 | 19454 | 50 |
GPM6A |
3.291e-02 | -3.41 | PCDHA2 (protocadherin alpha 2) | protein interactions | 56146 | 13 | 1 | 19454 | 50 |
NFIA |
3.291e-02 | -3.41 | MYO16 (myosin XVI) | protein interactions | 23026 | 13 | 1 | 19454 | 50 |
NRXN1 |
3.296e-02 | -3.41 | Carboxypeptidase-like, regulatory domain | gene3d domains | 2.60.40.1120 | 11 | 1 | 14470 | 44 |
CPE |
3.308e-02 | -3.41 | regulation of neuron projection development | biological process | GO:0010975 | 443 | 4 | 18204 | 50 |
MACF1,CTNNA2,NTRK2,TNIK |
3.310e-02 | -3.41 | urinary_tract | COSMIC cancer mutations | urinary_tract | 14112 | 46 | 16828 | 49 |
ITPR2,ABLIM1,NPAS3,PCDH9,PREX2,GPM6A,TRPS1,CDH20,TNIK,RORA,CPE,NTRK2,MACF1,NTM,GLUD1,ATP13A4,NRXN1,SOX5,SLC1A2,NFIA,SLC4A4,PITPNC1,SFXN5,FGFR3,PARD3B,ATP1A2,LSAMP,GLIS3,HIF3A,ZBTB20,PTPRZ1,GPC5,FMN2,MAML2,CTNND2,SLC1A3,NEBL,MSI2,LIFR,SPARCL1,AHCYL2,PTGDS,FBXL7,RYR3,BMPR1B,DTNA |
3.310e-02 | -3.41 | bladder | COSMIC cancer mutations | bladder | 14112 | 46 | 16828 | 49 |
NPAS3,ZBTB20,PREX2,PCDH9,GLIS3,LSAMP,HIF3A,ABLIM1,FGFR3,PARD3B,ATP1A2,SLC4A4,ITPR2,PITPNC1,SFXN5,NTRK2,MSI2,RORA,CPE,NEBL,TNIK,GPC5,FMN2,MAML2,CTNND2,SLC1A3,PTPRZ1,GPM6A,TRPS1,CDH20,PTGDS,FBXL7,ATP13A4,NTM,AHCYL2,GLUD1,SPARCL1,MACF1,LIFR,NFIA,DTNA,RYR3,SOX5,BMPR1B,SLC1A2,NRXN1 |
3.321e-02 | -3.40 | MH1 | pfam domains | PF03165 | 12 | 1 | 17795 | 50 |
NFIA |
3.321e-02 | -3.40 | CarboxypepD_reg | pfam domains | PF13620 | 12 | 1 | 17795 | 50 |
CPE |
3.333e-02 | -3.40 | Signaling by activated point mutants of FGFR3 | REACTOME pathways | R-HSA-1839130 | 12 | 1 | 10285 | 29 |
FGFR3 |
3.333e-02 | -3.40 | Regulation of gene expression by Hypoxia-inducible Factor | REACTOME pathways | R-HSA-1234158 | 12 | 1 | 10285 | 29 |
HIF3A |
3.333e-02 | -3.40 | Defective EXT2 causes exostoses 2 | REACTOME pathways | R-HSA-3656237 | 12 | 1 | 10285 | 29 |
GPC5 |
3.333e-02 | -3.40 | Defective EXT1 causes exostoses 1, TRPS2 and CHDS | REACTOME pathways | R-HSA-3656253 | 12 | 1 | 10285 | 29 |
GPC5 |
3.333e-02 | -3.40 | FGFR3 mutant receptor activation | REACTOME pathways | R-HSA-2033514 | 12 | 1 | 10285 | 29 |
FGFR3 |
3.363e-02 | -3.39 | CEP170P1 (centrosomal protein 170 pseudogene 1) | protein interactions | 645455 | 112 | 2 | 19454 | 50 |
TRPS1,MACF1 |
3.368e-02 | -3.39 | large_intestine-rectum-adenoma | COSMIC cancer mutations | large_intestine-rectum-adenoma | 99 | 2 | 16828 | 49 |
LIFR,NTRK2 |
3.387e-02 | -3.39 | skin-arm-malignant_melanoma | COSMIC cancer mutations | skin-arm-malignant_melanoma | 1308 | 8 | 16828 | 49 |
ZBTB20,NPAS3,NTM,PARD3B,ATP1A2,SLC4A4,MACF1,TRPS1 |
3.389e-02 | -3.38 | human chr18q21.33 | chromosome location | human chr18q21.33 | 18 | 1 | 26134 | 50 |
CDH20 |
3.389e-02 | -3.38 | human chr7q31.32 | chromosome location | human chr7q31.32 | 18 | 1 | 26134 | 50 |
PTPRZ1 |
3.395e-02 | -3.38 | potassium ion binding | molecular function | GO:0030955 | 13 | 1 | 18094 | 48 |
ATP1A2 |
3.395e-02 | -3.38 | monoatomic cation:bicarbonate symporter activity | molecular function | GO:0140410 | 13 | 1 | 18094 | 48 |
SLC4A4 |
3.395e-02 | -3.38 | transforming growth factor beta receptor activity | molecular function | GO:0005024 | 13 | 1 | 18094 | 48 |
BMPR1B |
3.405e-02 | -3.38 | NR3C1 (nuclear receptor subfamily 3 group C member 1) | protein interactions | 2908 | 950 | 6 | 19454 | 50 |
NFIA,ZBTB20,ATP13A4,SLC1A3,CTNND2,TRPS1 |
3.425e-02 | -3.37 | signal transduction | biological process | GO:0007165 | 4637 | 19 | 18204 | 50 |
NTRK2,BMPR1B,FGFR3,CTNND2,SPARCL1,DTNA,TNIK,NFIA,PITPNC1,ATP1A2,CPE,MACF1,FMN2,PREX2,RORA,RYR3,MAML2,LIFR,ITPR2 |
3.425e-02 | -3.37 | ZDHHC17 (zinc finger DHHC-type palmitoyltransferase 17) | protein interactions | 23390 | 277 | 3 | 19454 | 50 |
SLC1A3,GPM6A,NEBL |
3.432e-02 | -3.37 | oogenesis | biological process | GO:0048477 | 106 | 2 | 18204 | 50 |
BMPR1B,FMN2 |
3.435e-02 | -3.37 | LIM | smart domains | SM00132 | 71 | 2 | 9717 | 40 |
ABLIM1,NEBL |
3.438e-02 | -3.37 | diffuse_adenocarcinoma | COSMIC cancer mutations | diffuse_adenocarcinoma | 4383 | 19 | 16828 | 49 |
PREX2,PCDH9,GLIS3,HIF3A,ABLIM1,FGFR3,NHSL1,ATP1A2,MACF1,LIFR,DTNA,SOX5,RYR3,FMN2,CTNND2,SLC1A3,PTPRZ1,GPM6A,TRPS1 |
3.438e-02 | -3.37 | stomach-carcinoma-diffuse_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-diffuse_adenocarcinoma | 4383 | 19 | 16828 | 49 |
DTNA,SOX5,RYR3,CTNND2,SLC1A3,FMN2,PTPRZ1,GPM6A,TRPS1,PCDH9,PREX2,HIF3A,GLIS3,NHSL1,ATP1A2,ABLIM1,FGFR3,MACF1,LIFR |
3.439e-02 | -3.37 | ear | COSMIC cancer mutations | ear | 624 | 5 | 16828 | 49 |
LIFR,FGFR3,ZBTB20,SPARCL1,NPAS3 |
3.440e-02 | -3.37 | skin-face-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-face-carcinoma-basal_cell_carcinoma | 12 | 1 | 16828 | 49 |
FGFR3 |
3.440e-02 | -3.37 | skin-abdomen-malignant_melanoma-nodular | COSMIC cancer mutations | skin-abdomen-malignant_melanoma-nodular | 12 | 1 | 16828 | 49 |
PREX2 |
3.440e-02 | -3.37 | cervix-carcinoma-mixed_adenosquamous_carcinoma | COSMIC cancer mutations | cervix-carcinoma-mixed_adenosquamous_carcinoma | 12 | 1 | 16828 | 49 |
FGFR3 |
3.440e-02 | -3.37 | skin-benign_melanocytic_nevus | COSMIC cancer mutations | skin-benign_melanocytic_nevus | 12 | 1 | 16828 | 49 |
FGFR3 |
3.440e-02 | -3.37 | DNA-binding transcription factor activity | molecular function | GO:0003700 | 1441 | 8 | 18094 | 48 |
RORA,NFIA,GLIS3,ZBTB20,TRPS1,HIF3A,NPAS3,SOX5 |
3.469e-02 | -3.36 | GATAZNFINGER | prints domains | PR00619 | 8 | 1 | 5227 | 23 |
TRPS1 |
3.469e-02 | -3.36 | LIPOCALIN | prints domains | PR00179 | 8 | 1 | 5227 | 23 |
PTGDS |
3.484e-02 | -3.36 | cell-cell adhesion via plasma-membrane adhesion molecules | biological process | GO:0098742 | 261 | 3 | 18204 | 50 |
CDH20,SPARCL1,PCDH9 |
3.500e-02 | -3.35 | Cadherin_CS | interpro domains | IPR020894 | 109 | 2 | 18521 | 50 |
PCDH9,CDH20 |
3.500e-02 | -3.35 | Ion_trans_dom | interpro domains | IPR005821 | 109 | 2 | 18521 | 50 |
ITPR2,RYR3 |
3.514e-02 | -3.35 | negative regulation of cytosolic calcium ion concentration | biological process | GO:0051481 | 13 | 1 | 18204 | 50 |
ATP1A2 |
3.514e-02 | -3.35 | cerebellar Purkinje cell differentiation | biological process | GO:0021702 | 13 | 1 | 18204 | 50 |
RORA |
3.514e-02 | -3.35 | postsynaptic specialization assembly | biological process | GO:0098698 | 13 | 1 | 18204 | 50 |
NRXN1 |
3.514e-02 | -3.35 | prepulse inhibition | biological process | GO:0060134 | 13 | 1 | 18204 | 50 |
CTNNA2 |
3.514e-02 | -3.35 | glial cell fate commitment | biological process | GO:0021781 | 13 | 1 | 18204 | 50 |
NFIA |
3.514e-02 | -3.35 | regulation of respiratory gaseous exchange by nervous system process | biological process | GO:0002087 | 13 | 1 | 18204 | 50 |
ATP1A2 |
3.514e-02 | -3.35 | T-helper 17 cell differentiation | biological process | GO:0072539 | 13 | 1 | 18204 | 50 |
RORA |
3.530e-02 | -3.34 | SMAD7 (SMAD family member 7) | protein interactions | 4092 | 115 | 2 | 19454 | 50 |
BMPR1B,SOX5 |
3.530e-02 | -3.34 | TBXT (T-box transcription factor T) | protein interactions | 6862 | 115 | 2 | 19454 | 50 |
NFIA,TRPS1 |
3.533e-02 | -3.34 | regulation of plasma membrane bounded cell projection organization | biological process | GO:0120035 | 666 | 5 | 18204 | 50 |
CTNNA2,MACF1,GPM6A,TNIK,NTRK2 |
3.538e-02 | -3.34 | DNA-binding transcription repressor activity | molecular function | GO:0001217 | 272 | 3 | 18094 | 48 |
GLIS3,ZBTB20,TRPS1 |
3.540e-02 | -3.34 | BOD1L2 (biorientation of chromosomes in cell division 1 like 2) | protein interactions | 284257 | 14 | 1 | 19454 | 50 |
FMN2 |
3.540e-02 | -3.34 | Asap1 (ArfGAP with SH3 domain, ankyrin repeat and PH domain1) | protein interactions | 13196 | 14 | 1 | 19454 | 50 |
MACF1 |
3.540e-02 | -3.34 | MB (myoglobin) | protein interactions | 4151 | 14 | 1 | 19454 | 50 |
MAML2 |
3.540e-02 | -3.34 | SLC1A2 (solute carrier family 1 member 2) | protein interactions | 6506 | 14 | 1 | 19454 | 50 |
SLC1A2 |
3.540e-02 | -3.34 | PLXNA4 (plexin A4) | protein interactions | 91584 | 14 | 1 | 19454 | 50 |
GPM6A |
3.540e-02 | -3.34 | FGF7 (fibroblast growth factor 7) | protein interactions | 2252 | 14 | 1 | 19454 | 50 |
FGFR3 |
3.540e-02 | -3.34 | DACT2 (dishevelled binding antagonist of beta catenin 2) | protein interactions | 168002 | 14 | 1 | 19454 | 50 |
ZBTB20 |
3.540e-02 | -3.34 | VSX2 (visual system homeobox 2) | protein interactions | 338917 | 14 | 1 | 19454 | 50 |
AHCYL2 |
3.540e-02 | -3.34 | SYT5 (synaptotagmin 5) | protein interactions | 6861 | 14 | 1 | 19454 | 50 |
NRXN1 |
3.540e-02 | -3.34 | CTSO (cathepsin O) | protein interactions | 1519 | 14 | 1 | 19454 | 50 |
CST3 |
3.540e-02 | -3.34 | Nedd4 (neural precursor cell expressed, developmentally down-regulated 4) | protein interactions | 17999 | 14 | 1 | 19454 | 50 |
GLIS3 |
3.540e-02 | -3.34 | RHEBL1 (RHEB like 1) | protein interactions | 121268 | 14 | 1 | 19454 | 50 |
BMPR1B |
3.553e-02 | -3.34 | lung-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-carcinoma-adenocarcinoma | 15133 | 48 | 16828 | 49 |
CPE,RORA,NTRK2,TRPS1,GPM6A,CDH20,TNIK,NPAS3,PREX2,PCDH9,ITPR2,ABLIM1,SLC1A2,SOX5,NKAIN3,NFIA,NRXN1,NTM,GLUD1,ATP13A4,MACF1,NHSL1,NEBL,MSI2,PTPRZ1,GPC5,MAML2,FMN2,SLC1A3,CTNND2,LSAMP,GLIS3,HIF3A,ZBTB20,PITPNC1,SLC4A4,SFXN5,FGFR3,ATP1A2,PARD3B,BMPR1B,RYR3,DTNA,AHCYL2,PTGDS,FBXL7,LIFR,SPARCL1 |
3.559e-02 | -3.34 | side of membrane | cellular component | GO:0098552 | 715 | 5 | 19108 | 49 |
LIFR,GPC5,NTM,DTNA,LSAMP |
3.574e-02 | -3.33 | human chr6q24.1 | chromosome location | human chr6q24.1 | 19 | 1 | 26134 | 50 |
NHSL1 |
3.574e-02 | -3.33 | human chr5p15.2 | chromosome location | human chr5p15.2 | 19 | 1 | 26134 | 50 |
CTNND2 |
3.574e-02 | -3.33 | human chr11q25 | chromosome location | human chr11q25 | 19 | 1 | 26134 | 50 |
NTM |
3.574e-02 | -3.33 | human chr10q23.2 | chromosome location | human chr10q23.2 | 19 | 1 | 26134 | 50 |
GLUD1 |
3.575e-02 | -3.33 | lung-carcinoma-large_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-large_cell_carcinoma | 849 | 6 | 16828 | 49 |
BMPR1B,NTRK2,LIFR,PTPRZ1,TNIK,FGFR3 |
3.575e-02 | -3.33 | large_cell_carcinoma | COSMIC cancer mutations | large_cell_carcinoma | 849 | 6 | 16828 | 49 |
NTRK2,TNIK,FGFR3,PTPRZ1,LIFR,BMPR1B |
3.586e-02 | -3.33 | SKIL (SKI like proto-oncogene) | protein interactions | 6498 | 116 | 2 | 19454 | 50 |
MACF1,SPARCL1 |
3.590e-02 | -3.33 | Alpha-catenin/vinculin-like | gene3d domains | 1.20.120.230 | 12 | 1 | 14470 | 44 |
CTNNA2 |
3.593e-02 | -3.33 | skin-upper_leg-malignant_melanoma | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma | 850 | 6 | 16828 | 49 |
GLIS3,HIF3A,FMN2,NFIA,PCDH9,PREX2 |
3.606e-02 | -3.32 | CLEC7A (Dectin-1) induces NFAT activation | REACTOME pathways | R-HSA-5607763 | 13 | 1 | 10285 | 29 |
ITPR2 |
3.606e-02 | -3.32 | FGFR3c ligand binding and activation | REACTOME pathways | R-HSA-190372 | 13 | 1 | 10285 | 29 |
FGFR3 |
3.606e-02 | -3.32 | Phospholipase C-mediated cascade; FGFR3 | REACTOME pathways | R-HSA-5654227 | 13 | 1 | 10285 | 29 |
FGFR3 |
3.606e-02 | -3.32 | FGFR3 ligand binding and activation | REACTOME pathways | R-HSA-190239 | 13 | 1 | 10285 | 29 |
FGFR3 |
3.606e-02 | -3.32 | NOTCH2 intracellular domain regulates transcription | REACTOME pathways | R-HSA-2197563 | 13 | 1 | 10285 | 29 |
MAML2 |
3.606e-02 | -3.32 | Notch-HLH transcription pathway | REACTOME pathways | R-HSA-350054 | 13 | 1 | 10285 | 29 |
MAML2 |
3.612e-02 | -3.32 | chromophobe_renal_cell_carcinoma | COSMIC cancer mutations | chromophobe_renal_cell_carcinoma | 430 | 4 | 16828 | 49 |
BMPR1B,FGFR3,NTRK2,TNIK |
3.612e-02 | -3.32 | kidney-carcinoma-chromophobe_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-chromophobe_renal_cell_carcinoma | 430 | 4 | 16828 | 49 |
NTRK2,FGFR3,TNIK,BMPR1B |
3.612e-02 | -3.32 | postsynapse organization | biological process | GO:0099173 | 109 | 2 | 18204 | 50 |
CTNND2,NRXN1 |
3.617e-02 | -3.32 | small_intestine | COSMIC cancer mutations | small_intestine | 250 | 3 | 16828 | 49 |
MACF1,TNIK,FGFR3 |
3.621e-02 | -3.32 | regulation of nervous system development | biological process | GO:0051960 | 456 | 4 | 18204 | 50 |
NTRK2,MACF1,PTPRZ1,NRXN1 |
3.630e-02 | -3.32 | positive regulation of biological process | biological process | GO:0048518 | 6326 | 24 | 18204 | 50 |
PTPRZ1,NFIA,MACF1,SLC4A4,GLUD1,NPAS3,RORA,MAML2,FGFR3,GLIS3,NTRK2,SOX5,BMPR1B,ZBTB20,SLC1A2,TNIK,FMN2,SFXN5,ATP1A2,GPM6A,LIFR,NRXN1,SLC1A3,GPC5 |
3.635e-02 | -3.31 | YWHAB (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta) | protein interactions | 7529 | 965 | 6 | 19454 | 50 |
PARD3B,MACF1,PITPNC1,FGFR3,NHSL1,ABLIM1 |
3.642e-02 | -3.31 | ELK3 (ETS transcription factor ELK3) | protein interactions | 2004 | 117 | 2 | 19454 | 50 |
NFIA,TRPS1 |
3.642e-02 | -3.31 | SYT6 (synaptotagmin 6) | protein interactions | 148281 | 117 | 2 | 19454 | 50 |
AHCYL2,NRXN1 |
3.646e-02 | -3.31 | FOLN | smart domains | SM00274 | 9 | 1 | 9717 | 40 |
SPARCL1 |
3.652e-02 | -3.31 | microtubule minus-end binding | molecular function | GO:0051011 | 14 | 1 | 18094 | 48 |
MACF1 |
3.670e-02 | -3.31 | phosphatidylinositol binding | molecular function | GO:0035091 | 276 | 3 | 18094 | 48 |
PITPNC1,ITPR2,PARD3B |
3.672e-02 | -3.30 | positive regulation of cell junction assembly | biological process | GO:1901890 | 110 | 2 | 18204 | 50 |
NTRK2,NRXN1 |
3.678e-02 | -3.30 | bHLH_dom | interpro domains | IPR011598 | 112 | 2 | 18521 | 50 |
NPAS3,HIF3A |
3.678e-02 | -3.30 | HLH_DNA-bd_sf | interpro domains | IPR036638 | 112 | 2 | 18521 | 50 |
HIF3A,NPAS3 |
3.699e-02 | -3.30 | PLCD3 (phospholipase C delta 3) | protein interactions | 113026 | 118 | 2 | 19454 | 50 |
AHCYL2,TNIK |
3.715e-02 | -3.29 | Neurexin-like | interpro domains | IPR003585 | 14 | 1 | 18521 | 50 |
NRXN1 |
3.721e-02 | -3.29 | skin-scalp-malignant_melanoma-nodular | COSMIC cancer mutations | skin-scalp-malignant_melanoma-nodular | 13 | 1 | 16828 | 49 |
PREX2 |
3.721e-02 | -3.29 | cervix-carcinoma-adenocarcinoma | COSMIC cancer mutations | cervix-carcinoma-adenocarcinoma | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | skin-shoulder-malignant_melanoma-nodular | COSMIC cancer mutations | skin-shoulder-malignant_melanoma-nodular | 13 | 1 | 16828 | 49 |
PREX2 |
3.721e-02 | -3.29 | skin-back-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-back-carcinoma-basal_cell_carcinoma | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | endometrium-ovary-endometriosis | COSMIC cancer mutations | endometrium-ovary-endometriosis | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | Brenner_tumour | COSMIC cancer mutations | Brenner_tumour | 13 | 1 | 16828 | 49 |
FGFR3 |
3.745e-02 | -3.28 | PARD3 (par-3 family cell polarity regulator) | protein interactions | 56288 | 287 | 3 | 19454 | 50 |
DTNA,PARD3B,NTRK2 |
3.745e-02 | -3.28 | DHFR2 (dihydrofolate reductase 2) | protein interactions | 200895 | 287 | 3 | 19454 | 50 |
ITPR2,SLC1A3,CPE |
3.764e-02 | -3.28 | Ion_trans | pfam domains | PF00520 | 109 | 2 | 17795 | 50 |
ITPR2,RYR3 |
3.771e-02 | -3.28 | protein localization to membrane | biological process | GO:0072657 | 462 | 4 | 18204 | 50 |
CPE,TNIK,MACF1,NRXN1 |
3.777e-02 | -3.28 | VASP (vasodilator stimulated phosphoprotein) | protein interactions | 7408 | 288 | 3 | 19454 | 50 |
NEBL,FMN2,NHSL1 |
3.779e-02 | -3.28 | NEDD4 (NEDD4 E3 ubiquitin protein ligase) | protein interactions | 4734 | 494 | 4 | 19454 | 50 |
MAML2,GLIS3,TNIK,FGFR3 |
3.779e-02 | -3.28 | cellular response to purine-containing compound | biological process | GO:0071415 | 14 | 1 | 18204 | 50 |
RYR3 |
3.779e-02 | -3.28 | glutathione biosynthetic process | biological process | GO:0006750 | 14 | 1 | 18204 | 50 |
SLC1A2 |
3.779e-02 | -3.28 | cellular response to ethanol | biological process | GO:0071361 | 14 | 1 | 18204 | 50 |
ITPR2 |
3.779e-02 | -3.28 | negative regulation of sodium ion transmembrane transporter activity | biological process | GO:2000650 | 14 | 1 | 18204 | 50 |
ATP1A2 |
3.779e-02 | -3.28 | relaxation of cardiac muscle | biological process | GO:0055119 | 14 | 1 | 18204 | 50 |
ATP1A2 |
3.780e-02 | -3.28 | axolemma | cellular component | GO:0030673 | 15 | 1 | 19108 | 49 |
SLC1A2 |
3.788e-02 | -3.27 | TIAM2 (TIAM Rac1 associated GEF 2) | protein interactions | 26230 | 15 | 1 | 19454 | 50 |
TNIK |
3.788e-02 | -3.27 | FGF9 (fibroblast growth factor 9) | protein interactions | 2254 | 15 | 1 | 19454 | 50 |
FGFR3 |
3.788e-02 | -3.27 | TAFA5 (TAFA chemokine like family member 5) | protein interactions | 25817 | 15 | 1 | 19454 | 50 |
NEBL |
3.788e-02 | -3.27 | TESPA1 (thymocyte expressed, positive selection associated 1) | protein interactions | 9840 | 15 | 1 | 19454 | 50 |
ITPR2 |
3.788e-02 | -3.27 | RNASE13 (ribonuclease A family member 13 (inactive)) | protein interactions | 440163 | 15 | 1 | 19454 | 50 |
CPE |
3.788e-02 | -3.27 | XIRP1 (xin actin binding repeat containing 1) | protein interactions | 165904 | 15 | 1 | 19454 | 50 |
NEBL |
3.788e-02 | -3.27 | IGSF1 (immunoglobulin superfamily member 1) | protein interactions | 3547 | 15 | 1 | 19454 | 50 |
BMPR1B |
3.794e-02 | -3.27 | rhythmic process | biological process | GO:0048511 | 270 | 3 | 18204 | 50 |
NTRK2,RORA,BMPR1B |
3.796e-02 | -3.27 | regulation of membrane potential | biological process | GO:0042391 | 463 | 4 | 18204 | 50 |
SLC4A4,NRXN1,ATP1A2,NTRK2 |
3.798e-02 | -3.27 | Cadherin-like_dom | interpro domains | IPR002126 | 114 | 2 | 18521 | 50 |
CDH20,PCDH9 |
3.810e-02 | -3.27 | CEP128 (centrosomal protein 128) | protein interactions | 145508 | 289 | 3 | 19454 | 50 |
NEBL,GLUD1,ABLIM1 |
3.814e-02 | -3.27 | HOXB9 (homeobox B9) | protein interactions | 3219 | 120 | 2 | 19454 | 50 |
NFIA,AHCYL2 |
3.829e-02 | -3.26 | carboxylic acid biosynthetic process | biological process | GO:0046394 | 271 | 3 | 18204 | 50 |
SLC1A3,GLUD1,PTGDS |
3.851e-02 | -3.26 | stomach-carcinoma | COSMIC cancer mutations | stomach-carcinoma | 439 | 4 | 16828 | 49 |
BMPR1B,NTRK2,TNIK,FGFR3 |
3.864e-02 | -3.25 | GATA | pfam domains | PF00320 | 14 | 1 | 17795 | 50 |
TRPS1 |
3.873e-02 | -3.25 | regulation of cell projection organization | biological process | GO:0031344 | 683 | 5 | 18204 | 50 |
NTRK2,TNIK,CTNNA2,MACF1,GPM6A |
3.878e-02 | -3.25 | DCC mediated attractive signaling | REACTOME pathways | R-HSA-418885 | 14 | 1 | 10285 | 29 |
ABLIM1 |
3.902e-02 | -3.24 | GATA_ZN_FINGER_2 | prosite domains | PS50114 | 11 | 1 | 12186 | 44 |
TRPS1 |
3.902e-02 | -3.24 | RECEPTOR_TYR_KIN_II | prosite domains | PS00239 | 11 | 1 | 12186 | 44 |
NTRK2 |
3.902e-02 | -3.24 | LIPOCALIN | prosite domains | PS00213 | 11 | 1 | 12186 | 44 |
PTGDS |
3.908e-02 | -3.24 | neurexin family protein binding | molecular function | GO:0042043 | 15 | 1 | 18094 | 48 |
CPE |
3.908e-02 | -3.24 | tropomyosin binding | molecular function | GO:0005523 | 15 | 1 | 18094 | 48 |
NEBL |
3.908e-02 | -3.24 | filamin binding | molecular function | GO:0031005 | 15 | 1 | 18094 | 48 |
NEBL |
3.908e-02 | -3.24 | phosphatidylglycerol binding | molecular function | GO:1901611 | 15 | 1 | 18094 | 48 |
PITPNC1 |
3.918e-02 | -3.24 | regulation of circadian rhythm | biological process | GO:0042752 | 114 | 2 | 18204 | 50 |
PTGDS,RORA |
3.918e-02 | -3.24 | negative regulation of protein catabolic process | biological process | GO:0042177 | 114 | 2 | 18204 | 50 |
FMN2,CST3 |
3.920e-02 | -3.24 | Cadherin-like_sf | interpro domains | IPR015919 | 116 | 2 | 18521 | 50 |
CDH20,PCDH9 |
3.930e-02 | -3.24 | BRK1 (BRICK1 subunit of SCAR/WAVE actin nucleating complex) | protein interactions | 55845 | 122 | 2 | 19454 | 50 |
NHSL1,DTNA |
3.936e-02 | -3.24 | organic acid biosynthetic process | biological process | GO:0016053 | 274 | 3 | 18204 | 50 |
PTGDS,GLUD1,SLC1A3 |
3.943e-02 | -3.23 | human chr4q32.3 | chromosome location | human chr4q32.3 | 21 | 1 | 26134 | 50 |
CPE |
3.943e-02 | -3.23 | human chr13q31.3 | chromosome location | human chr13q31.3 | 21 | 1 | 26134 | 50 |
GPC5 |
3.943e-02 | -3.23 | cell migration | biological process | GO:0016477 | 921 | 6 | 18204 | 50 |
GPC5,GPM6A,CTNNA2,NTRK2,CDH20,FMN2 |
3.947e-02 | -3.23 | pulmonary_blastoma | COSMIC cancer mutations | pulmonary_blastoma | 648 | 5 | 16828 | 49 |
NTM,TRPS1,BMPR1B,NEBL,ATP13A4 |
3.947e-02 | -3.23 | pleura-pulmonary_blastoma | COSMIC cancer mutations | pleura-pulmonary_blastoma | 648 | 5 | 16828 | 49 |
TRPS1,NTM,NEBL,BMPR1B,ATP13A4 |
3.954e-02 | -3.23 | Cadherin | pfam domains | PF00028 | 112 | 2 | 17795 | 50 |
PCDH9,CDH20 |
3.959e-02 | -3.23 | NAD+ Signalling and Aging | SMPDB pathways | SMP0084271 | 11 | 1 | 1369 | 5 |
RORA |
3.959e-02 | -3.23 | Ammonia Recycling | SMPDB pathways | SMP0000009 | 11 | 1 | 1369 | 5 |
GLUD1 |
3.967e-02 | -3.23 | skin-head_neck-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-head_neck-carcinoma-squamous_cell_carcinoma | 14191 | 46 | 16828 | 49 |
BMPR1B,RYR3,DTNA,LIFR,SPARCL1,AHCYL2,FBXL7,PTPRZ1,CTNND2,SLC1A3,FMN2,GPC5,MAML2,NEBL,SFXN5,PITPNC1,SLC4A4,ATP1A2,PARD3B,FGFR3,HIF3A,GLIS3,LSAMP,ZBTB20,NRXN1,SLC1A2,SOX5,NKAIN3,NFIA,MACF1,NHSL1,GLUD1,NTM,ATP13A4,CDH20,TRPS1,GPM6A,TNIK,CPE,RORA,NTRK2,ITPR2,ABLIM1,PCDH9,PREX2,NPAS3 |
3.970e-02 | -3.23 | bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 649 | 5 | 16828 | 49 |
MACF1,ABLIM1,FGFR3,TNIK,PREX2 |
3.971e-02 | -3.23 | gliogenesis | biological process | GO:0042063 | 275 | 3 | 18204 | 50 |
NTRK2,NFIA,PTPRZ1 |
3.975e-02 | -3.23 | Znf_GATA | interpro domains | IPR000679 | 15 | 1 | 18521 | 50 |
TRPS1 |
3.975e-02 | -3.23 | FH2_Formin | interpro domains | IPR015425 | 15 | 1 | 18521 | 50 |
FMN2 |
3.975e-02 | -3.23 | CNH_dom | interpro domains | IPR001180 | 15 | 1 | 18521 | 50 |
TNIK |
3.975e-02 | -3.23 | ATPase_P-typ_cation-transptr_C | interpro domains | IPR006068 | 15 | 1 | 18521 | 50 |
ATP1A2 |
3.975e-02 | -3.23 | FH2_Formin_sf | interpro domains | IPR042201 | 15 | 1 | 18521 | 50 |
FMN2 |
3.988e-02 | -3.22 | PAX7 (paired box 7) | protein interactions | 5081 | 123 | 2 | 19454 | 50 |
NFIA,TRPS1 |
4.002e-02 | -3.22 | endometriosis | COSMIC cancer mutations | endometriosis | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | soft_tissue-small_round_cell_tumour | COSMIC cancer mutations | soft_tissue-small_round_cell_tumour | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | in_situ_neoplasm | COSMIC cancer mutations | in_situ_neoplasm | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | urinary_tract-renal_pelvis-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-renal_pelvis-carcinoma-transitional_cell_carcinoma | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | small_round_cell_tumour | COSMIC cancer mutations | small_round_cell_tumour | 14 | 1 | 16828 | 49 |
FGFR3 |
4.008e-02 | -3.22 | telencephalon development | biological process | GO:0021537 | 276 | 3 | 18204 | 50 |
SLC1A2,ATP1A2,NTRK2 |
4.008e-02 | -3.22 | transcription cis-regulatory region binding | molecular function | GO:0000976 | 1485 | 8 | 18094 | 48 |
ZBTB20,TRPS1,HIF3A,SOX5,NPAS3,RORA,NFIA,GLIS3 |
4.015e-02 | -3.22 | rhabdomyosarcoma | COSMIC cancer mutations | rhabdomyosarcoma | 4150 | 18 | 16828 | 49 |
MACF1,NHSL1,PARD3B,SPARCL1,FGFR3,GLIS3,PREX2,NPAS3,CDH20,PTPRZ1,TRPS1,SLC1A3,CTNND2,FMN2,MAML2,RYR3,RORA,NFIA |
4.023e-02 | -3.21 | Prot_kinase_dom | interpro domains | IPR000719 | 480 | 4 | 18521 | 50 |
BMPR1B,TNIK,NTRK2,FGFR3 |
4.027e-02 | -3.21 | postsynaptic density, intracellular component | cellular component | GO:0099092 | 16 | 1 | 19108 | 49 |
TNIK |
4.035e-02 | -3.21 | transcription regulatory region nucleic acid binding | molecular function | GO:0001067 | 1487 | 8 | 18094 | 48 |
NFIA,GLIS3,RORA,HIF3A,NPAS3,SOX5,ZBTB20,TRPS1 |
4.035e-02 | -3.21 | SAPCD1 (suppressor APC domain containing 1) | protein interactions | 401251 | 16 | 1 | 19454 | 50 |
CTNNA2 |
4.035e-02 | -3.21 | Sumo3 (small ubiquitin-like modifier 3) | protein interactions | 20610 | 16 | 1 | 19454 | 50 |
ITPR2 |
4.035e-02 | -3.21 | SYT9 (synaptotagmin 9) | protein interactions | 143425 | 16 | 1 | 19454 | 50 |
NRXN1 |
4.035e-02 | -3.21 | FNDC8 (fibronectin type III domain containing 8) | protein interactions | 54752 | 16 | 1 | 19454 | 50 |
SPARCL1 |
4.035e-02 | -3.21 | CTSK (cathepsin K) | protein interactions | 1513 | 16 | 1 | 19454 | 50 |
FGFR3 |
4.035e-02 | -3.21 | GALNT13 (polypeptide N-acetylgalactosaminyltransferase 13) | protein interactions | 114805 | 16 | 1 | 19454 | 50 |
TNIK |
4.035e-02 | -3.21 | HLA-H (major histocompatibility complex, class I, H (pseudogene)) | protein interactions | 3136 | 16 | 1 | 19454 | 50 |
FGFR3 |
4.035e-02 | -3.21 | CDH12 (cadherin 12) | protein interactions | 1010 | 16 | 1 | 19454 | 50 |
CTNNA2 |
4.035e-02 | -3.21 | CNTFR (ciliary neurotrophic factor receptor) | protein interactions | 1271 | 16 | 1 | 19454 | 50 |
LIFR |
4.035e-02 | -3.21 | AMMECR1L (AMMECR1 like) | protein interactions | 83607 | 16 | 1 | 19454 | 50 |
MACF1 |
4.035e-02 | -3.21 | SYTL2 (synaptotagmin like 2) | protein interactions | 54843 | 16 | 1 | 19454 | 50 |
NRXN1 |
4.035e-02 | -3.21 | TWIST2 (twist family bHLH transcription factor 2) | protein interactions | 117581 | 16 | 1 | 19454 | 50 |
ZBTB20 |
4.035e-02 | -3.21 | SYT4 (synaptotagmin 4) | protein interactions | 6860 | 16 | 1 | 19454 | 50 |
NRXN1 |
4.043e-02 | -3.21 | response to caffeine | biological process | GO:0031000 | 15 | 1 | 18204 | 50 |
RYR3 |
4.043e-02 | -3.21 | protein homotrimerization | biological process | GO:0070207 | 15 | 1 | 18204 | 50 |
SLC1A2 |
4.043e-02 | -3.21 | intracellular potassium ion homeostasis | biological process | GO:0030007 | 15 | 1 | 18204 | 50 |
ATP1A2 |
4.043e-02 | -3.21 | cerebellar Purkinje cell layer formation | biological process | GO:0021694 | 15 | 1 | 18204 | 50 |
RORA |
4.043e-02 | -3.21 | chondrocyte proliferation | biological process | GO:0035988 | 15 | 1 | 18204 | 50 |
FGFR3 |
4.043e-02 | -3.21 | exit from mitosis | biological process | GO:0010458 | 15 | 1 | 18204 | 50 |
NFIA |
4.043e-02 | -3.21 | regulation of circadian sleep/wake cycle, sleep | biological process | GO:0045187 | 15 | 1 | 18204 | 50 |
PTGDS |
4.043e-02 | -3.21 | peripheral nervous system neuron development | biological process | GO:0048935 | 15 | 1 | 18204 | 50 |
NTRK2 |
4.043e-02 | -3.21 | synapse maturation | biological process | GO:0060074 | 15 | 1 | 18204 | 50 |
NFIA |
4.043e-02 | -3.21 | sarcoplasmic reticulum calcium ion transport | biological process | GO:0070296 | 15 | 1 | 18204 | 50 |
RYR3 |
4.043e-02 | -3.21 | regulation of neuron projection arborization | biological process | GO:0150011 | 15 | 1 | 18204 | 50 |
MACF1 |
4.043e-02 | -3.21 | neuroblast division | biological process | GO:0055057 | 15 | 1 | 18204 | 50 |
SOX5 |
4.043e-02 | -3.21 | negative regulation of sodium ion transmembrane transport | biological process | GO:1902306 | 15 | 1 | 18204 | 50 |
ATP1A2 |
4.043e-02 | -3.21 | peripheral nervous system neuron differentiation | biological process | GO:0048934 | 15 | 1 | 18204 | 50 |
NTRK2 |
4.065e-02 | -3.20 | membrane protein complex | cellular component | GO:0098796 | 1261 | 7 | 19108 | 49 |
SLC1A2,CDH20,ATP1A2,BMPR1B,CTNNA2,SLC1A3,RYR3 |
4.081e-02 | -3.20 | Circadian rythm related genes | WikiPathways | WP3594 | 207 | 3 | 5310 | 20 |
PTGDS,CST3,RORA |
4.101e-02 | -3.19 | Ig-like_dom_sf | interpro domains | IPR036179 | 483 | 4 | 18521 | 50 |
FGFR3,NTRK2,LSAMP,NTM |
4.106e-02 | -3.19 | SLAMF1 (signaling lymphocytic activation molecule family member 1) | protein interactions | 6504 | 125 | 2 | 19454 | 50 |
CPE,LIFR |
4.106e-02 | -3.19 | SCGB1D1 (secretoglobin family 1D member 1) | protein interactions | 10648 | 125 | 2 | 19454 | 50 |
CPE,LIFR |
4.107e-02 | -3.19 | regulation of synapse assembly | biological process | GO:0051963 | 117 | 2 | 18204 | 50 |
NTRK2,NRXN1 |
4.117e-02 | -3.19 | secondary active transmembrane transporter activity | molecular function | GO:0015291 | 289 | 3 | 18094 | 48 |
SLC4A4,SLC1A2,SLC1A3 |
4.128e-02 | -3.19 | positive regulation of cellular process | biological process | GO:0048522 | 5719 | 22 | 18204 | 50 |
FGFR3,GLIS3,PTPRZ1,NTRK2,SOX5,BMPR1B,ZBTB20,NFIA,TNIK,SLC1A2,MACF1,SLC4A4,FMN2,GLUD1,GPM6A,LIFR,NPAS3,NRXN1,RORA,MAML2,SLC1A3,GPC5 |
4.134e-02 | -3.19 | Cation_ATPase_C | pfam domains | PF00689 | 15 | 1 | 17795 | 50 |
ATP1A2 |
4.134e-02 | -3.19 | CNH | pfam domains | PF00780 | 15 | 1 | 17795 | 50 |
TNIK |
4.134e-02 | -3.19 | FH2 | pfam domains | PF02181 | 15 | 1 | 17795 | 50 |
FMN2 |
4.150e-02 | -3.18 | Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | REACTOME pathways | R-HSA-2162123 | 15 | 1 | 10285 | 29 |
PTGDS |
4.163e-02 | -3.18 | oxysterol binding | molecular function | GO:0008142 | 16 | 1 | 18094 | 48 |
RORA |
4.166e-02 | -3.18 | SYP (synaptophysin) | protein interactions | 6855 | 126 | 2 | 19454 | 50 |
GPM6A,PITPNC1 |
4.168e-02 | -3.18 | positive regulation of phosphorus metabolic process | biological process | GO:0010562 | 697 | 5 | 18204 | 50 |
NTRK2,TNIK,FGFR3,SLC4A4,ZBTB20 |
4.168e-02 | -3.18 | positive regulation of phosphate metabolic process | biological process | GO:0045937 | 697 | 5 | 18204 | 50 |
NTRK2,TNIK,SLC4A4,FGFR3,ZBTB20 |
4.170e-02 | -3.18 | synapse assembly | biological process | GO:0007416 | 118 | 2 | 18204 | 50 |
GPM6A,NRXN1 |
4.171e-02 | -3.18 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | 1117 | 7 | 16828 | 49 |
ATP13A4,RYR3,SOX5,SLC1A2,FMN2,GPC5,CDH20 |
4.193e-02 | -3.17 | cell surface receptor signaling pathway | biological process | GO:0007166 | 1992 | 10 | 18204 | 50 |
MAML2,TNIK,LIFR,NFIA,CPE,NTRK2,BMPR1B,MACF1,FGFR3,CTNND2 |
4.193e-02 | -3.17 | response to stimulus | biological process | GO:0050896 | 7803 | 28 | 18204 | 50 |
SPARCL1,CTNND2,DTNA,CTNNA2,PITPNC1,NFIA,MACF1,RORA,PTGDS,MAML2,ITPR2,SOX5,NTRK2,BMPR1B,FGFR3,TNIK,SLC1A2,ZBTB20,CPE,ATP1A2,FMN2,PREX2,CST3,RYR3,SLC1A3,LIFR,GPM6A,NRXN1 |
4.208e-02 | -3.17 | mesothelioma | COSMIC cancer mutations | mesothelioma | 4477 | 19 | 16828 | 49 |
SOX5,BMPR1B,RORA,MSI2,NTRK2,PTPRZ1,TRPS1,CTNND2,TNIK,MAML2,FMN2,HIF3A,PREX2,ATP13A4,FBXL7,ITPR2,PITPNC1,LIFR,FGFR3 |
4.225e-02 | -3.16 | EF_HAND_2 | prosite domains | PS50222 | 215 | 3 | 12186 | 44 |
RYR3,MACF1,SPARCL1 |
4.226e-02 | -3.16 | PAX9 (paired box 9) | protein interactions | 5083 | 127 | 2 | 19454 | 50 |
TRPS1,NFIA |
4.235e-02 | -3.16 | CarboxyPept-like_regulatory | interpro domains | IPR008969 | 16 | 1 | 18521 | 50 |
CPE |
4.267e-02 | -3.15 | neuron projection terminus | cellular component | GO:0044306 | 128 | 2 | 19108 | 49 |
SLC1A2,NTRK2 |
4.268e-02 | -3.15 | TyrKc | smart domains | SM00219 | 80 | 2 | 9717 | 40 |
FGFR3,NTRK2 |
4.282e-02 | -3.15 | ureter | COSMIC cancer mutations | ureter | 15 | 1 | 16828 | 49 |
FGFR3 |
4.282e-02 | -3.15 | DPP6 (dipeptidyl peptidase like 6) | protein interactions | 1804 | 17 | 1 | 19454 | 50 |
GPM6A |
4.282e-02 | -3.15 | TAGAP (T cell activation RhoGTPase activating protein) | protein interactions | 117289 | 17 | 1 | 19454 | 50 |
DTNA |
4.282e-02 | -3.15 | PAX4 (paired box 4) | protein interactions | 5078 | 17 | 1 | 19454 | 50 |
NTM |
4.282e-02 | -3.15 | Shcbp1 (Shc SH2-domain binding protein 1) | protein interactions | 20419 | 17 | 1 | 19454 | 50 |
GPC5 |
4.282e-02 | -3.15 | NOTCH4 (notch receptor 4) | protein interactions | 4855 | 17 | 1 | 19454 | 50 |
MAML2 |
4.282e-02 | -3.15 | RASL12 (RAS like family 12) | protein interactions | 51285 | 17 | 1 | 19454 | 50 |
BMPR1B |
4.282e-02 | -3.15 | MSANTD2 (Myb/SANT DNA binding domain containing 2) | protein interactions | 79684 | 17 | 1 | 19454 | 50 |
SOX5 |
4.282e-02 | -3.15 | SEPSECS (Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase) | protein interactions | 51091 | 17 | 1 | 19454 | 50 |
ABLIM1 |
4.282e-02 | -3.15 | Sqstm1 (sequestosome 1) | protein interactions | 18412 | 17 | 1 | 19454 | 50 |
BMPR1B |
4.286e-02 | -3.15 | SYT2 (synaptotagmin 2) | protein interactions | 127833 | 128 | 2 | 19454 | 50 |
NRXN1,AHCYL2 |
4.286e-02 | -3.15 | MYB (MYB proto-oncogene, transcription factor) | protein interactions | 4602 | 128 | 2 | 19454 | 50 |
NFIA,TRPS1 |
4.286e-02 | -3.15 | ATF7IP (activating transcription factor 7 interacting protein) | protein interactions | 55729 | 128 | 2 | 19454 | 50 |
MACF1,SOX5 |
4.286e-02 | -3.15 | TEAD2 (TEA domain transcription factor 2) | protein interactions | 8463 | 128 | 2 | 19454 | 50 |
TRPS1,ZBTB20 |
4.297e-02 | -3.15 | RAC1 (Rac family small GTPase 1) | protein interactions | 5879 | 1005 | 6 | 19454 | 50 |
AHCYL2,DTNA,PREX2,FMN2,MACF1,SLC1A3 |
4.307e-02 | -3.14 | asymmetric cell division | biological process | GO:0008356 | 16 | 1 | 18204 | 50 |
SOX5 |
4.307e-02 | -3.14 | regulation of amino acid import across plasma membrane | biological process | GO:0010958 | 16 | 1 | 18204 | 50 |
ATP1A2 |
4.307e-02 | -3.14 | regulation of respiratory system process | biological process | GO:0044065 | 16 | 1 | 18204 | 50 |
ATP1A2 |
4.307e-02 | -3.14 | nonribosomal peptide biosynthetic process | biological process | GO:0019184 | 16 | 1 | 18204 | 50 |
SLC1A2 |
4.307e-02 | -3.14 | neuron cell-cell adhesion | biological process | GO:0007158 | 16 | 1 | 18204 | 50 |
NRXN1 |
4.307e-02 | -3.14 | tricarboxylic acid metabolic process | biological process | GO:0072350 | 16 | 1 | 18204 | 50 |
GLUD1 |
4.307e-02 | -3.14 | non-proteinogenic amino acid biosynthetic process | biological process | GO:0170043 | 16 | 1 | 18204 | 50 |
SLC1A3 |
4.307e-02 | -3.14 | regulation of amino acid transmembrane transport | biological process | GO:1903789 | 16 | 1 | 18204 | 50 |
ATP1A2 |
4.307e-02 | -3.14 | S-adenosylmethionine metabolic process | biological process | GO:0046500 | 16 | 1 | 18204 | 50 |
AHCYL2 |
4.307e-02 | -3.14 | insulin metabolic process | biological process | GO:1901142 | 16 | 1 | 18204 | 50 |
CPE |
4.307e-02 | -3.14 | locomotory exploration behavior | biological process | GO:0035641 | 16 | 1 | 18204 | 50 |
ATP1A2 |
4.307e-02 | -3.14 | glutamine family amino acid biosynthetic process | biological process | GO:0009084 | 16 | 1 | 18204 | 50 |
GLUD1 |
4.307e-02 | -3.14 | cardiac left ventricle morphogenesis | biological process | GO:0003214 | 16 | 1 | 18204 | 50 |
CPE |
4.313e-02 | -3.14 | Lactose Intolerance | SMPDB pathways | SMP0000458 | 12 | 1 | 1369 | 5 |
ATP1A2 |
4.313e-02 | -3.14 | Lactose Degradation | SMPDB pathways | SMP0000457 | 12 | 1 | 1369 | 5 |
ATP1A2 |
4.318e-02 | -3.14 | HCO3TRNSPORT | prints domains | PR01231 | 10 | 1 | 5227 | 23 |
SLC4A4 |
4.329e-02 | -3.14 | ovary-carcinoma-mucinous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-mucinous_carcinoma | 456 | 4 | 16828 | 49 |
TNIK,NTRK2,FGFR3,BMPR1B |
4.340e-02 | -3.14 | cell junction assembly | biological process | GO:0034329 | 285 | 3 | 18204 | 50 |
GPM6A,CDH20,NRXN1 |
4.346e-02 | -3.14 | CHD7 (chromodomain helicase DNA binding protein 7) | protein interactions | 55636 | 129 | 2 | 19454 | 50 |
SOX5,ZBTB20 |
4.346e-02 | -3.14 | POLA2 (DNA polymerase alpha 2, accessory subunit) | protein interactions | 23649 | 129 | 2 | 19454 | 50 |
CPE,FGFR3 |
4.388e-02 | -3.13 | mucinous_carcinoma | COSMIC cancer mutations | mucinous_carcinoma | 458 | 4 | 16828 | 49 |
BMPR1B,NTRK2,FGFR3,TNIK |
4.388e-02 | -3.13 | Z disc | cellular component | GO:0030018 | 130 | 2 | 19108 | 49 |
NEBL,RYR3 |
4.417e-02 | -3.12 | transmembrane receptor protein phosphatase activity | molecular function | GO:0019198 | 17 | 1 | 18094 | 48 |
PTPRZ1 |
4.417e-02 | -3.12 | transmembrane receptor protein tyrosine phosphatase activity | molecular function | GO:0005001 | 17 | 1 | 18094 | 48 |
PTPRZ1 |
4.432e-02 | -3.12 | MFAP5-mediated ovarian cancer cell motility and invasiveness | WikiPathways | WP3301 | 12 | 1 | 5310 | 20 |
RYR3 |
4.432e-02 | -3.12 | Bone Morphogenic Protein (BMP) Signalling and Regulation | WikiPathways | WP1425 | 12 | 1 | 5310 | 20 |
BMPR1B |
4.432e-02 | -3.12 | endomembrane system | cellular component | GO:0012505 | 4764 | 18 | 19108 | 49 |
MACF1,FGFR3,CPE,NTRK2,SPARCL1,ATP1A2,CST3,PTGDS,GLUD1,GPC5,AHCYL2,FMN2,ATP13A4,TNIK,ITPR2,PARD3B,NRXN1,RYR3 |
4.467e-02 | -3.11 | Formin, FH2 domain | gene3d domains | 1.20.58.2220 | 15 | 1 | 14470 | 44 |
FMN2 |
4.468e-02 | -3.11 | ZNF609 (zinc finger protein 609) | protein interactions | 23060 | 131 | 2 | 19454 | 50 |
SOX5,NFIA |
4.468e-02 | -3.11 | NCOA2 (nuclear receptor coactivator 2) | protein interactions | 10499 | 131 | 2 | 19454 | 50 |
RORA,NFIA |
4.468e-02 | -3.11 | TRPS1 (transcriptional repressor GATA binding 1) | protein interactions | 7227 | 131 | 2 | 19454 | 50 |
SOX5,NFIA |
4.477e-02 | -3.11 | Helix-loop-helix DNA-binding domain | gene3d domains | 4.10.280.10 | 111 | 2 | 14470 | 44 |
NPAS3,HIF3A |
4.493e-02 | -3.10 | CA_dom_sf | interpro domains | IPR036398 | 17 | 1 | 18521 | 50 |
PTPRZ1 |
4.493e-02 | -3.10 | PAC | interpro domains | IPR001610 | 17 | 1 | 18521 | 50 |
HIF3A |
4.493e-02 | -3.10 | Cystatin_dom | interpro domains | IPR000010 | 17 | 1 | 18521 | 50 |
CST3 |
4.493e-02 | -3.10 | CA_dom | interpro domains | IPR001148 | 17 | 1 | 18521 | 50 |
PTPRZ1 |
4.499e-02 | -3.10 | AFDN (afadin, adherens junction formation factor) | protein interactions | 4301 | 309 | 3 | 19454 | 50 |
DTNA,NRXN1,MACF1 |
4.507e-02 | -3.10 | ductal_carcinoma | COSMIC cancer mutations | ductal_carcinoma | 15798 | 49 | 16828 | 49 |
GLIS3,LSAMP,HIF3A,ZBTB20,CST3,PITPNC1,SLC4A4,SFXN5,FGFR3,ATP1A2,PARD3B,NEBL,MSI2,PTPRZ1,FMN2,MAML2,GPC5,CTNND2,SLC1A3,AHCYL2,PTGDS,FBXL7,LIFR,SPARCL1,BMPR1B,RYR3,DTNA,NPAS3,PREX2,PCDH9,ITPR2,ABLIM1,CPE,RORA,NTRK2,TRPS1,GPM6A,CDH20,TNIK,NTM,GLUD1,ATP13A4,MACF1,NHSL1,SLC1A2,SOX5,NFIA,NKAIN3,NRXN1 |
4.517e-02 | -3.10 | PROTEIN_KINASE_TYR | prosite domains | PS00109 | 94 | 2 | 12186 | 44 |
FGFR3,NTRK2 |
4.529e-02 | -3.09 | NKIRAS1 (NFKB inhibitor interacting Ras like 1) | protein interactions | 28512 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.529e-02 | -3.09 | ACAP1 (ArfGAP with coiled-coil, ankyrin repeat and PH domains 1) | protein interactions | 9744 | 18 | 1 | 19454 | 50 |
NEBL |
4.529e-02 | -3.09 | Tgfbr1 (transforming growth factor, beta receptor I) | protein interactions | 21812 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.529e-02 | -3.09 | KLHL1 (kelch like family member 1) | protein interactions | 57626 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.529e-02 | -3.09 | NECTIN1 (nectin cell adhesion molecule 1) | protein interactions | 5818 | 18 | 1 | 19454 | 50 |
FGFR3 |
4.529e-02 | -3.09 | OPCML (opioid binding protein/cell adhesion molecule like) | protein interactions | 4978 | 18 | 1 | 19454 | 50 |
NTM |
4.529e-02 | -3.09 | TTC29 (tetratricopeptide repeat domain 29) | protein interactions | 83894 | 18 | 1 | 19454 | 50 |
MACF1 |
4.529e-02 | -3.09 | PTGFR (prostaglandin F receptor) | protein interactions | 5737 | 18 | 1 | 19454 | 50 |
PTGDS |
4.529e-02 | -3.09 | Cnot2 (CCR4-NOT transcription complex, subunit 2) | protein interactions | 72068 | 18 | 1 | 19454 | 50 |
MACF1 |
4.530e-02 | -3.09 | GPIHBP1 (glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1) | protein interactions | 338328 | 132 | 2 | 19454 | 50 |
FGFR3,CPE |
4.560e-02 | -3.09 | action potential | biological process | GO:0001508 | 124 | 2 | 18204 | 50 |
NTRK2,ATP1A2 |
4.561e-02 | -3.09 | renal_pelvis | COSMIC cancer mutations | renal_pelvis | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | normal | COSMIC cancer mutations | normal | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | flank | COSMIC cancer mutations | flank | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | urinary_tract-carcinoma | COSMIC cancer mutations | urinary_tract-carcinoma | 16 | 1 | 16828 | 49 |
FGFR3 |
4.565e-02 | -3.09 | ovary-carcinoma-endometrioid_carcinoma | COSMIC cancer mutations | ovary-carcinoma-endometrioid_carcinoma | 464 | 4 | 16828 | 49 |
BMPR1B,FGFR3,NTRK2,TNIK |
4.570e-02 | -3.09 | cGMP metabolic process | biological process | GO:0046068 | 17 | 1 | 18204 | 50 |
RORA |
4.570e-02 | -3.09 | cellular response to ATP | biological process | GO:0071318 | 17 | 1 | 18204 | 50 |
RYR3 |
4.570e-02 | -3.09 | cell migration in hindbrain | biological process | GO:0021535 | 17 | 1 | 18204 | 50 |
CTNNA2 |
4.570e-02 | -3.09 | microvillus assembly | biological process | GO:0030033 | 17 | 1 | 18204 | 50 |
TNIK |
4.570e-02 | -3.09 | T-helper 17 type immune response | biological process | GO:0072538 | 17 | 1 | 18204 | 50 |
RORA |
4.570e-02 | -3.09 | cell communication by electrical coupling involved in cardiac conduction | biological process | GO:0086064 | 17 | 1 | 18204 | 50 |
ATP1A2 |
4.570e-02 | -3.09 | retinal rod cell differentiation | biological process | GO:0060221 | 17 | 1 | 18204 | 50 |
NTRK2 |
4.570e-02 | -3.09 | protein trimerization | biological process | GO:0070206 | 17 | 1 | 18204 | 50 |
SLC1A2 |
4.570e-02 | -3.09 | viral genome replication | biological process | GO:0019079 | 17 | 1 | 18204 | 50 |
NFIA |
4.570e-02 | -3.09 | membrane depolarization during cardiac muscle cell action potential | biological process | GO:0086012 | 17 | 1 | 18204 | 50 |
ATP1A2 |
4.570e-02 | -3.09 | ureter development | biological process | GO:0072189 | 17 | 1 | 18204 | 50 |
NFIA |
4.596e-02 | -3.08 | CARBOXYPEPT_ZN_2 | prosite domains | PS00133 | 13 | 1 | 12186 | 44 |
CPE |
4.596e-02 | -3.08 | CARBOXYPEPT_ZN_1 | prosite domains | PS00132 | 13 | 1 | 12186 | 44 |
CPE |
4.607e-02 | -3.08 | response to hypoxia | biological process | GO:0001666 | 292 | 3 | 18204 | 50 |
RORA,ITPR2,FMN2 |
4.613e-02 | -3.08 | PDZ | pfam domains | PF00595 | 122 | 2 | 17795 | 50 |
PARD3B,PREX2 |
4.615e-02 | -3.08 | cell cortex | cellular component | GO:0005938 | 313 | 3 | 19108 | 49 |
PARD3B,FMN2,ITPR2 |
4.629e-02 | -3.07 | Hypoxic and oxygen homeostasis regulation of HIF-1-alpha | Pathway Interaction DB | hif1apathway | 15 | 1 | 2226 | 7 |
HIF3A |
4.631e-02 | -3.07 | modulation of chemical synaptic transmission | biological process | GO:0050804 | 494 | 4 | 18204 | 50 |
ATP1A2,NTRK2,SLC1A3,NRXN1 |
4.636e-02 | -3.07 | PROTEIN_KINASE_ATP | prosite domains | PS00107 | 377 | 4 | 12186 | 44 |
BMPR1B,TNIK,FGFR3,NTRK2 |
4.660e-02 | -3.07 | regulation of trans-synaptic signaling | biological process | GO:0099177 | 495 | 4 | 18204 | 50 |
NRXN1,SLC1A3,ATP1A2,NTRK2 |
4.665e-02 | -3.07 | Argininemia | SMPDB pathways | SMP0000357 | 13 | 1 | 1369 | 5 |
GLUD1 |
4.665e-02 | -3.07 | Citrullinemia Type I | SMPDB pathways | SMP0000001 | 13 | 1 | 1369 | 5 |
GLUD1 |
4.665e-02 | -3.07 | Ornithine Transcarbamylase Deficiency (OTC Deficiency) | SMPDB pathways | SMP0000205 | 13 | 1 | 1369 | 5 |
GLUD1 |
4.665e-02 | -3.07 | Carbamoyl Phosphate Synthetase Deficiency | SMPDB pathways | SMP0000002 | 13 | 1 | 1369 | 5 |
GLUD1 |
4.665e-02 | -3.07 | Trehalose Degradation | SMPDB pathways | SMP0000467 | 13 | 1 | 1369 | 5 |
ATP1A2 |
4.665e-02 | -3.07 | Urea Cycle | SMPDB pathways | SMP0000059 | 13 | 1 | 1369 | 5 |
GLUD1 |
4.665e-02 | -3.07 | Argininosuccinic Aciduria | SMPDB pathways | SMP0000003 | 13 | 1 | 1369 | 5 |
GLUD1 |
4.671e-02 | -3.06 | phosphatidylcholine transporter activity | molecular function | GO:0008525 | 18 | 1 | 18094 | 48 |
PITPNC1 |
4.671e-02 | -3.06 | NAD+ binding | molecular function | GO:0070403 | 18 | 1 | 18094 | 48 |
GLUD1 |
4.673e-02 | -3.06 | Carb_anhydrase | pfam domains | PF00194 | 17 | 1 | 17795 | 50 |
PTPRZ1 |
4.673e-02 | -3.06 | ZZ | pfam domains | PF00569 | 17 | 1 | 17795 | 50 |
DTNA |
4.673e-02 | -3.06 | Cystatin | pfam domains | PF00031 | 17 | 1 | 17795 | 50 |
CST3 |
4.690e-02 | -3.06 | Elevation of cytosolic Ca2+ levels | REACTOME pathways | R-HSA-139853 | 17 | 1 | 10285 | 29 |
ITPR2 |
4.696e-02 | -3.06 | Cadherins | gene3d domains | 2.60.40.60 | 114 | 2 | 14470 | 44 |
CDH20,PCDH9 |
4.716e-02 | -3.05 | FOXP1 (forkhead box P1) | protein interactions | 27086 | 135 | 2 | 19454 | 50 |
SOX5,NFIA |
4.716e-02 | -3.05 | SOX15 (SRY-box transcription factor 15) | protein interactions | 6665 | 135 | 2 | 19454 | 50 |
TRPS1,NFIA |
4.722e-02 | -3.05 | central_nervous_system-brain-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brain-glioma-astrocytoma_Grade_IV | 15813 | 49 | 16828 | 49 |
HIF3A,GLIS3,LSAMP,ZBTB20,CST3,SFXN5,PITPNC1,SLC4A4,ATP1A2,PARD3B,FGFR3,NEBL,MSI2,PTPRZ1,SLC1A3,CTNND2,MAML2,FMN2,GPC5,AHCYL2,FBXL7,PTGDS,LIFR,SPARCL1,BMPR1B,RYR3,DTNA,PCDH9,PREX2,NPAS3,ITPR2,ABLIM1,CPE,RORA,NTRK2,CDH20,TRPS1,GPM6A,TNIK,GLUD1,NTM,ATP13A4,MACF1,NHSL1,SLC1A2,SOX5,NKAIN3,NFIA,NRXN1 |
4.728e-02 | -3.05 | localization | biological process | GO:0051179 | 4474 | 18 | 18204 | 50 |
PITPNC1,PARD3B,SLC1A2,TNIK,NTRK2,ITPR2,GPM6A,NRXN1,ATP13A4,PTGDS,SLC1A3,RYR3,SLC4A4,MACF1,FMN2,CPE,SFXN5,ATP1A2 |
4.743e-02 | -3.05 | striated_muscle | COSMIC cancer mutations | striated_muscle | 4228 | 18 | 16828 | 49 |
NFIA,RORA,RYR3,MAML2,FMN2,SLC1A3,CTNND2,TRPS1,PTPRZ1,CDH20,NPAS3,PREX2,GLIS3,FGFR3,SPARCL1,NHSL1,PARD3B,MACF1 |
4.752e-02 | -3.05 | Leu-rich_rpt_Cys-con_subtyp | interpro domains | IPR006553 | 18 | 1 | 18521 | 50 |
FBXL7 |
4.754e-02 | -3.05 | ZYX (zyxin) | protein interactions | 7791 | 316 | 3 | 19454 | 50 |
MACF1,NEBL,ABLIM1 |
4.760e-02 | -3.05 | response to amino acid | biological process | GO:0043200 | 127 | 2 | 18204 | 50 |
SLC1A2,NTRK2 |
4.761e-02 | -3.04 | postsynaptic density | cellular component | GO:0014069 | 317 | 3 | 19108 | 49 |
TNIK,CTNND2,NTRK2 |
4.764e-02 | -3.04 | cation-transporting ATPase complex | cellular component | GO:0090533 | 19 | 1 | 19108 | 49 |
ATP1A2 |
4.764e-02 | -3.04 | postsynaptic specialization, intracellular component | cellular component | GO:0099091 | 19 | 1 | 19108 | 49 |
TNIK |
4.764e-02 | -3.04 | parallel fiber to Purkinje cell synapse | cellular component | GO:0098688 | 19 | 1 | 19108 | 49 |
GPM6A |
4.764e-02 | -3.04 | astrocyte projection | cellular component | GO:0097449 | 19 | 1 | 19108 | 49 |
SLC1A2 |
4.772e-02 | -3.04 | haematopoietic_and_lymphoid_tissue-abdomen-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-abdomen-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 120 | 2 | 16828 | 49 |
CTNND2,FMN2 |
4.774e-02 | -3.04 | OSM (oncostatin M) | protein interactions | 5008 | 19 | 1 | 19454 | 50 |
LIFR |
4.774e-02 | -3.04 | PHYHIPL (phytanoyl-CoA 2-hydroxylase interacting protein like) | protein interactions | 84457 | 19 | 1 | 19454 | 50 |
GPM6A |
4.774e-02 | -3.04 | INKA1 (inka box actin regulator 1) | protein interactions | 389119 | 19 | 1 | 19454 | 50 |
ZBTB20 |
4.774e-02 | -3.04 | SPZ1 (spermatogenic leucine zipper 1) | protein interactions | 84654 | 19 | 1 | 19454 | 50 |
DTNA |
4.774e-02 | -3.04 | GCHFR (GTP cyclohydrolase I feedback regulator) | protein interactions | 2644 | 19 | 1 | 19454 | 50 |
NEBL |
4.774e-02 | -3.04 | RIT2 (Ras like without CAAX 2) | protein interactions | 6014 | 19 | 1 | 19454 | 50 |
DTNA |
4.774e-02 | -3.04 | SYT7 (synaptotagmin 7) | protein interactions | 9066 | 19 | 1 | 19454 | 50 |
NRXN1 |
4.774e-02 | -3.04 | CNTNAP4 (contactin associated protein family member 4) | protein interactions | 85445 | 19 | 1 | 19454 | 50 |
MACF1 |
4.774e-02 | -3.04 | TNR (tenascin R) | protein interactions | 7143 | 19 | 1 | 19454 | 50 |
PTPRZ1 |
4.774e-02 | -3.04 | C3orf62 (chromosome 3 open reading frame 62) | protein interactions | 375341 | 19 | 1 | 19454 | 50 |
ATP1A2 |
4.774e-02 | -3.04 | NLGN1 (neuroligin 1) | protein interactions | 22871 | 19 | 1 | 19454 | 50 |
NRXN1 |
4.785e-02 | -3.04 | anion binding | molecular function | GO:0043168 | 2412 | 11 | 18094 | 48 |
ATP13A4,GLUD1,FGFR3,TNIK,ITPR2,ATP1A2,SLC1A3,PITPNC1,BMPR1B,NTRK2,PTGDS |
4.793e-02 | -3.04 | Cell-type Dependent Selectivity of CCK2R Signaling | WikiPathways | WP3679 | 13 | 1 | 5310 | 20 |
RYR3 |
4.793e-02 | -3.04 | skin-back-malignant_melanoma | COSMIC cancer mutations | skin-back-malignant_melanoma | 280 | 3 | 16828 | 49 |
TNIK,ATP1A2,PREX2 |
4.804e-02 | -3.04 | muscle system process | biological process | GO:0003012 | 297 | 3 | 18204 | 50 |
RYR3,DTNA,ATP1A2 |
4.832e-02 | -3.03 | DWA | smart domains | SM00523 | 12 | 1 | 9717 | 40 |
NFIA |
4.832e-02 | -3.03 | ZnF_GATA | smart domains | SM00401 | 12 | 1 | 9717 | 40 |
TRPS1 |
4.832e-02 | -3.03 | dicarboxylic acid catabolic process | biological process | GO:0043649 | 18 | 1 | 18204 | 50 |
GLUD1 |
4.832e-02 | -3.03 | negative regulation of anoikis | biological process | GO:2000811 | 18 | 1 | 18204 | 50 |
NTRK2 |
4.832e-02 | -3.03 | positive regulation of circadian rhythm | biological process | GO:0042753 | 18 | 1 | 18204 | 50 |
RORA |
4.832e-02 | -3.03 | cardiac myofibril assembly | biological process | GO:0055003 | 18 | 1 | 18204 | 50 |
NEBL |
4.832e-02 | -3.03 | regulation of extracellular matrix disassembly | biological process | GO:0010715 | 18 | 1 | 18204 | 50 |
CST3 |
4.832e-02 | -3.03 | negative regulation of sodium ion transport | biological process | GO:0010766 | 18 | 1 | 18204 | 50 |
ATP1A2 |
4.832e-02 | -3.03 | dendritic spine morphogenesis | biological process | GO:0060997 | 18 | 1 | 18204 | 50 |
CTNND2 |
4.839e-02 | -3.03 | non_chronically_sun_exposed_site | COSMIC cancer mutations | non_chronically_sun_exposed_site | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | skin-non_chronically_sun_exposed_site-malignant_melanoma | COSMIC cancer mutations | skin-non_chronically_sun_exposed_site-malignant_melanoma | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | breast-carcinoma-neuroendocrine_carcinoma | COSMIC cancer mutations | breast-carcinoma-neuroendocrine_carcinoma | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | squamous_cell_carcinoma_BRAF_inhibitor_related | COSMIC cancer mutations | squamous_cell_carcinoma_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | skin-other-verrucal_keratosis_BRAF_inhibitor_related | COSMIC cancer mutations | skin-other-verrucal_keratosis_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | verrucal_keratosis_BRAF_inhibitor_related | COSMIC cancer mutations | verrucal_keratosis_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | skin-carcinoma-squamous_cell_carcinoma_BRAF_inhibitor_related | COSMIC cancer mutations | skin-carcinoma-squamous_cell_carcinoma_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.842e-02 | -3.03 | Bmpr1a (bone morphogenetic protein receptor, type 1A) | protein interactions | 12166 | 137 | 2 | 19454 | 50 |
LIFR,GLUD1 |
4.842e-02 | -3.03 | TBL1X (transducin beta like 1 X-linked) | protein interactions | 6907 | 137 | 2 | 19454 | 50 |
NFIA,SOX5 |
4.859e-02 | -3.02 | human chr18q12.1 | chromosome location | human chr18q12.1 | 26 | 1 | 26134 | 50 |
DTNA |
4.893e-02 | -3.02 | kidney-other-neoplasm | COSMIC cancer mutations | kidney-other-neoplasm | 10653 | 37 | 16828 | 49 |
ITPR2,SFXN5,ABLIM1,FGFR3,ATP1A2,LSAMP,NPAS3,ZBTB20,PREX2,PCDH9,GPM6A,PTPRZ1,TRPS1,CDH20,FMN2,TNIK,MAML2,GPC5,SLC1A3,CTNND2,RORA,CPE,NEBL,NTRK2,MACF1,SPARCL1,NHSL1,AHCYL2,GLUD1,FBXL7,ATP13A4,NRXN1,SOX5,RYR3,SLC1A2,NKAIN3,DTNA |
4.894e-02 | -3.02 | response to organophosphorus | biological process | GO:0046683 | 129 | 2 | 18204 | 50 |
RYR3,ITPR2 |
4.911e-02 | -3.01 | sequence-specific double-stranded DNA binding | molecular function | GO:1990837 | 1547 | 8 | 18094 | 48 |
HIF3A,NPAS3,SOX5,TRPS1,ZBTB20,NFIA,GLIS3,RORA |
4.924e-02 | -3.01 | transmembrane receptor protein serine/threonine kinase activity | molecular function | GO:0004675 | 19 | 1 | 18094 | 48 |
BMPR1B |
4.924e-02 | -3.01 | alkali metal ion binding | molecular function | GO:0031420 | 19 | 1 | 18094 | 48 |
ATP1A2 |
4.931e-02 | -3.01 | TRIM67 (tripartite motif containing 67) | protein interactions | 440730 | 4804 | 18 | 19454 | 50 |
PITPNC1,ATP1A2,GLUD1,MSI2,TNIK,PTPRZ1,CTNND2,MACF1,CTNNA2,CST3,SLC1A3,GPM6A,NTM,ITPR2,DTNA,SLC4A4,LSAMP,AHCYL2 |
4.951e-02 | -3.01 | cellular response to organonitrogen compound | biological process | GO:0071417 | 505 | 4 | 18204 | 50 |
ITPR2,SLC1A3,RYR3,SLC1A2 |
4.960e-02 | -3.00 | PI-3K cascade:FGFR3 | REACTOME pathways | R-HSA-5654710 | 18 | 1 | 10285 | 29 |
FGFR3 |
4.960e-02 | -3.00 | SHC-mediated cascade:FGFR3 | REACTOME pathways | R-HSA-5654704 | 18 | 1 | 10285 | 29 |
FGFR3 |
4.987e-02 | -3.00 | ligand-gated monoatomic cation channel activity | molecular function | GO:0099094 | 135 | 2 | 18094 | 48 |
RYR3,ITPR2 |